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Transmissible spongiform encephalopathies (TSEs) are a group of fatal 
neurodegenerative diseases that are characterised by long incubation periods, protein 
aggregation and vacuolation. During TSE pathogenesis the normal, cellular prion 
protein, (PrP
C
), which is encoded by the gene PRNP, misfolds and accumulates as 
abnormal disease associated prion protein, (PrP
Sc
) within the central nervous system.  
Variants of the Prion protein gene are associated with susceptibility to TSE disease. 
For example sheep scrapie disease is modulated by several PRNP alleles, with 
certain alleles carried by susceptible animals being different from those carried by 
resistant animals. The mechanisms linking PRNP genetics and disease is poorly 
understood but may involve protein sequence, PrP
C
 expression levels, and possibly 
differences in protein processing.  
 
Post-translational modification of PrP
C
 leads to specific cleavage (alpha cleavage) 
between amino acids 115/116 of ovine PrP, producing two fragments C1 and N1. 
Cleavage of PrP may occur as a protective mechanism, as a response to changes in 
the cellular environment or as a feature of an as yet unknown biological function. In 
the context of TSEs, alpha cleavage may inadvertently provide a protective role by 
reducing available PrP
C
 protein for conversion into PrP
Sc
, assuming that the C1 
fragment would be an inefficient substrate for conversion, the opposite theory was 
also proposed. 
 
The former hypothesis became the focus of this present study, with the idea that total 
full-length PrP
C
, total C1 or the ratio between full-length PrP
C
 and C1 may be linked 
to differences in scrapie susceptibility. To investigate these aims the C1 fragment 
was measured as a percentage of total PrP
C
 in different PRNP genotypes with 
varying degrees of susceptibility to scrapie and in different brain regions. This study 
found that PrP
C
 alpha cleavage increased during development from the new born 
lamb to the adult sheep, which may have consequences for the susceptibility 
differences related to age. There are also variations in the amount of alpha cleavage 
 
 x
between brain regions such as cortex and medulla that may influence scrapie strain 
targeting. Overall the amount of the C1 fragment in the different brain areas varied as 
much as 10x (range 5% to 60%). There was a significant difference in the ratio of C1 
to the other PrP
C
 forms between two PRNP genotype groups carrying the VRQ and 
ARQ allele but there was no correlation between C1 level and scrapie susceptibility 
or scrapie incubation period in our scrapie models.  
 
Alpha cleavage of PrP
C
 also occurs in various transgenic mouse models expressing 
different ruminant PrP sequences. In PrP
C
 over-expressing transgenic mouse models 
a higher ratio of C1 was observed, this may suggest a link between PrP
C
 expression 
levels and alpha cleavage. Transgenic mice are therefore important models to further 
investigate the link between PrP
C
 biology and scrapie disease phenotype. 
 
In conclusion, this thesis has shown for the first time that certain ovine PRNP alleles 
can influence alpha cleavage of the PrP
C
 protein; however it appears not to be a 
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Chapter 1 Introduction 
 
1.1 Transmissible spongiform encephalopathies  
  
1.1.1 General Introduction 
Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of 
fatal infectious neurodegenerative diseases that affect both humans and animals. 
Examples of prion diseases include bovine spongiform encephalopathy (BSE), 
scrapie, chronic wasting disease (CWD) and Creutzfeldt-Jakob disease (CJD) (Table 
1.1). TSEs are associated with degeneration of the central nervous system (CNS) that 
can be observed histologically by vacuolation of neuronal cell bodies, astrocytic 
gliosis, reduction in neural tissue and sometimes the presence of amyloid within the 
brain. Common clinical signs observed with human prion diseases include ataxia, 
dizziness, and at later stages cognitive deficits. In scrapie, behavioural changes are 
followed by pruritus that causes sheep to scrape, which results in wool loss.  
 




 for scrapie) 
(Prusiner, 1982). PrP
Sc










 for resistant) is the term used to describe proteinase K resistant forms of 
PrP. There are also abnormal forms of PrP that are sensitive to Proteinase K 




 for sensitive). In 
microscopy abnormal forms of PrP are referred to PrP
d
 since protease digestion is 
often not tested. 
 
There have been cases where the levels of abnormal PrP do not correlate with 
infectivity titre and mouse/TSE strain combinations have been identified that show 
little quantitative association with abnormal PrP deposition (Lasmezas et al., 1997, 




 protein consists of 256 amino acids (Figure 1.1); PrP
C
 in other 
mammalian species is of similar length. The structure of the prion protein was 
 
 2
determined by nuclear magnetic resonance (NMR). The NMR analysis showed that 
the prion protein contained two structural domains; an N-terminal region of around 
100 amino acids which is highly flexible and unstructured, and a globular highly 
structured C-terminal region (Riek et al., 1996, 1997, Zahn et al., 2000, Lysek et al., 
2005). The N-terminal domain of PrP contains the signal peptide and the octapeptide 
repeat region (PHGGGWGQ). The number of repeats within the octapeptide region 
can vary among species. Within the octapeptide repeat region cleavage ( cleavage) 
occurs at amino acid 90 which results in the formation of two fragments, C2 and N2 
which are 21 kDa and 7 kDa in size. 
 
The globular C-terminal domain of PrP is important for membrane attachment via a 
glycophosphotidylinositol (GPI) anchor and is arranged in three -helices 
corresponding to amino acids 147-157, 176-197 and 203-231 (ovine PrP numbering) 
and two anti-parallel -strands forming a small sheet. The C-terminal domain of PrP 
also contains a highly conserved hydrophobic domain which contains a 
transmembrane region. Within the hydrophobic region another cleavage event occurs 
at amino acid 115/116 which results in the formation of two fragments, C1 and N2 
which are 18 kDa and 9 kDa in size. A disulphide bond between cysteine residues at 
amino acid 179 and 214 stabilises the strucuture of the prion protein (Linden et al., 
2008) whereas two N-linked glycosylation sites at asparagines 181 and 197 give rise 
to diglycosylated and monoglycosylated forms of PrP.  
 




during TSE infection is not fully understood but 
involves a shift from predominantly alpha helical structure to a structure rich in beta 
sheet. The beta sheet structure allows the protein to form oligomers and eventually 
aggregates that accumulate in the brains of TSE infected animals, sometimes as 
amyloid fibrils/plaques. Upon Proteinase K digestion PrP
Sc
 loses residues 23-89 and 
leaves behind a hydrophobic, protease resistant core. Proteinase K is added to brain 





There is some evidence to suggest that increased concentration of PrP
C
 at the cell 
membrane can cause the protein to form dimmers which can lead to the formation of 
beta sheet structure (Elfrink et al., 2008). In a separate study incubation of 
recombinant PrP under acidic conditions, in the presence of guanidine hydrochloride 
resulted in an increase in -sheet structure (Zhou, 2009) of recombinant PrP. Two 
models of prion conversion have been proposed, the nucleated polymerisation 
seeding model and refolding model. In the nucleated polymerisation seeding model 




 is thermodynamically controlled, and 
under equilibrium PrP
C





 able to convert to PrP
Sc









TSEs can occur sporadically, may be inherited genetically in humans and other 
animals through mutations in the PRNP gene (PRNP, prn-p), or can be acquired 
iatrogenically. TSEs are special, in terms of protein misfolding diseases because of 
their infectious nature (Parchi et al., 2000). TSEs can also be experimentally 
transmitted to animals as was first demonstrated by Cuille & Chelle in 1939. 
Throughout this thesis PrP
Sc
 will be used to describe the disease associated form of 
PrP
C



















Figure 1.1 Structure of Ovine PrP
C
 
Linear representation of ovine PrP
C 
prior to cleavage of the N-terminal signal peptide (1-25) 
and C terminal GPI-signal peptide (233-256) including the  and  cleavage sites, 
glyscosylation sites at amino acid 181 and 197 (Highlighted in red), octapeptide repeat 
region and the position of the  helixes and  sheets. Disulphide linkages between cysteine 
residues at amino acid 179 and 214 help to stabilise the structure of the prion protein (area 
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    Table 1.1 Transmissible spongiform encephalopathies 
Natural Host Disease Aetiology References 









(Cuille & Chelle, 
1939, Pattison & 
Millson, 1960) 
(Benestad et al., 
2003, Hunter, 2007, 
Nentwig et al., 2007) 
review  
(Benestad et al., 
2008) 




Infectious (Williams & Young, 
1980,1982) 
Cattle Bovine spongiform 
encephalopathy 
(BSE) 
Contaminated feed (Wells et al., 1987) 
Mink Transmissible mink 
encephalopathy 
(TME) 
Idiopathic (Hartsough & Burger, 
1965, Kimberlin & 
Marsh, 1975) 
Cats Feline spongiform 
encephalopathy 
(FSE) 
Contaminated meat (Wyatt et al., 1991) 
Human CJD (sCJD) 
 





















Consumption of BSE 
contaminated food 
(Bruce et al., 1997, 















(Will et al., 1996) 
Kuru Ritual cannibalism (Gajdusek & Zigas, 
1957) 
* review  (Wadsworth 





Classical scrapie is an infectious TSE of sheep and goats (Parry, 1962). The disease 
is endemic in many countries with the exception of New Zealand and Australia 
which are thought to be free of classical scrapie. In the United Kingdom, scrapie is a 
notifiable disease. Since 1993 any animal suspected of having scrapie must be 
reported to the local Animal Health Divisional Office (AHDO). Sheep that are 
positive for scrapie must be culled, as the disease could spread to other sheep within 
the flock. 
  
Clinical signs that are observed in scrapie infected sheep and goats include increased 
excitability, aggression, depression, incoordination, skin irritation, weight loss and 
eventually death (McGowan, 1922, Parry, 1962, Wood et al., 1992, Capucchio et al., 
2001, Houston & Gravenor, 2003). Post-mortem histopathological examination of 
the CNS of scrapie infected sheep shows astrocytosis, neurodegeneration with 
vacuolation of neurones and spongiform changes, which are characteristic of TSEs 
(Bruce & Fraser, 1975, Jeffrey & Gonzalez, 2007). Like for all TSEs there are no 
pre-mortem diagnostic tests available for scrapie, so detection is usually carried out 
on post-mortem tissue. PrP
Sc 
is detected from tissue by immunohistochemistry (IHC) 
or Western blot after treatment with proteinase K. Proteinase K is added to the tissue 
prior to immunodetection as this protease degrades the normal PrP protein (PrP
C
) 




Scrapie was first experimentally transmitted to sheep by intra-ocular administration 
of a scrapie infected brain homogenate Cuille & Chelle (1939). Since then scrapie 
has been successfully experimentally transmitted to sheep, goats, cattle, mice, rats 
and hamsters. In sheep the route of transmission for natural scrapie is unclear, both 
horizontal (between sheep) (Brotherston et al., 1968) and vertical transmission 
(between ewe and the lamb) (Dickinson et al., 1974) have been suggested. 
 
Evidence for horizontal transmission comes from studies that show that healthy 
“scrapie free” sheep can develop disease when they are housed in contact with 
scrapie infected sheep (Foster et al., 2006). Earliest evidence for vertical 
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transmission comes from Dickinson et al., (1965) who observed that lambs born 
from infected ewes were more likely to develop disease than lambs born to non-
infected mothers. More recent embryo transfer studies have shown vertical 
transmission in sheep; those results however did not allow an assessment of the 
efficiency of this mode of transmission (Foster et al., 1992, Wang et al., 2001, 
Wrathall et al., 2008). 
 
Oral route of transmission has been favoured as the main candidate in natural scrapie 
cases (Kimberlin & Walker, 1989a) although scrapie can also be transmitted through 
skin abrasions (Taylor et al., 1996) and through infected milk (Konold et al., 2008). 
Other routes of transmission may also be possible. For e.g. transmission may occur 
through the environment by soil contaminated with infected urine (Seeger et al., 
2005, Siso et al., 2006, Andrievskaia et al., 2008) or faeces (Georgsson et al., 2006, 
Johnson et al., 2006). Evidence of scrapie infection in the placenta has also been 
investigated (Race et al., 1998). Most recently scrapie infection has been shown to 
occur after infected donor blood has been transfused to an uninfected animal 
(Houston et al., 2008, Siso et al., 2010). 
 
1.1.3 Atypical scrapie 
The first cases of atypical scrapie were identified in Norway in 1998 (Benestad et al., 
2003). These cases were distinct from classical scrapie and were designated Nor98. 
The most common clinical sign in atypical scrapie is ataxia (Benestad et al., 2003). 
Vacuolation and PrP
Sc 
deposition is found more commonly within the cerebellar 
region of the brain (Benestad et al., 2003, Hunter, 2007, Nentwig et al., 2007). 
Atypical scrapie is also distinct from classical scrapie when PrP
Sc
 is analysed by 
Western blot (Figure 1.2).  
 
Atypical scrapie has been successfully transmitted to sheep (Simmons et al., 2007) 
and transgenic (Tg) mice (Tg 338) that over-express ovine PrP
C
 (Le Dur et al., 
2005), providing evidence that atypical scrapie is a true prion disease. It has been 
proposed that atypical scrapie may be a sporadic disease as these cases occur in small 
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numbers within sheep flocks with no indication of horizontal or vertical transmission 















Figure 1.2 Expected Western blot PrP
Sc
 banding patterns and molecular weight 
distribution in classical and atypical scrapie 
Approximation of molecular weight for classical and atypical scrapie with PK treatment on 
SDS PAGE.  For classical scrapie without treatment with PK the di-glycosylated protein is 
detectable at 35-36 kDa, monoglycosylated protein at 30-32 kDa and unglycosylated protein 
at 25-27 kDa. For classical scrapie with treatment with PK the di-glycosylated protein is 
detectable at 26-30 kDa, mono-glycosylated protein at 23-25 kDa and unglycosylated protein 
at 20-22 kDa. Atypical forms have also been reported to have additional bands at 12 kDa 
















1.1.4 TSE and ovine PrP polymorphisms 
A major factor that has been associated with susceptibility to TSE disease is PRNP 
genetics. The most common type of polymorphism found in PRNP is the single 
nucleotide polymorphism (SNP). SNPs can produce either a missense mutation 
(amino acid replaced with a different amino acid) or a silent mutation (amino acid 
remains the same). The other type of polymorphisms found in PrP are insertions or 
deletions within the octapeptide repeat region of the N-terminal domain of PrP. In 
most species there are five copies of an eight amino acid sequence PHGGGWGQ 
(octapeptide). However, in ruminants this number can vary between three and seven 
copies (Goldmann et al., 1991b,1998, Schlapfer et al., 1999).  
 
Polymorphisms located at 136 [valine (V) or alanine (A)], 154 [arginine (R) or 
histidine (H)] and 171 [glutamine (Q), (H) or (R)] are associated with susceptibility 
or resistance to natural and experimental scrapie (classical scrapie) (Figure 1.3) and 
produce five common alleles: ARR, ARQ, AHQ, ARH and VRQ.  
 
Evidence for a linkage between codon 136 and disease susceptibility was discovered 
after sheep carrying the valine allele at codon 136 were experimentally challenged 
with scrapie (Goldmann et al., 1991a). Following inoculation with scrapie brain 
homogenate SSBP/1, homozygous animals for V136 had a mean incubation period 
of 168 days compared to a mean incubation period of 309 days for heterozygous 
animals V136/A136 and A136/A136 sheep survived. Further evidence for a linkage 
between codon 136 and scrapie disease susceptibility came from epidemiological 
data from France that showed that all scrapie infected sheep from IIe-de-France and 
Romanov breeds were either homozygous for valine at 136 (V136/V136) or 
heterozygous for valine at 136 (V136/A136) (Laplanche et al., 1993).  
 
To add complexity to the situation, some breeds which only carry the A136 allele i.e. 
Suffolk sheep are highly susceptible to scrapie (Westaway et al., 1994b). Therefore 
A136 appears only to provide partial resistance against scrapie and other factors such 
as breed of sheep and strain of scrapie may influence the effects of PRNP genotype 
on scrapie susceptibility or resistance (Goldmann et al., 1994). In terms of disease 
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the most susceptible genotype to classical scrapie is therefore VRQ/VRQ and the 
most resistant to classical scrapie is ARR/ARR (Belt et al., 1995, Hunter et al., 
1996).  
 
The genetics of sheep with atypical scrapie are different from the genetics of sheep 
with classical scrapie. Atypical scrapie cases tend to have genotypes that are 
associated with resistance to classical scrapie. An association at codon 141 has also 
been found in these cases, with phenylalanine (F) more commonly found than 
leucine (L) (Moum et al., 2005). 
 
Scrapie is not a genetic disease as susceptible genotypes are found in sheep in 
Australia and New Zealand that are free from scrapie (Hunter et al., 1997, Bossers et 
al., 1999). Also the ARR/ARR homozygotes that are resistant to classical scrapie are 
susceptible to intracerebral (i.c.) inoculation of BSE (Houston et al., 2003) and sheep 
with susceptible genotypes living in the UK that are reared in clean “scrapie free 
environments” do not succumb to disease (Foster et al., 2006). Heterozygote animals 
from different breeds also have varying incubation periods (Houston et al., 2002a) 
which suggests that other factors must be involved in disease susceptibility. One of 
these factors could be the age of the animal as natural infection with scrapie is 
thought to occur mainly in young sheep (St Rose et al., 2007). The biochemistry of 
the prion protein such as its proteolytic processing could also play a role (Refer to 
1.4.7 for further details).  
 
1.1.5 The National Scrapie Plan 
In an attempt to control scrapie within the UK sheep population the British 
Government established the National Scrapie Plan (NSP) in 2001 with an aim to 
reduce and eventually eradicate scrapie from the national sheep flock by breeding for 
genetic resistance (DEFRA, 2007). In 2004 the compulsory scrapie flocks scheme 
was also set up following EU legislation. The National Scrapie Plan was to “initially 
concentrate on promoting the use of the ARR gene and excluding the VRQ gene and 
allow the continued use of sheep with the AHQ, ARQ and ARH genes for a limited 
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period”. However, a potential problem has arisen in the past ten years in the form of 
atypical scrapie that affects animals that are more resistant to classical scrapie. 
 
The NSP and the EU regulations have been successful in that the number of VRQ 
allele carriers has been reduced significantly. Arnold et al., 2002, Tongue et al., 
2008, Melchior et al., 2010, Hagenaars et al., 2010. The breeding schemes in the UK 




Figure 1.3 Ovine genotypes with different levels of susceptibility to classical scrapie 
Polymorphisms in the coding region of PrP have an effect on the susceptibility to scrapie. 
Animals most susceptible to classical scrapie are homozygous for VRQ and animals most 








































1.1.6 TSE strains and the species barrier 
Many isolates from naturally occurring scrapie cases in sheep and goats have been 
passaged into inbred mice. From these passages approximately twenty different 
strains of scrapie have been identified (Kimberlin et al., 1989). Each new scrapie 
strain shows unique clinical presentation, neuropathology, PrP
Sc
 deposition pattern, 
PrP
Sc
 glycoform pattern or incubation period (Fraser & Dickinson, 1967, Somerville, 
1999). The pattern of vacuolation within the brain of scrapie infected mice can also 
be used to distinguish between scrapie strains. Brain areas are scored according to 
the severity and distribution of the vacuolation and the values are plotted on a graph 
to form a lesion profile (Fraser & Dickinson, 1968, Bruce & Fraser, 1991). 
 
Some strains can be distinguished by differential PrP glycosylation which gives rise 
to different glycoform patterns, when observed on SDS-PAGE (Parchi et al., 1996). 
However, two strains or isolates can have identical glycoform patterns. For example 
the scrapie isolates CH1641 and BSE have been found to have similar banding 
patterns (Hope et al., 1999, Baron et al., 2000). These two isolates can be 
distinguished using Immunohistochemistry (IHC), as PrP
Sc
 staining is intracellular in 
CH1641 and extracellular in BSE (Jeffrey et al., 2006). PrP
Sc
 deposition in the CNS 
and lympho-reticular system (LRS) of classical scrapie and atypical scrapie also 
differs. In classical scrapie, PrP
Sc
 deposition is located in the LRS as well as the CNS 
whereas in atypical scrapie PrP
Sc 
is mainly confined to the CNS (Benestad et al., 
2003).  
 
Inter-species susceptibility to TSE disease is dependent on many factors including 
route of inoculation, dose of inoculum, genetic factors but it also appears to be 
dependent on the sequence homology between species (Scott et al., 1993). 
Transmission of prion infection from one species to another is generally inefficient 
and is usually accompanied by long incubation periods in the initial passage; this 
effect is known as the species barrier. In some cases this barrier can be overcome by 
secondary passage into the same species, this usually results in shortened incubation 
periods (Pattison, 1966, Dickinson, 1976). The species barrier can also be overcome 
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through the use of transgenic mice that express the PrP transgene identical to the 
infected donor. For example wild type mice are resistant to TSE disease after 
challenge with hamster scrapie, while transgenic mice that express hamster PrP are 
susceptible to this challenge (Scott et al., 1989,1993, Race et al., 1995). This 
indicates that the primary sequence is important in the susceptibility to TSE disease.  
 
In some cases the species barrier is breached; this has been shown in the ability of 
BSE to infect cats (Wells et al., 1987, Wyatt et al., 1991) and humans (Will et al., 
1996). The bank vole is an unusual model as it appears to be susceptible to many 
TSEs even when there is low PrP sequence homology between the species (Cartoni 
et al., 2005, Nonno et al., 2006, Agrimi et al., 2008). In other cases it may not be 
possible for the species barrier to be crossed; for example there have been no 
reported cases of sheep scrapie transmission to humans or any reports of TSE disease 
in dogs.  
 
1.1.7 TSE pathogenesis  
The site of entry, accumulation and replication of the prion agent within the body 
appears to vary between species (Mabbott & MacPherson, 2006). Most natural TSE 
diseases are thought to occur following exposure to an infectious agent. In sheep 
infected with classical scrapie, PrP
Sc
 usually accumulates and replicates within the 
LRS (van Keulen et al., 1996, Andreoletti et al., 2000) before spreading to the CNS. 
As PrP
C
 is expressed widely throughout the body this protein does not produce a 
specific immunological response to the TSE agent (Porter et al., 1973). However, 
activation of microglial cells and astrocytes has been observed during the disease 
process (Prusiner, 1994, Crozet et al., 2008). 
 
In classical scrapie cases PrP
Sc
 has been detected in gut associated lymphoid tissues 
(GALT) and Peyer’s patches (van Keulen et al., 1996, Andreoletti et al., 2000) as 
well as central nervous tissue. Soon after experimental inoculation with scrapie, there 
is rapid accumulation of PrP
Sc
 in the spleen which is detectable weeks or even 
months before detection of PrP
Sc
 in the CNS. Studies have shown that the peripheral 
 
 14
system plays an important role in the pathogenesis of some TSEs as the removal of 
the Peyer’s patches and the spleen in mice infected with the scrapie agent increases 
the incubation period and the time which it takes infectivity to reach the CNS (Fraser 
& Dickinson, 1970, Prinz et al., 2003). 
 
Scrapie susceptibility is also reduced in B cell deficient mice and in severe combined 
immunodeficient mice (SCID) that lack T and B lymphocytes (Fraser et al., 1996) as 
well as follicular dendritic cells (FDCs) (Brown et al., 1999). SCID mice are 
resistant to scrapie infection following peripheral exposure to low doses of inoculum, 
however grafting of bone marrow from wild type donors restores susceptibility to 
disease. It has been shown that early accumulation of PrP
Sc 
occurs on FDCs (Brown 
et al., 1999, Mabbott et al., 2000) which normally expresses high levels of PrP
C
 on 
their cell surface (McBride et al., 1992, Mabbott et al., 2000). 
 
However, not all TSE diseases accumulate PrP
Sc
 within the LRS: for example, PrP
Sc
 
in cattle BSE appears to be confined to the CNS (Terry et al., 2003, Iwata et al., 
2006, van Keulen et al., 2008). This indicates that the TSE agent is able to bypass the 
LRS on the way to the CNS. The most direct route for this would be through the 
peripheral nerves (Beekes & McBride, 2007). Once the agent reaches the CNS it 
appears to target neurones and in particular the GABAergic neurones (Guentchev et 
al., 1998). Generally the most commonly observed neuronal changes associated with 
TSE disease are loss of synapses, dendritic atrophy and neuronal loss (Giese et al., 
1995, Lucassen et al., 1995, Williams et al., 1997, Fraser, 2002, Unterberger et al., 
2005, Kovacs & Budka, 2008). 
 
1.1.8 The effect of age on TSE susceptibility 
The effect of age on TSE susceptibility was first noted when neonatal mice were 
found to be partially resistant to peripheral infection with doses that normally 
produced disease in adult mice. The incubation period of the neonatal mice that did 
succumb to disease was also longer than adult mice (Outram et al., 1973, Ierna et al., 
2006). The reason behind this age phenomenon was attributed to lack of spleen 




Susceptibility to TSE disease in other species also appears to be age dependent, for 
example most cattle that developed BSE were infected as calves (Arnold & 
Wilesmith, 2004) and young lambs have been shown to be more susceptible than 
adults to natural infection with scrapie (Elsen et al., 1999). An age related 
susceptibilities also appears to be important in vCJD as clinical disease occurs 
predominantly in young adults (Ghani et al., 2003) although the reasons behind this 
are unknown. 
 
As animals age there is a dramatic decline in immune function, this is partially due to 
a reduction in T cell production which makes older animals more susceptible to 
infection with various diseases. (Maue, 2008). However, in terms of TSE disease it 
has been shown that sheep first exposed to infection at an older age are less 
susceptible to scrapie than animals infected at early ages (Matthews et al., 2001, 
Diaz et al., 2005, St Rose et al., 2007). It has been shown by Brown et al., (2009) 
that there is a decline in the follicular dendritic network in aged mice, which impairs 
TSE accumulation and neuroinvasion. None of the mice in this study developed 
clinical TSE disease although histopathological signs of the disease were observed in 
the brains of these animals (Brown et al., 2009). If this phenomenon occurs in 
humans then this might explain why vCJD has not been observed in older adults who 
were exposed to BSE by dietary route. These studies collectively illustrate that the 
age of the animal is an important factor in TSE susceptibility. 
 
1.2 The TSE agent 
 
1.2.1 Identifying and understanding the infectious agent 
One of the most debated areas of TSE research is identifying and understanding the 
infectious agent that causes disease. TSE diseases were initially thought to involve a 
slow virus (Sigurdsson et al., 1957, Hadlow, 1959) because of the long incubation 
periods associated with the agent. However, studies carried out by Alper et al., 
(1966, 1967) showed that the scrapie agent was extremely resistant to treatments that 
normally destroy nucleic acids, including UV and ionizing radiation and that the 
molecular weight necessary for infectivity was so small that it excluded any known 
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viruses. The work by Griffith, (1967) suggested that the TSE agent could consist 
solely of a protein. This idea was supported by observations that showed that the 
agent was sensitive to treatments that denature and degrade proteins (Bolton et al., 
1982, McKinley et al., 1983). From these experiments two hypotheses were 
produced to explain the nature of the infectious agent.  
 
1.2.2 The prion hypothesis 
In 1982 Prusiner hypothesised that the infectious agent that causes scrapie consists of 
a novel class of particles which he termed prion (proteinaceous infectious particles) 
(Prusiner, 1992). This hypothesis was based on experimental work (Bolton et al., 
1982, Prusiner, 1982) that involved the purification and isolation of a partially 
protease resistant protein from the brains of scrapie-infected hamsters. The protein 




 for scrapie). PrP
Sc
 is thought to be the 




co-purifies with infectivity. However, there have been individual cases where PrP
Sc
 
has been present with no infectivity (Piccardo et al., 2007) and cases where PrP
Sc
 has 
been absent in the presence of infectivity (Lasmezas et al., 1997).  
 
The prion hypothesis also does not fully explain why PrP
Sc
 with identical primary 
sequence can give rise to different agent strains, for example the mouse ME7, 22A 
and 22C (Kimberlin et al., 1989). These reproducible and inherited characteristics 
are conventionally thought to be the preserve of a nucleic acid as different strains of 
bacteria and viruses arise due to variability in their nucleic acid genomes. To 
overcome the issues of reproducible TSE strains it has been suggested that PrP
Sc
 
from different strains may exist in different conformations (Prusiner, 1998) that can 
replicate using host PrP
C
 (Soto & Castilla, 2004). 
 
To confirm whether the prion protein is essential for scrapie transmission transgenic 
mice were created that did not express the PrP protein (Prn-p
0/0
). When these mice 
were challenged with scrapie they did not succumb to disease and appeared to 
develop normally with no apparent phenotype. When transgenic mice that expressed 
only one copy of the PrP gene (Prn-p
0/+
) were challenged with scrapie they showed 
 
 17
an increase in incubation period compared to wild type mice (Manson et al., 1994, 
Weissmann et al., 1994). These experiments do not prove that PrP alone is sufficient 
for TSE development, only that it is necessary for disease propagation and 
infectivity. When PrP is over-expressed the incubation time decreases and there is 
increased PrP
Sc
 formation (Prusiner et al., 1990,1998). Certain mutations in the PrP 
gene are linked to inherited forms of prion disease, which also provides support for 
the role of PrP
Sc
 in disease pathogenesis (Soto & Castilla, 2004). Other evidence in 
support for the prion hypothesis is that prions created in vitro can be infectious when 
used in vivo (Legname et al., 2004, Castilla et al., 2005). 
 
1.2.3 The virino hypothesis 
The virino hypothesis speculates that the infectious agent consists of an 
informational component (i.e. nucleic acid) which may interact or be coated with a 
host-encoded protein; most likely to be PrP
C 
(Dickinson & Outram, 1988, Farquhar 
et al., 1998, Aguzzi et al., 2007). This host encoded protein would allow the 
informational component to reside undetected by the host immune system; this 
would help explain why there is a lack of immunological response to TSEs. The 
existence of a nucleic acid would help explain the existence of TSE strains as viral 
nucleic acids can carry strain specific information (Dickinson & Outram, 1988). 
Viral like structures have been found in TSE affected brains (Diringer et al., 1997) 
but to date no evidence of a nucleic acid has been found, although this may be 
because the molecule involved is too small to be detected (Bruce & Dickinson, 
1987). In conclusion, both the prion hypothesis and the virino hypothesis do not fully 
explain the nature of the TSE agent although the prion hypothesis is more universally 
accepted. 
 
1.2.4 Conversion models 




 based on the  
prion hypothesis; the refolding model (Prusiner, 1991) and the nucleated 
polymerisation seeding model (Come et al., 1993, Jarrett & Lansbury, 1993). The 





 are in equilibrium with each other, with PrP
C
 being the most 
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abundant. Aggregates of PrP
Sc 
can break off which can facilitate the seeding of more 
PrP
Sc
. The conformational model proposes that PrP
C
 interaction with PrP
Sc
 triggers 






 has interacted with PrP
C





 by an unknown mechanism that creates a continuous 
chain reaction.  
 




 has been demonstrated in vitro (Kocisko et 
al., 1994, Caughey et al., 1995, Castilla et al., 2005) which provides some evidence 
that information may be transmitted by molecules other than nucleic acid; this 
provides support for the prion hypothesis. Early studies showed that PrP
Sc
 
synthesised in vitro was not infectious or transmissible (Caughey et al., 1995, Hill et 
al., 1999). However, Castilla et al., (2005) showed that they were able to transmit 
scrapie to hamsters by inoculation of in vitro generated forms of the infectious 
protein through the PMCA method using PrP
Sc
 as a seed for the conversion reaction. 
It has been shown that additional co-factors such as RNA and proteoglycan 




 (Deleault et al., 2003, 
2007). 
 
1.2.5 Protein misfolding cyclic amplification (PMCA) and the quaking 
induced conversion assay (QUIC) 
The protein misfolding cyclic amplification method was developed by Saborio et al., 
(2001) with the aim of accelerating prion replication in vitro. The PMCA reaction is 
a cyclic process composed of two phases. During phase one, the sample which 
contains small amounts of PrP
Sc
 and large amounts of PrP
C
 are incubated together to 
form PrP
Sc
 polymers. During the second phase, sonication is used to break the newly 
formed polymers into smaller pieces to increase the number of particles for the next 




 (Saa et al., 2006; Soto et al., 2002). It has been 
shown that the addition of proteoglycans and RNA in the PMCA reaction can 
increase prion protein conversion (Delaut et al., 2003). 
 
Another method that has been developed with the aim of amplifying infectious PrP
Sc 
is the quaking induced conversion assay (QUIC) (Atarashi et al., 2007). In this assay 
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recombinant (rPrP) is used as a substrate for amplifying PrP
Sc
 and instead of 
sonication, automated tube shaking is used to induce conversion. The QUIC assay 
has been able to detect PrP
Sc
 amplification at similar levels to the PMCA assay but 
with more sensitivity and faster output than the PMCA method (Atarashi et al., 
2007). As there is currently no pre-diagnostic test available for the detection of PrP
Sc
 
either of these assays could be used to detect small amounts of infectivity that may 
be present in sub-clinical individuals who want to donate blood. However, as the test 
may take many hours to run both the PMCA and QUIC method would be no good 
for mass screening.  
 
1.3 The mammalian prion protein family 
 
1.3.1 Ovine PRNP Gene Structure  
The normal cellular PrP protein (PrP
C
) and the disease associated form (PrP
Sc
) are 
transcribed from the same gene (Goldmann, 1993); this gene is known as the PrP 
gene (PRNP). These two forms of the proteins therefore have the same primary 
amino acid sequence. The length of PRNP is approximately 21 kb and depending 
upon the species the PRNP gene contains either two or three exons, of which a single 
exon codes for the prion protein (Oesch et al., 1985, Baylis & Goldmann, 2004, 
Michalczyk & Ziman, 2007). For all species, the open reading frame (ORF) is found 
on the last exon of PRNP.  
 
Ovine PRNP transcripts are produced as both a 4.6 kb and a 2.1 kb mRNA. The 4.6 
kb transcript is found predominantly within the brain whereas both transcripts are 
found at approximately equal levels in the spleen. The smaller sheep transcript is the 
result of an alternative polyadenylation signal within the 3’ UTR (Goldmann et al., 
1999). The PRNP promoter region has four conserved sequence motifs (Westaway et 




1.3.2 PRNP gene expression 
PrP
C
 is critical to TSE development with high levels of expression in the brain, 
intermediate levels in the peripheral tissues and lowest levels found in the liver 
where PrP expression is almost undetectable. The PrP
C
 protein is widely expressed in 
a range of cell types including neurones (Kretzschmar et al., 1986, Moya et al., 2000, 
Mironov et al., 2003), glial cells (Moser et al., 1995) and FDCs (Bruce et al., 2000, 
Mabbott & Bruce, 2001,Glatzel et al., 2004).  
 
During scrapie infection PRNP mRNA levels have been shown to increase in certain 
PRNP genotypes after infection with scrapie (Austbo et al., 2007). This group also 
showed that PrP mRNA levels within the ileal Peyer’s patch follicles increase in 
susceptible VRQ lambs but not in lambs with more resistant genotypes after oral 
inoculation with scrapie. The expression of PrP
C
 within different blood components  
in sheep is also highest in VRQ homozygotes and lowest in ARR homozygotes 
(Halliday et al., 2005). These results indicate that an increase in mRNA levels may 
be linked to scrapie susceptibility, although an increase in PRNP mRNA levels is not 
always indicative of an increase in protein expression. In comparison a recent study 
by Gossner et al., (2009) showed that PrP transcripts did not increase after scrapie 
infection. This group also confirmed that expression levels of PrP transcripts 
appeared to be influenced by PRNP genotype although VRQ animals did not have 
the highest levels of PrP expression after inoculation with SSBP/1. If incubation 
periods are affected by PrP expression levels then individuals who become infected 
with low levels of PrP expression may have extended incubation periods and vice 
versa. 
 
1.3.3 PrP paralogues 
Several other genes belong to the prion gene family; the first of these genes is Prnd 
which produces a protein called Doppel (Dpl). Dpl lacks an octapeptide repeat 
domain but has similarity to the C-terminal domain of PrP. Prnd shares with Prnp a 
similar genomic structure. Prnd is normally expressed in the testis (Silverman et al., 
2000, Mo et al., 2001) and heart but not in the brain (Moore et al., 1999). In one PrP 
null mouse line with deletions in the ORF and flanking region, mice developed a 
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syndrome characterised by ataxia, Purkinje cell degeneration and cerebellar atrophy 
(Sakaguchi et al., 1996). The cause of this syndrome was due to a splicing event that 
allowed Prnd to be under the control of the Prnp promoter (Sakaguchi et al., 1996, 
Moore & Melton, 1997) this consequently caused inappropriate expression of Prnd 
in the brain. By reintroducing the Prnp transgene this syndrome was reversed. A 
study by Tuzi et al., (2002) concluded that Dpl was unlikely to be involved in 
naturally occurring TSEs as it did not appear to influence TSE disease in their 
transgenic mouse models.  
 
Another gene that belongs to the prion gene family is Sprn which produces a protein 
called shadoo (Sho). The gene Sprn is found in zebrafish, humans and many other 
mammalian species. Like Prnp, Sprn encodes the entire open reading frame within 
one exon. Sho demonstrates a number of biochemical and cell biological properties 
which are similarly displayed in PrP
C
. These include N-glycosylation, the addition of 
a GPI-anchor and a cleavage event that results in the formation of truncated 
fragments (Watts et al., 2007). These truncated fragments have yet to be identified in 
vivo. The hydrophobic region of PrP and Sho is well conserved amongst species and 
may provide an important functional role for the protein.  
 
Sho is thought to provide neuroprotection within the brain and is known to protect 
neuronal cells from the neurotoxic effects of Dpl and various deleted forms of PrP 
(Watts et al., 2007, Gossner et al., 2009). PrP and Sho also share an alanine rich 
sequence within their hydrophobic region (Figure 1.4). Like PrP, Sho is also 
expressed in the brain but unlike PrP Sho is expressed at very low levels in 
peripheral tissues (Watts et al., 2007, Gossner et al., 2009).  
 
As Sho is a newly discovered member of the prion family there is little information 
about whether it may play a role in TSE susceptibility, although this is highly likely 
based on a CJD study by Beck et al., (2008). It has been suggested that Sho may 
interact directly with PrP, this has been shown in co-immunoprecipitation 
experiments (Jiayu et al., 2009) but it is unknown whether this interaction occurs in 




           PrP 
          KPSKPKTNMKHVAGAAAAGAVVGGLGGVMLGSAMSRP 
                            
  RVRPVRPAPRYAGSSVRVAAAGAAAGAAAGVAAGLAAGS 
           Sho 
 
Figure 1.4 Comparison of the hydrophobic region of PrP and Sho proteins 
Codons 104-140 of PrP and codons 45-83 of Sho are shown. The bold area highlights the 
alanine/glycine rich region of the hydrophobic region. 
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1.4 The normal prion protein, PrPC 
 
1.4.1 PrPC function 
PrP
C
 is thought to be involved in many cellular processes, although the major 
function of PrP
C 
remains to be clarified. As most PrP
C
 is located on the cell surface it 
may be involved in synaptic function (Collinge et al., 1994, Manson et al., 1995) cell 
signalling , cell adhesion or uptake of ligands (Collinge, 2001). PrP null mice (Prnp 
0/0
) that do not express PrP showed no gross abnormal phenotype (Bueler et al., 
1992, Manson et al., 1994). In later studies it was shown that PrP null mice show 
signs of altered circadian rhythms, abnormal sleep patterns and electrophysiological 
abnormalities in synaptic function (Collinge et al., 1994, Tobler et al., 1996, Huber 
et al., 2002, Fuhrmann et al., 2006, Powell et al., 2008, Le Pichon et al., 2009,  
Singh et al., 2009). Loss of sleep is also associated with human FFI (Lugaresi et al., 
1998) which suggests that certain areas of the brain associated with circadian 






has been shown to bind copper within the octapeptide repeat region in vivo 
(Brown et al., 1997, Kramer et al., 2001). Copper binding studies have also been 
carried out with synthetic peptides (Hornshaw et al., 1995) and with recombinant PrP 
(Stockel et al., 1998). These studies suggest that PrP may function as a copper 
transport protein for the internalisation of copper ions (Pauly & Harris, 1998) or it 
may be involved in the cellular response to oxidative stress (Wong et al., 2000, 
Legname et al., 2004) as it has been suggested to have an antioxidant activity similar 
to superoxide dismutase (SOD) (Brown et al., 1999). Copper has also been shown to 




 (Liu et al., 2008) when it is present 
at low pH conditions. PrP knockout mice have lower levels of Zn/Cu superoxide 
dismutase activity than wild type mice, therefore they are unable to accumulate and 
bind as much copper as PrP expressing mice. Cultured cells derived from PrP-null 





 is also thought to be neuroprotective and is known to protect against 
proapoptotic stimuli and plays a role in cellular antioxidative defence (Klamt et al., 
2001, Rachidi et al., 2003). Evidence for this neuroprotective function comes from in  
vivo studies of transgenic mice with internal deletions mutants in PrP and PrP null 
mice. It has also been reported that PrP is up regulated in response to ischemic brain 
injury (Weise et al., 2004, Mitsios et al., 2007) and that over-expression of PrP can 
reduce this ischemic injury (Shyu et al., 2005), this also supports the role of PrP in 
neuroprotection. 
 
1.4.2 PrPC Trafficking and synthesis 
After transcription and processing, mature messenger RNA (mRNA) is exported out 
of the nucleus into the cytoplasm. In the cytoplasm, mRNA binds to ribosomes on 
the rough endoplasmic reticulum (ER) where it is translated into protein. Within the 
ER, cleavage of the prion protein signal peptide occurs as well as correct folding of 
the protein (Figure 1.5). Also within the ER, PrP
C
 can be synthesised into three 
topologies, two transmembrane forms and secreted full-length PrP
C
 which follows 
the main synthesis pathway.  
 
From the ER reticulum, PrP
C
 is transported to the Golgi. Within the Golgi several 
post-translational modifications take place including the addition of a glycosyl 
phosphatidylinositol (GPI) anchor which is modified with the addition of a sialic acid 
residue and alterations of the N-linked oligosaccharide chains (Stahl et al., 1990). 
Alpha cleavage of the prion protein is thought to occur as PrP
C
 cycles between 
intracellular compartments (possibly the Golgi) and the cell surface. C1 and N1 
fragments, produced by alpaha cleavage are transported to the cell surface. The C1 
fragment remains attached to the membrane whereas the N1 fragment is released into 
the cell medium.  
 
At the cell surface PrP
C
 is localised in detergent insoluble microdomains (DIMs) 
which contain cholesterol and glycoshpingolipids (Sarnataro et al., 2004). When 
PrP
C
 is located on these cholesterol-rich domains it interacts with the laminin 
receptor precursor (LRP) where it undergoes copper mediated endocytosis via a 
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clathrin coated pit. In addition copper sulphated glycans may also induce 
internalisation of PrP
C
 (Collins et al., 2004, Campana et al., 2005). Certain studies 
have suggested that the C-terminal signal sequence may help target the proteins to 
caveolae-like domains within the cell membrane (Harmey et al., 1995, Kaneko et al., 
1997, Peters et al., 2003). Cell culture studies have shown that PrP
C 
is endocytosed 
with a half life of twenty minutes taking approximately 60 minutes to travel between 
the cell surface and the endocytic compartments (Shyng et al., 1993) 
 
On the cell surface -cleavage can occur in response to oxidative stress and produces 
two fragments termed C2 and N2. The majority of cellular PrP
C
 (>95%) is recycled 
as full-length protein, a percentage undergoes endoproteolytic cleavage at both N and 
C terminals, and the rest of the protein is degraded. Cleavage of the GPI anchor also 
takes place. Following cleavage of the GPI anchor some of the membrane bound 
PrP
C
 is released into the extracellular medium (Shyng et al., 1993). Finally, 
degradation of PrP
C
 is thought to take place via the endoplasmic reticulum associated 
degradation (ERAD) proteasome pathway (Yedidia et al., 2001). A small fraction of 
PrP
C
 is thought to be degraded by lysosomes while the large fraction of PrP
C
 is 
recycled back to the cell surface.  During this recycling some PrP
C
 may also be 







Figure 1.5  General trafficking of PrPC (© Lehmann et al., 1999) 
After transcription and processing, mature messenger RNA is exported out of the nucleus 
into the cytoplasm. Mature messenger RNA then binds to ribosomes on the rough 
endoplasmic reticulum where it is translated into protein. In the ER the prion protein signal 
peptide is cleave and correct folding of the protein takes place.Transmembrane forms of 
PrP
C
 are also synthesised within the ER. From the ER reticulum PrP
C
 is transported to the 
Golgi. Within the gogli several post-translational modifications take place including the 
addition of a glycosylphosphatidylinositol (GPI) anchor which is modified with the addition of 
a sialic acid residues and alterations of the N-linked oligosaccharide chains. Full-length PrP
C
 
can be cleaved within the Golgi (a process called alpha cleavage). The products of this 
cleavage C1 and N1 are transported to the cell surface where C1 remains anchored and N1 
secreted from the cell. PrP
C
 is integrated into detergent insoluble microdomains (DIM) and 
sorted. PrP
C
 is then transported to the cell membrane where it is located on cholesterol rich 
lipid rafts where it interacts with receptors and copper where it undergoes endocytosis. Once 
PrP
C




Many cell surface glycoproteins have N-linked glycans which are important for 
protein structure and cellular trafficking (Lowe & Marth, 2003). The prion protein 
contains two sites for N-glycosylation these sites are located at amino acids 180 and 
196 in mice (Oesch et al., 1985, Cancellotti et al., 2005). The glycosylation sites 
within the C-terminal domain produce on Western blots three bands of apparent 
molecular mass between 33 and 35 kDa (Oesch et al., 1985). These three bands are 
interpreted as di-glycosylated PrP (when a carbohydrate is attached to both 
glycosylation sites), mono-glycosylated (when a carbohydrate is attached to either 
glycosylation sites) and unglycosylated PrP. 
 
Three lines of gene targeted mice have been produced in which the glycosylation 
sites have been mutated (Cancellotti et al., 2005, Tuzi et al., 2008). These three lines 
of mice are referred to as G1 (N180T), G2 (N196T) and G3 (N180T-N196T) 
(mutations shown in bold letters, numbering refers to murine PrP). G1 and G2 mice 
lack diglycosylated PrP but express mono and unglycosylated PrP whereas G3 mice 
only express the unglycosylated form of PrP (Cancellotti et al., 2005). In vivo 
analysis of these mice show that the lack of glycans do not influence stability and 
maturation of PrP however trafficking of PrP
C
 in the G3 mice appears to be impaired 
as most PrP was intracellular in these mice. As PrP in G1 and G2 mice were 
localised to the cell membrane the authors concluded that that only one sugar is 
required for correct cellular trafficking (Cancellotti et al., 2005). Interestingly, the 
G3 mice did not show any overt phenotype with impaired trafficking. Overall, these 
results suggest that disease susceptibility may only be partially dependent on 
glycosylation.   
 
1.4.4 Proteolytic processing of the Alzheimer precursor protein (APP) 
In recent years there has been a rising interest in the possibility of an association 
between TSE disease and Alzheimer’s disease (Senior, 2000, Checler & Vincent, 
2002, Hooper & Turner, 2008). In both situations abnormal misfolding of a protein 
leads to neurodegeneration. TSE disease is transmissible to humans and animals; to 
date there is no evidence that Alzheimer’s disease is infectious (Godec et al., 1994).  
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Alzheimer’s disease is characterised by the presence of amyloid fibrils, senile 
plaques and neurofibrillary tangles. In Alzheimer’s disease the release of the A 
peptide is crucial for the development of Alzheimer’s disease (Hooper & Turner, 
2008). The proteolytic processing of the APP is thought to occur by  and  
secretases within the amyloidogenic pathway which results in the release of the toxic 
A peptide. Alternative non-amyloidogenic proteolytic processing occurs within the 
toxic A domain of APP which inhibits the production of A. This alternative 
cleavage is thought to occur through the action of ADAM (a desintegrin and 
metalloprotease) proteases.  
 
Proteolytic processing of the prion protein also occurs within a toxic domain (For 
further details refer to 1.4.7). Cleavage within the PrP toxic domain produces two 
fragments N1 and C1 and is thought to involve some of the ADAM proteases that are 
involved in the release of APP (Vincent et al., 2001). Under pathological conditions 
both APP and PrP
C 
undergo alternative cleavage events which leave the toxic 
domains intact (Chen et al., 1995, Vassar, 2001, Checler & Vincent, 2002). The 
enhancement of these ADAM proteases could therefore provide a therapeutic target 
for the Alzheimer’s and TSE disease.  
 
1.4.5 Transgenic mouse models 
Although mice are not a natural host for scrapie, they have been used extensively as 
a model for TSE pathogenesis to expand our knowledge about PrP expression and 
disease progression. The benefits of PrP transgenesis was observed when mice 
expressing Syrian hamster PrP were rendered susceptible to the 237K hamster 
adapted scrapie strain, in which wild-type counterparts were resistant (Scott et al., 
1989). Since this discovery, mice transgenic for the PRNP gene of many different 
species have been created. Ovine PrP transgenic mice are much easier to maintain 
and manage than ruminants and have contributed to the current understanding of 
natural scrapie and atypical scrapie. These ovine PrP transgenic mice are more 
accurate for studying sheep scrapie pathogenesis than wild type mice as issues such 
as strain adaptation (Priola, 1999) or failure to elicit a disease response (Hunter, 
1997) have been overcome with the introduction of the ovine PRNP sequence. For 
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example, it has been shown that transgenic mice that over-express ovine PrP
C
 are 
more susceptible to disease than transgenic mice that over-express murine PrP
C 
(Vilotte et al., 2001). This indicates that transgenic mice that express ovine PrP
C
 may 
be a more useful model for studying the effects of natural scrapie.  
 
In some transgenic models over-expression of the PrP transgene leads to a 
neurodegenerative disease. In many over-expressing transgenic mouse models 
shortened incubation times are observed after inoculation with scrapie. For example, 
TgOvPrP4 mice that express 2-4 fold more PrP compared to a normal sheep have 
significantly shorter incubation periods compared to wild type mice. Shortened 
incubation periods were thought to result from a combination of PrP
C 
over-
expression and a reduced species barrier (Crozet et al., 2001). 
 
Transgenic mice have also been created that express various truncated forms of PrP 
(Table 1.2).  Mice with deletions at residues 32-121, 32-134 (Shmerling et al., 1998), 
94-134 (Baumann et al., 2007), and 105-125 (Li et al., 2007)  went on to develop a 
neurodegenerative condition whereas mice with deletions at residues 32-80, 32-93, 
32-106 (Shmerling et al., 1998), 108-121 (Muramoto et al., 1997) and 114-121 
(Baumann et al., 2007) did not develop disease. The area of PrP within the central 
domain of PrP appears to be crucial for disease development in these mice. 
 
Within the central domain of PrP, proteolyitc cleavage of the murine protein occurs 
at codons 111/112 (alpha cleavage), this produces two truncated fragments termed 
C1 and N1. In all of the mice with deletions that went on to develop disease the alpha 
cleavage site was also disrupted except for deletion 108-121 and in mice that did not 
develop disease the alpha cleavage site was intact. This suggests that the function of 
this cleavage event may be important factor in neuroprotection. (This is discussed in 
relation to PrP in 1.4.7). With the introduction of the wild type PrP gene the 
symptoms of these animals were reversed. This evidence supports the idea that PrP
C
 
provides a protective role against neurodegeneration.  
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In another study Muramoto et al., (1997) showed that mice with deletions within the 
alpha helix region of PrP (177-190 and 201-217)  went on to develop a neurological 
disease. This region of PrP may be critical for correct conformation of the prion  
protein. These mice showed different clinical phenotypes to mice that had deletions 
within the central domain of PrP (Table 1.2). 
  
In conclusion, studies that have used deleted forms of PrP (Muramoto et al., 1997, 
Shmerling et al., 1998, Baumann et al., 2007, Li et al., 2007) have shown that 
particular areas of the prion protein appear to be critical in maintaining essential 




Table 1.2 Effects of deletions within PrP (adapted from Linden et al., 2008) 





 No Not  required 
32 - 93
1
 No Not required 
32 - 106
1
 No Not required 
32 - 121
1
 Yes-demyelination and axonal loss 




 Yes-demyelination and axonal loss 












Yes- cerebral atrophy death within 1 
month of birth 




 No Not required 
114 – 121
2
 No Not required 
177 – 200
4




Yes – extensive nerve cell loss in 
CA1 of hippocampus 
Not carried out in study 
 
1
(Shmerling et al., 1998) 
2
(Baumann et al., 2007) 
3
(Li et al., 2007) 
4
 (Muramoto et al., 1997) 
Deletion mutants of PrP and the phenotypes that are produced are shown above. If there is 
any neurodegeneration associated with these mutants reintroduction of wild type PrP 




1.4.6 Transmembrane forms of PrP 
Several alternative forms of PrP
C
 distinct from GPI-anchored PrP
C
 and disease 
associated PrP
Sc
 have also been proposed as key pathogenic entities in prion disease 







PrP) which span the membrane at amino acids 113-135 in the 
area termed transmembrane region or TM1 (Brockes, 1999). The C-terminus of 
Ctm
PrP and the N-terminus of 
Ntm
PrP is situated within the ER lumen (Hegde et al., 
1998b, Stewart & Harris, 2001). However, in it has been shown that 
Ctm
PrP does not 
remain in the ER and localises to the Golgi (Stewart & Harris, 2005).  
 
Transmembrane forms of PrP are thought to arise when PrP signals fail to initiate 
translocation (Ranee et al., 2010). This results in either the release of cytosolic PrP, 




PrP depending on the 
orientation in the ER lumen. The synthesis of these transmembrane forms within the 
ER is dependent on prion protein sequence 104-135, as it has been shown that 
mutations, deletions and insertions within this region can alter the amount of 
transmembrane PrP that is synthesised (Hedge et al., 1998).  
 
Ctm
PrP has been implicated in prion disease pathogenesis as transgenic mice 
expressing 
Ctm
PrP mutations develop a spontaneous neurodegenerative illness similar 
to prion disease but without detectable levels of PrP
Sc
 (Hegde et al., 1998a, Stewart 
& Harris, 2005) and it is usually not transmissible (Hegde et al., 1998b). An increase  
of 
Ctm
PrP has also been observed in some patients with the A117V mutation in GSS 
disease and in mice expressing a PrP transgene with the A117V mutation (Hegde et 
al., 1998a, Stewart & Harris, 2001). 
 
1.4.7 PrPC cleavage 
PrP
C 
usually exists as a membrane attached glycoprotein but minor fragmentss can 
span the membrane and be released as soluble PrP
C
. During post-translational 
modification of the protein, specific cleavage (alpha cleavage) of full-length PrP 
occurs within the hydrophobic “toxic” region (106-126) of the prion protein, C-
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terminal to amino acid 115 (Chen et al., 1995, Mange et al., 2004, Tveit et al., 2005). 
PrP 106-126 is rich in beta sheet structure, forms aggregates that are detergent-
insoluble and PK resistant and is toxic to primary cultures of Neurones (Ettaiche et 
al., 2000, Haik et al., 2000). 
 
Alpha cleavage of the prion protein can substantially reduce the level of full-length 
prion protein and generates PrP fragments with a molecular mass of 9 kDa (N1) and 
18 kDa (C1), respectively (Harris et al., 1993, Chen et al., 1995, Jimenez-Huete et 
al., 1998) (Figure 1.6 and 1.7). The C1 fragment is attached to the plasma membrane 
via a GPI anchor whilst the N1 fragment is realeased from the membrane by 
shedding (Vincent et al., 2000). Both fragments appear to have some function in 
normal cell biology, which is not fully understood (Haigh et al., 2010). Their 
involvement in scrapie disease is also still unclear. It is possible that alpha cleavage 
can reduce the amount of available PrP
C
 for conversion to PrP
Sc 




 in cultured cells indicates that PrP
C
 undergoes cleavage as part 
of its normal metabolism (Mange et al., 2004) and that the processing of PrP
C
 
appears to take place as it cycles between the plasma membrane and endosomal 
compartment (Harris, 1999, Mange et al., 2004, Tveit et al., 2005). This endosomal 





(Caughey et al., 1991, Borchelt et al., 1992 Harris, 1999). Recently, it has been 
shown that the generation of the truncated fragment C1 occurs in a late compartment 
of the secretory pathway and is independent of lipid rafts (Walmsley et al., 2009) as 
blocking exit of proteins from the endoplasmic reticulum reduced the amount of C1 
fragment produced. 
 
The precise nature of how PrP
C 
is processed is not fully understood. ADAM10 and 
ADAM17 (TNF-alpha converting enzyme), members of the ADAM family of cell 
surface disintegrin and metalloprotease proteins are linked to the formation of 
truncated PrP fragments (Vincent et al., 2001) as ADAM 10 and ADAM17 inhibitors 
result in a reduction of the N1 fragment (Alfa Cisse et al., 2008). However a paper 





 in vitro (Endres et al., 2009), this suggests that other factors must be 
involved in this cleavage process. ADAM 9 has been suggested as a candidate for 
alpha cleavage but requires ADAM 10 to activate its -secretase activity (Cisse et 
al., 2005). Most recently ADAM 23 has been shown to interact and co-localise with 






Figure 1.6 The different catabolites of PrP 
A) PrP after the cleavage of the N- terminus, with the addition of two glycosylation sites and 
attached to the membrane by a GPI anchor. The molecular weight of this form of PrP is 33-
35 kDa B) C1 catobolite that is produced after cleavage at amino acid 115 in relation to ovine 
PrP. This catobolite has a molecular weight of 18 kDa. C) The N1 catobolite that is produced 
after cleavage at amino acid 115. This catobolite has a molecular weight of 9 kDa. D) C2 
catobolite that is produced after cleavage within the octapeptide region of PrP at 
approximately amino acid 89 after exposure to ROS. The molecular weight of the C2 
catobolite is 21 kDa. E) PrP
Sc 
after digestion with PK. This form of PrP has a molecular 
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Catabolites of PrP may have functional importance within the brain as the C1 
fragment has been shown to be pro-apoptotic (Sunyach et al., 2007) which is 
contradictory to the function of the N1 fragment which has been shown to down 
regulate p53 transcription and protects cells against caspase-3 activation (Guillot-
Sestier et al., 2009). This suggests that under normal circumstances the N1 fragment 
is likely to be dominant and may represent the neuroprotection function associated 
with PrP
C
. It can be hypothesised that under disease situations the C1 fragment 
becomes dominant and activates pro-apoptotic stimuli that lead to neuronal death 
within the brain. An alternative hypothesis would be that alpha cleavage results in 
loss of neuroprotective function as full-length PrP
C
 itself is reduced. At the moment 
these theories are yet to be investigated.  
 
PrP can also be alternatively cleaved within the octapeptide region (- cleavage) to 
generate a 21kDa C-terminal fragment (C2) and corresponding N-terminal fragment 
(N2) (Caughey et al., 1989, Chen et al., 1995, Parchi et al., 1999, Mange et al., 2004 
Watt et al., 2005).  In vitro -cleavage takes place after exposure to reactive oxygen 
species (ROS) in the presence of a copper ion (McMahon et al., 2001, Watt et al., 
2005). The C2 and N2 fragments do not appear to have any effect on the p53 
pathway and show no pro-apoptotic or anti-apoptotic functions which have been 
associated with C1 and N1. It is possible that C2 and N2 could be potential 
neurotoxic intermediates in prion conversion as these fragments are not commonly 
observed under normal circumstances. 
 
Similar size fragments have also been generated by the action of calpains (Yadavalli 
et al., 2004, Watt et al., 2005). As well as C1, C2 and corresponding N1 and N2 
different sized fragments have been found in human brain (Gatti et al., 2002, Pan et 
al., 2002). Similar small fragmentss have been detected in ovine brain, epididymal 
fluid and milk (Pan et al., 2002, Maddison et al., 2007, Didier et al., 2008). The 
functions of these additional catabolites have not be investigated and it is unknown if 




It is important to gain an understanding of PrP
 
shedding and cleavage from the cell 
surface as increased shedding of the prion protein may reduce the amount of protein 




(Parkin et al., 2004, Walmsley et al., 
2009). The hydrophobic region has been shown to be neurotoxic in vitro and in vivo 
(Bergstrom et al., 2005, Fioriti et al., 2005) and is dependent on the presence of the 
palindrome sequence which is located at amino acid 116-123 in ovine PrP (Figure 
1.4) (Jobling et al., 1999). Without the palindrome sequence PrP
C
 may not be 
converted into PrP
Sc 
(Norstrom & Mastrianni, 2005). If the central region of PrP is 
indeed essential for conversion then  cleavage of PrP could be an important 
mechanism in disrupting this process.  
 
The proteolytic processing of PrP
C
 and the formation of C1 has been investigated 
previously in vivo and in vitro. These studies were carried out on ovine PrP
C 
(Kuczius et al., 2007a) bovine PrP
C 
(Kuczius et al., 2007a) human PrP
C
 (Chen et al., 
1995, Jimenez-Huete et al., 1998, Laffont-Proust et al., 2006, Kuczius et al., 2007a, 
Kuczius et al., 2007b) porcine PrP
C
 (Nieznanski et al., 2005) and murine PrP
C  
(Laffont-Proust et al., 2005, Kuczius et al., 2007a). 
 
In some of these studies the percentage of C1 observed was highly variabale between 
individual animals of the same species (Jimenez-Huete et al., 1998, Laffont-Proust et 
al., 2005). The percentage of C1 was also reported to vary between different species, 
for example Laffont-Proust et al., (2006) reported that the percentage of C1 differed 
between primates and rodents with higher signal intensities of C1 in primates. In a 
seperate study by Kuczius et al., (2007a) the signal intensity of C1 was higher than 
full-length PrP in sheep, human and cattle but mice showed dominance for full-
length PrP. The presence of -cleavage products has not yet been demonstrated for 
peripheral tissue, possibly because the total level of PrP is considerably lower than in 
brain.  
 
Overall these studies show that C1 is produced in substantial amounts in the brains of 
many species. However, the function of this proteolytic event and the role this has on 














Figure 1.7 Different PrP catabolites and their apparent molecular weight in SDS PAGE 
Approximation of molecular weight for the different fragmentss of PrP. PrP
Sc
 with PK the di-
glycosylated protein is detectable at 26-29 kDa, mono-glycosylated protein at 23-25 kDa and 
unglycosylated protein at 20-22 kDa. PrP
C
 the di-glycosylated protein is detectable at 33-
35kDa, mono- glycosylated protein at 26-29 kDa and unglycosylated protein at 23-25 kDa. 
The C1 fragment is glycosylated; diglycosylated C1 migrates at 23-25 kDa, 
monoglycosylated C1 at 20-22 kDa and unglycosylated C1 at 18 kDa. The corresponding N1 
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To investigate the role of alpha cleavage in scrapie disease susceptibility.   
 
1.5.1 Hypotheses 
a) The total amount of full-length PrP
C
 in sheep brain is associated with differences 
in scrapie susceptibility and incubation periods. 
 
b) The total amount of the C1 fragment in sheep brain is associated with differences 
in scrapie susceptibility and incubation periods. 
 
c) The ratio between full-length PrP
C
 and C1 is important in scrapie disease 
susceptibility or resistance. 
 
1.5.3 Main Objective 
 
1) Is the amount of C1 associated with polymorphisms located at codons 136, 
154 and 171? 
C1 as a percentage of total PrP
C
 was measured in the brains of healthy sheep with 
scrapie susceptible and resistant PRNP genotypes at codons 136, 154 and 171.  
 
1.5.4 Subsidiary objectives 
 
1) Is the degree of alpha cleavage affected by brain area/ and or age? 
As PrP
Sc
 accumulates at different levels in different brain areas it was investigated 
whether the degree of alpha cleavage is affected by brain area and/or age. C1 as a 
percentage of total PrP
C
 was measured in four different brain areas. The amount of 





2) How accurately do PrP transgenic mouse models reflect the level of alpha 
cleavage observed in sheep brain? 
PrP transgenic mice are often used as alternative TSE models to replace experimental 
challenges of ruminants, but it remains to be shown that PrP is processed in these 
mice similarly to sheep. To investigate whether and to what level PrP is cleaved in 
PrP transgenic mice, 10 different mouse lines were analysed. (Nine transgenic and 
one control non-transgenic). These transgenic mice expressed murine, ovine or 
bovine PrP at different expression levels. 
 
3) Does alpha cleavage occur at significant levels in peripheral ovine tissues to 
affect susceptibility to scrapie?  
Animals are most likely exposed to the infectious prion agent through the peripheral 
route which implies that processing of PrP in peripheral tissue can have a significant 
effect on susceptibility, but it remains to be established if alpha cleavage is active in 
the periphery. Methods were examined to analyse the low levels of PrP in sheep 
lymph nodes and spleen.  
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Chapter 2 Material and methods 
All chemical are from BDH unless otherwise stated. All experiments were carried 
out at room temperature unless otherwise stated. 
 
2.1 Methods for protein analysis 
 
2.1.1 Preparation of sheep and mouse brain homogenate 
100 mg of brain tissue was homogenized in 1 ml of lysis buffer (50 ml of Phosphate 
buffered saline (PBS) pH 7.5 [Oxoid] in 100 mls of dH2O, containing 0.25 g sodium 
deoxycholate (0.5%) and 250 l of  (5%) non ident (NP40) [Sigma] ) to give a 10% 
(w/v) homogenate. Samples were centrifuged at 1000 x g for 10 minutes at 4°C. 
Supernatants were frozen in liquid N2 (LN2) and stored at -70°C. 10 l of 100 mM 
phenylmethylsulfonyl fluoride (PMSF) [Sigma] and 100 mM N- 
ethylmaleimide (NEM) [Sigma] were added to prevent the generation of degradation 
products. 
 
2.1.2 Sucrose gradient of brain homogenate 
100 mg of brain tissue was homogenized in 1 ml of buffer A (10.95 g sucrose in 50 
ml dH2O containing 10 ml 10 mM MgCl2, 5 ml 20 mM NaHCO3 and 2.5 ml 20 mM 
KCl) pH 7.5. 57.5 l of 100 mM PMSF [Sigma] and 12 l of 100 mM Dithiothreitol 
(DTT) were added. Samples were centrifuged at 3000 x g for 10 minutes at 4°C. The 
pellet was then resuspended in 0.8 ml of buffer A and centrifuged at 3000 x g for 10 
minutes at 4°C. Supernatants were overlayed onto a 0.4 ml 0.85 M sucrose gradient. 
Samples were centrifuged at 100,000 x g for 1 hour at 4°C. Supernatants were frozen 
in LN2 and stored at -70°C. 
 
Sucrose gradients are used to separate particles of different densities. In the above 
case a density barrier was used where the sample was overlayed on top of the 
sucrose. Therefore, the heavier more dense macromolecules migrated to the bottom 
of the tube faster than the lighter material. The lighter material stayed at the interface 
of the sucrose bed and the heavy material was pelleted at the bottom of the tube. 
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What components sediment out or stay at the interface will depend on the 
concentration of the sucrose bed.  
 
2.1.3 Total protein estimation – the bicinchoninic acid (BCA) assay 
Total protein estimation was carried out following the microwell plate protocol of a 
BCA protein assay kit [Pierce]. The BCA assay detects cuprous ions generated from 
cupric ions by reacting with protein in the samples under alkaline conditions. To a 3 
l aliquot of brain homogenate  57 l of lysis buffer (PBS [Oxoid], containing 0.5% 
sodium deoxycholate and 0.5% of NP40) was added, i.e. 1:20 dilution of original 
homogenate. A range BSA standards [Pierce] were prepared following the BCA 
protocol (2.1.3 and Table 2.1) using the lysis buffer as a diluent. 25 l of each 
standard and diluted sample were added in duplicate to wells of a 96 well microplate. 
The BCA working reagent was prepared by combining BCA reagents A and B 
[Pierce] in a ratio 50:1. 200 l of this working reagent was added to the standards 
and diluted samples. The working reagent was also used as the negative control 
blank. The microplate was incubated at 37°C for 30 minutes and then cooled to room 
temperature (RT). The samples and standards were read and analysed on a molecular 
devices v-max microplate reader. Absorbance was read at 570 nm and from the 
standards a sample curve was produced. Protein concentrations for each sample were 
derived from the Bovine serum albumin (BSA) standard curve.  
  
Table 2.1 Dilution scheme for standard test tube protocol and microplate procedure  
Vial Volume of diluent Volume of BSA 
Final BSA 
concentration 
A 125 l 375 l stock 1500 g/ml 
B 325 l 325 l stock 1000 g/ml 
C 175 l 175 l of vial A 750 g/ml 
D 325 l 325 l stock of vial B 500 g/ml 
E 325 l 325 l stock of vial D 250 g/ml 
F 325 l 325 l stock of vial E 125 g/ml 




2.1.4 Protein deglycosylation 
25 l of 10% (w/v) sheep brain homogenate was denatured in 1 x glycoprotein 
denaturing buffer [0.5%) sodium dodecylsulphate (SDS), (1%) -mercaptoethanol] 
by boiling at 100°C for 10 minutes. Samples were incubated with 1000 U/ml of 
peptide N-glycosidase F (PNGase F) [New England Biolabs] in 50 mM NaPO4, pH 
7.5 (1 x G7 reaction buffer, New England Biolabs) with 1% NP40 [New England 
Biolabs] at 37°C for 2 hours, according to the manufacturer’s instructions. 200 µl of 
methanol and 100 µl of chloroform were then added to the sample reaction before 
centrifugation at 2000 x g for 10 minutes. The reaction was stopped by freezing at -
20°C or by SDS denaturation at 100°C. When samples were ready to be used for 
SDS gel electrophoresis (2.1.6) they were centrifuged at 13000 x g, supernatants 
were discarded and pellets resuspended in 25 l of 4 x laemmli (LDS) sample buffer 
[Invitrogen]. 
 
2.1.5 Proteinase K digestion of brain homogenate 
0.5 µl of Proteinase K was added from a stock solution of 5 mg/ml (100 mM Tris-
HCl, 1 mM CaCl2, pH 7) to 20 µl of a 10% (w/v) sheep brain homogenated prepared 
in NP-40 lysis buffer and incubated for 1 hour at  37°C. 
 
2.1.6 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Principles of SDS Gel electrophoresis 
Native polyacrylamide gel electrophoresis is used to separate individual proteins by 
size, shape and charge. PAGE can also be performed under denaturing conditions in 
the presence of Sodium Dodecyl Sulfate (SDS-PAGE) or under reducing and 
denaturing conditions in the presence of DTT or beta mercaptoethanol. Prior to SDS-
PAGE the protein is denatured by heating the sample in the presence of a detergent 
containing SDS. SDS denatures secondary and tertiary structures and applies a 
negative charge to each protein in proportion to its mass. Protein samples 
fractionated by denaturing SDS-PAGE are therefore resolved according to their 
molecular weight regardless of charge. 
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When mixtures of proteins are loaded onto a gel and an electric current applied, 
smaller proteins migrate faster than larger proteins through the gel. The rate of 
movement is influence by the gel’s pore size and the strength of the electric field.  
Pores in polyacrylamide gels are quite small therefore only small proteins and 
peptides are able to pass through. 
 
Prior to electrophoresis brain tissue samples were deglycosylated (2.1.4) and 
incubated in 4 x LDS sample buffer (final concentration glycerol 10%, Tris 157 mM, 
lithium dodecyl sulphate 2%, Ethylenediaminetetracetic acid (EDTA) 0.51 mM, 
SERVA Blue
®
 G250 0.22 mM, Phenol Red 0.175 mM pH 8.5,  [Invitrogen] for 10 
minutes at 100°C. Proteins were then separated on the basis of molecular weight by 
gel electrophoresis at 150V for 1 hour using Novex 12% Bis-Tris Gels 1.0 mm 
[Invitrogen] in NuPAGE
® 
1 x MES SDS running buffer (MES 50 mM pH 7.2, Tris 
50 mM, SDS 0.1%, EDTA 1 mM, [Invitrogen]). Lysis buffer (2.1.1) and NuPAGE 
LDS 4 x sample buffer were used as negative controls. SeeBlue [Invitrogen] and 
magic-marker [Invitrogen] were used as molecular weight markers. 
 
2.1.7 Western blot 
 
Principles of the Western blot 
Transfer of the proteins fractionated by SDS-PAGE to a solid support membrane can 
be achieved by electroblotting using semi dry or tank transfer systems. In this assay a 
sandwich of gel and a solid support membrane (nitrocellulose or polyvinylidine 
fluoride (PVDF) is compressed in a cassette and immersed in buffer between two 
parallel electrodes. A current is passed through the gel, which causes the separated 
proteins to electrophorese out of the gel and onto the solid support membrane PVDF. 
The efficiency with which proteins transfer to the blot is dependent on the protein 
binding capacity of the membrane used and the transfer method. While SDS is 
required to facilitate migration of the protein out of the gel in response to an electric 




Once the proteins have been transferred to the solid support membrane it is essential 
that the membrane is blocked prior to the addition of the primary antibody. A 
blocking agent such as BSA or dried milk powder in PBS, will inhibit remaining 
hydrophobic binding sites on the membrane and will consequently reduce 
background and prevent binding of the primary antibody to the membrane itself. 
After blocking the membrane, the primary antibody can be added for 1 hour at 37°C 
or overnight at 4°C with gentle agitation. The time of incubation will vary for 
different antibodies. Following incubation of the primary antibody, the blot is 
washed in wash buffer containing PBS with the addition of Tween 20 before addition 
of a secondary labelled antibody.  
 
The method of detection is dependent upon the label that has been conjugated to the 
secondary antibody. The most common antibody label used in Western blotting is an 
enzyme such as alkaline phosphatase or horseradish peroxidise. Chemiluminescent 
substrates are employed which emit light upon conversion by the enzyme. The light 
emitted at the site of substrate conversion can therefore be captured on x-ray film. 
 
2.1.7.1 Transfer of separated proteins to a membrane 
Proteins separated by SDS gel electrophoresis were transferred to PVDF membrane 
[Millipore] at 25V for 1 hour, using the NuPAGE transfer system, in 1 x NuPAGE 
transfer buffer [Invitrogen], final concentration, bicine 25 mM, Bis-Tris (free base) 
25 mM, EDTA 1.0 mM, chlorobutanol 0.05 mM) and 20% methanol [Fischer]. 
 
2.1.7.2 Detection of protein bound to a membrane 
To reduce unspecific binding of antibodies, membranes were blocked with 1% 
blocking solution [Roche Diagnostics] for 1 hour. Overnight incubation of the 
primary antibody was carried out in 0.5% blocking solution [Roche Diagnostics] at 
RT. Membranes were then washed 2 x 10 minutes with TBS and 1% Tween (TBST) 
and 2 x 10 minutes in 0.5% blocking solution [Roche Diagnostics]. Incubation of 
HRP-conjugated anti-mouse secondary antibody (0.08 g/ml) [Stratech] was carried 
out in 0.5% blocking solution [Roche Diagnostics] for 1 hour. Membranes were 
washed in TBST to remove excess secondary antibody prior to incubation with 
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chemiluminescent substrate [Roche Diagnostics] for 1 minute followed by exposure 
to Kodak XAR-5 film [Roche Diagnostics]. The film was developed for 1 minute, 3 
minutes and 10 minutes, respectively. 
 
2.1.7.3 Stripping of PVDF membrane 
To allow for re-probing of the PVDF membrane with a second antibody, blots were 
stripped with “restore stripping” solution [Thermo Scientific] by shaking overnight. 
Prior to reprobing blots were washed in TBS, TBST and 0.5% blocking solution 
[Roche Diagnostics] following instructions for (2.1.7.2).  
 
2.1.8 Coomassie stain of PVDF membrane 
To visually observe membrane bound proteins on a NuPAGE gel a Coomassie blue 
stain was performed. The gel was incubated for 1-2 hours in Coomassie brilliant blue 
stain (0.625 g coomassie blue, 125 mls methanol [Fischer], 23 mls acetic acid and 
102 mls of dH2O) either before or after transfer to the PVDF membrane. The gel was 
then incubated for 1-2 hours with destain solution (23% Ethanol, 7% acetic acid) 
with approximately 6 washes or left overnight if necessary.  
 
2.1.9 Testing Protein degradation kinetics  
300 mg of brain tissue was thawed and left in the fridge for 2, 24 and 48 hours 
without the presence of protease inhibitors. At the indicated time points 100 mg of 
the tissue was prepared as described in (2.1.1), sheep brain homogenate protocol. 
The sample was then deglycoslyated following the protein deglycosylation protocol 
(2.1.4). The sample was stored at -20°C ready for polyacrylamide gel electrophoresis 
(2.1.6). 
 
500 mg of brain tissue was thawed for 15 minutes. The sample was then refrozen at -
20°C for 1 hour. This process was repeated four times. 100 mg of tissue was then 
prepared following the sheep brain homogenate protocol (2.1.1). The sample was 
then deglycosylated following the protein deglycosylation protocol (2.1.4) and then 





Tissue homogenates (10% w/v) were prepared in extraction buffer (0.5% NP-40, 
0.5% sodium deoxycholate, PBS [Oxoid]), clarified by centrifugation (913 x g, 10 
minutes) and the supernatants collected. Aliquots (10 l) of tissue homogenate were 
mixed with 1 l of IgM MAb or 1 l of a non PrP related control IgM [Sigma] in 100 
l final volumes in PBS [Oxoid], and incubated on a rotary mixer overnight at 4°C. 
Rat anti-IgM conjugated dynabeads (10 l) [Invitrogen] were added to each sample 
and mixed on a rotary mixer for 60 minutes. Samples were placed in a magnetic rack 
to pull down the beads and the attached proteins. The beads were washed three times 
in PBS supplemented with 0.1% Tween, resuspended in 25 l 1 x NuPAGE LDS 
sample buffer (Invitrogen) and sonicated 3 x 30 seconds in a water bath. Each sample 
was then boiled for 10 minutes at 100°C. Electrophoresis and Western blotting were 
then performed as previously described (2.1.6-2.1.7.2).  
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2.1.11 Analysis of the amount of PrP in ovine brain tissue homogenate 
by dissociation enhanced lanthanide fluoroimmunoassay DELFIA® 
 
2.1.11.1 Preparation of brain homogenate for DELFIA® 
PrP
C 
was extracted from total protein brain homogenate (100 mg/ml) NP-40 lysis 
buffer, 1 M PMSF [Sigma] and 1 M NEM [Sigma] by mechanical homogenisation in 
2 M Gnd HCl [Sigma] and (0.5%) Triton X-100 [Sigma]. Brain homogenate was 
then diluted in DELFIA
®
 assay buffer [Perkin Elmer Life Sciences] leading to a final 
concentration equivalent to 10 mg/ml of original brain tissue. Proteins insoluble in 2 
M Gnd HCl (PrP
Sc
) were separated from those that were soluble (PrP
C
) by 
centrifugation at 12000 x g for 10 minutes. Pellets were resuspended in 6 M Gnd 
HCl prior to dilution in DELFIA
®
 assay buffer [Perkin Elmer Life Sciences] to a 
concentration equivalent to 10 mg/ml of original brain tissue.  
 
2.1.11.2 Preparation of recombinant PrP standard for DELFIA® 
Sheep recombinant PrP (Kind gift from Dr. Louise Kirby, Compton) was serially 
diluted 2 fold in DELFIA
® 
assay buffer [Perkin Elmer Life Sciences] (100 – 0.3905  
ng/ml) for use as a standard. All samples that were used in the DELFIA
® 
assay were 
within this range. 
 
2.1.11.3 Spectrophotomeric determination of recombinant PrP 
concentration 
Concentration of total protein in recombinant PrP was determined using 
spectrophotomeric analysis. In 1.5 ml eppendorfs, a 20 l aliquot of the recombinant 
protein was added to 200 l of dH2O (to give 1:10 dilution), and a 2 l aliquot of 
recombinant protein was added to 200 l of dH2O (to give 1:100 dilution). Samples 
were mixed well and transferred to a silica spectrophotometer cuvette [Sigma]. 
Absorbance at 280 nm and 320 nm was determined using a UV spectrophotometer.   
The following calculation was performed to determine the total protein concentration 
(mg/ml). The extinction Co-efficient for PrP is 57780.  
Absorbance (280-320) x Molecular Weight 
      Extinction Co-efficient (57780)                 =     protein concentration (mg/ml) 
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2.1.11.4 DELFIA® time-resolved fluorescence immunoassay 
Capture antibody FH11 (1 mg/ml) was bound to 96 well plates by overnight 
incubation at 4°C. Plates were then blocked with 2% (BSA) [Roche Diagnostics] in 
sterile 1 x PBS [Oxoid] with 3 M NaN3 (sodium-azide) for 1 hour with shaking. The 
block solution was discarded and the plate was incubated with samples and 
standards, shaking at for 1 hour. Samples and standards were discarded and the plate 
was incubated with europium (Eu
3+
) labelled detector antibody 8H4 (kind gift from 
Mr Declan King, Neuropathogenesis Division, Roslin Institute) shaking for 1 hour. 
The plate was then incubated with DELFIA
®
 enhancement solution [Perkin Elmer 
Life Sciences]. After shaking for 5 minutes Eu
3+
 emission was read (615 nm), using 
a time-resolved technique.  Between each step, the plate was washed in 1 x 
DELFIA
®
 wash concentrate [Perkin Elmer Life Sciences] using a DELFIA
®
 
automatic plate washer [Wallac]. The Wallac 1420 workstation [Wallac] was used to 
analyse absorbance from the standards and samples and to produce the standard 
curve.  
 
2.2 General methods for DNA analysis 
 
2.2.1 DNA extraction from sheep brain tissue 
DNA was extracted from sheep brain tissue using the following method. To a thin 
slice of tissue, 200 l of PBS [Oxoid], 200 l of tissue lysis buffer [Applied 
Biosystems] and 200 l of Proteinase K [Qiagen] was added and incubated overnight 
at 37°C. After overnight incubation 400 l of phenol and 400 l of chloroform was 
added and the sample centrifuged at 1200 x g for 3 minutes (This step was repeated 
twice). The aqueous phase was transferred to a fresh eppendorf in each case. 400 l 
of chloroform was added and the aqueous phase was transferred to a fresh eppendorf. 
To the aqueous phase 15 l of 3M NaAc pH 5.2 and 225 l of cold 100% ethanol 
[Fischer] was added. Samples were stored at -20°C for 30 minutes. The sample was 
then centrifuged at 1200 x g for 10 minutes and the supernatant discarded. 500 l of 
cold 75% ethanol [Fischer] was added to sample and the sample was centrifuged at 
1200 x g for 5 minutes. The supernatant was discarded and the pellet was left to air 




2.2.2 Spectrophotomeric determination of DNA sample concentration 
and purity 
DNA sample concentration was determined by spectrophotomeric analysis. 
Absorbance at 260 nm and 280 nm was determined using UV spectrophotometer 
(Beckman DU
® 
650). DNA Samples were diluted 1:40 prior to spectrophotometric 
analysis. DNA purity was determined by dividing the absorbance value at 260 nm by 
the value at 280 nm.  
 
2.2.3 Agarose gel electrophoresis  
DNA was separated by electrophoresis in a 1% agarose gel [Roche Diagnostics] with 
0.5µg/ml ethidium bromide [Sigma] for 1 hour at 120 V. A 1 Kb DNA ladder (12216 
– 75 base pair fragments); [New England Biolabs] was used as a size standard. A 
positive control and a negative control were loaded alongside experimental samples. 
The resulting DNA bands were visualised using UV light and photographed using 
video imager [Appligene].  
 
2.2.4 PCR of genomic sheep DNA  
The target region of the prion gene was amplified using the polymerase chain 
reaction (PCR)     
 
Sample mix per reaction: 
dH2O - 38.7 l 
X 10 reaction buffer [Applied biosystems] – 5 l 
dNTPs [Promega] - 0.4 l 




- 0.2 l 




- 0.2 l 
Taq polymerase [Invitrogen] – 2.5 l 







95°C 3 minutes: 1 cycle 
95°C 30 seconds: 40 cycles                                          
63°C 30 seconds: 40 cycles 
72°C 1 Minute: 40 cycles 
72°C 10 Minutes: 1 cycle 
Held at 4°C 
 
PCR conditions vary depending on the oligonucleotides that are being used. For each 
reaction a positive control (a sample known to contain amplifiable DNA) and a 
negative sample (dH2O) were added.  
 
2.2.5 Detection of the G1, G2, G3 mutant and wild type prnp alleles by 
PCR 
The presence of the G1 mutant allele was determined by mismatch PCR using an 
oligo specific for the G1 mutation. These mice express an alteration at codon 180 
(N180T), which disrupts N-linked glycosylation at this site. 
 
G1 mutant sample mix per reaction (50 l) 
H2O - 40.1 l 
PCR reaction buffer x 10 [Invitrogen] – 5 l 
10mM dNTPs [Promega] – 1 l 
50mM MgCl2 [Invitrogen] - 1.5 l 
Taq polymerase [Invitrogen] – 0.4 l 
G1 oligo mix - 1l of a 3 oligo mix [9910 (100 pmol/l), 9911 (100 pmol/l), 9912 
(100 pmol/l)] 





  5 
GCTGCTTGATGGTGATAG 
3 









G1 mutant PCR conditions: 
94°C 3 minutes: 1 cycle 
94°C 50 seconds: 35 cycles 
60°C 30 seconds: 35 cycles 
72°C 1 minute: 35 cycles 
72°C 10 minutes: 1 cycle 
Held at 4°C 
 
The presence of the G2 mutant allele was determined by mismatch PCR using an 
oligo specific for the G2 mutation. These mice express an alteration in codon 196 
(N196T), which disrupts N-linked glycosylation at these sites. The presence of the  
G3 mutant allele was also determined by mismatch PCR using an oligo specific for 
the G1 or G2 mutant allele. 
 
G2 mutant sample mix per reaction (50 l) 
H2O - 40.1 l 
PCR reaction buffer x 10 [Invitrogen] – 5 l 
10mM dNTPs [Promega] – 1 l 
50mM MgCl2 [Invitrogen] - 1.5 l 
Taq polymerase [Invitrogen] – 0.4 l 
G2 oligo mix – 1 l of a 3 oligo mix [9910 (100 pmol/l), 9912 (100 pmol/l), 9913 
(100 pmol/l) 
Oligo 9910 
  5 
AACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGG 
3 








DNA – 1 l 
 
G2 mutant PCR conditions: 
94°C 3 minutes: 1 cycle 
94°C 50 seconds: 30 cycles 
60°C 30 seconds: 30 cycles 
72°C 1 minute: 30 cycles 
 
 53
72°C 10 minutes: 1 cycle 
Held at 4°C 
 
The presence of the glycosylation wild-type allele for G1, G2 and G3 mice was 
determined by Mismatch PCR. PCR conditions were the same as for the G1 mutant 
allele. 
 
Glycosylation wild type sample mix per reaction (50 l) 
H2O - 40.1 l 
PCR reaction buffer x 10 [Invitrogen] – 5 l 
10mM dNTPs [Promega] – 1 l 
50mM MgCl2 [Invitrogen] - 1.5 l 
Taq polymerase [Invitrogen] – 0.4 l 
Oligos – 1 l 
Oligo 9910 
  5 
AACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGG 
3 








[9910 (100 pmol/l), G1-WT (100 





[9910 (100 pmol/l), G2-WT (100 
pmol/l), 9912 (100 pmol/l) 
DNA – 1 l 
 
2.2.6 Activated charcoal purification of PCR products 
0.8 g of activated charcoal [Sigma] was added to 5 ml of dH2O to make a PCR clean 
up mix. 15 l of the clean up mix was added to 40 l of the PCR reaction which was 
mixed gently and incubated at RT for 10 minutes. The PCR reaction was centrifuged 
at 12000 x g for 5 minutes to pellet the charcoal. 8 l of this cleaned up-amplified 




2.2.7 Sequence reaction 
  
Make up master mix as below. 
Sample mix per reaction: 
H2O – 12 l 
Big dye kit 3.1 [Applied biosystems] – 2 l 
X 5 buffer [Microzone limited] – 3 l 
Oligo 9612 [Sigma] 
5’ 
GGT GAA GTT CTC CCC CTT GGT
 3’ 
– 1 l 




– 1 l 
Purified PCR product – 2 l 
 
To a strip tube 2 l of purified PCR product and 18 l of sample reaction mix were 
added. The sequence reaction was carried out as below. 
 
PCR Sequence reaction conditions: 
96°C for 10 seconds – 25 cycles 
53°C for 15 seconds – 25 cycles 
60°C for 4 minutes – 25 cycles 
Held at 25°C  
 
To each sample 5 l of 125 mM EDTA and 60 l of 100% ethanol [Fischer] were 
added. Samples were mixed and left for 15 minutes. Samples were centrifuged at 
1400 x g for 30 minutes at 4°C and then centrifuged at 1000 x g at 4°C. To each 
sample 60 l of 70% ethanol [Fischer] were added and lightly mixed. Samples were 
centrifuged at 1400 x g for 15 minutes at 4°C.  Excess alcohol was removed and the 
samples centrifuged at 1000 x g at 4°C. Samples were left to air dry for 
approximately 30 minutes. 12 l of Hi-di formamide [Applied Biosystems] were 
added to each sample and lightly mixed. The samples were then centrifuged at 1000 
x g at 4°C. 12 l of each sample were loaded onto the Applied Biosystems 3130 
genetic analyser. Data was viewed and analysed using the Applied Biosystems 
sequencing analysis software version 5.2 and the software chromas lite V2.01 
[Technelysium Pty Ltd]. 
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2.3 Methods for monoclonal antibody production 
 
2.3.1 Preparation of R10 media 
To make R10 cell growth medium, 50 ml of foetal calf serum (FCS) and 15 ml of 
AB/AM (5 ml antimycotic solution, 5 mls L-glutamine and 5mls of sodium pyruvate) 
was added to 500 ml of  Rosewell Park Memorial Institute medium (RPMI) [Sigma]. 
When a new batch of medium was prepared, 2 ml of R10 medium was incubated at 
37°C in 5% CO2 for 24 hours to check for bacterial sterility. The remaining R10 
media was stored at 4°C.  
 
2.3.2 Retrieval of cells from LN2 storage 
A vial of the required cell line was removed from LN2 storage and defrosted in a 
37°C water bath for 5 minutes. Once the cells were defrosted they were immediately 
transferred to 10 ml of fresh R10 media. The solution was mixed briefly and 
centrifuged at 1000 x g for 5 minutes. The supernatant was decanted into a fresh 50 
ml centrifuge tube and stored at -40°C (2.3.6) and to the remaining pellet 5 ml of 
fresh warm R10 media was added. The pellet was gently resuspended in the media 
and transferred to a 25cm
2 
cell culture flask. Cell density was checked under the 
microscope and more R10 was added if the cells were covering more than 90% of the 
flask. The 25cm
2
 flask was placed in a 5% CO2 humidified incubator at 37°C and 
after several hours, cell density was checked under microscope. More R10 media 
was added if it was required. 
 
2.3.3 Single cell cloning by limiting dilution 
All reagents were warmed in a water bath, to 37°C before starting. Cells were 
detached from the surface of the well by pipetting the media thereby dislodging the 
cells. 10 l of cell suspension was mixed with 10 l of trypan blue. 10 l of this 1:1 
mix was pipetted under the coverslip of a haemocytometer and the number of cells in 
one of the large squares counted. The volume required to give 60 cells was calculated 
using the following equation: No. of cells x 10
4
/ ml. 100 l/well of the diluted cell 
suspension was added to the inner 60 wells of a 96 well plate. The 96 well plate was 
then incubated in a 37°C humidified incubator with 5% CO2 for 7 days. After this   
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time the colony growth was recorded and the cells were fed with 100 l of 20% FCS 
growth media and left to grow.  
 
2.3.4 Culturing of cells expressing IgM monoclonal antibodies H1.8, 
H3.2 and H3.3 
Cells were grown in R10 media RPMI (2.3.1) supplemented with 0.5 ml of mixed 
thymocyte media (MTM). Cells were incubated at 37°C with 5% CO2 in 225cm
2
 
flasks until confluency was reached. Cultured cells were fed approximately every 2 
days with fresh R10 media. Hybridoma cells were prepared for passage by diluting 
approximately 1:10 with fresh R10 media.  
 
2.3.5 Freezing down cell lines  
To preserve a cell line, cells which had grown in 75cm
2 
flasks were dislodged from 
the surface and centrifuged at 1000 x g for 5 minutes. Media supernatant was 
decanted into a fresh 50 ml centrifuge tube and stored at -40°C for screening and 
antibody purification. The remaining pellet was resuspended in 5 ml of freezing 
medium [90% FCS, 10% dimethyl sulfoxide (DMSO)]. 1 ml of the cell/freezing 
medium solution was transferred to an individual vial. Vials were stored in a 
Nalgene
®
 Cryol°C freezing container, filled with 250 mls of 100% isopropanol and 
stored at -80°C.  
 
2.3.6 Collection and Purification of monoclonal antibody rich media  
At any point during the expansion or freezing of the cell lines where media was taken 
off it was retained as antibody rich media and stored at -40°C. 
 
500ml of saturated ammonium sulphate solution was added to 500 ml of cell free 
culture supernatant and stirred for 60 minutes. The solution was centrifuged at 3300 
x g for 20 minutes. The supernatant was retained and the pellet resuspended in 30 ml 
of PBS [Oxoid]. The solution was concentrated down to a 1 ml final volume using a 
Biomax 50K NMWL 15 ml volume centrifugal filter device [Millipore]. The solution 
was centrifuged at 2000 x g until the desired 1ml final volume was achieved. 9 ml of 
PBS [Oxoid] was added to the centrifugal filer device and centrifuged to a 1 ml final 
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volume; this step was repeated two more times. Maltose (10% [w/v]) and sodium 
azide (0.001% [w/v]) were added to inhibit bacterial growth; the monoclonal 
antibodies (MAbs) were dispensed into 100 l aliquots and stored at -40°C.  
 
2.3.7 Isotyping of monoclonal antibodies 
Isotyping of MAbs was carried out using a mouse monoclonal antibody isotyping kit 
[Roche]. Following the manufacturer’s instructions 15 l of antibody containing 
media was diluted 1:10 with 10% FCS growth media (150 l final volume). This 
solution was added to the supplied development tube, which was agitated to 
resuspend the colour latex beads. The isotyping strip was the placed into solution. 
After approximately 5 minutes a blue band appeared on the strip to indicate the 
isotype of the MAb (Figure 2.1). 
 
 
                                          
 
Figure 2.1 Isotype result for H3.2 
Blue line indicates a positive result. When the control (+) turns blue this indicates that the 




2.3.8 Determinatation of MAb concentration by ELISA 
Principles of the ELISA technique 
The ELISA assay is used to determine the antigen concentration in unknown 
samples. To perform this assay one antibody (the capture antibody) is bound to the 
bottom of a plate well. The wells are then washed to remove any unbound antibody 
and blocked using an unspecific protein or protein mixture to prevent non-specific 
binding of the secondary antibody (the detector antibody). If the wells are not 
blocked then the secondary antibody may stick to non-specific proteins due to their 
charge. Common blocking agents used in the ELSIA assay include dried milk 
powder, bovine serum albumin and casein. 
 
After the blocking step antigen is added and allowed to form a complex with the 
bound antibody. Unbound products are then removed with a wash step and a labelled 
second antibody (the detector antibody) is allowed to bind to the antigen. The second 
antibody is modified to carry a reporter enzyme, such as horseradish peroxidase or 
alkaline phosphatase which is designed to form a colour change when the enzyme 
reacts with its substrate. The sample is then rinsed to remove any unbound 
antibodies. If the antigen is present, a complex will have formed that includes the 
antibody bound to the well, the antigen and the enzyme conjugated antibody. The 
enzyme’s substrate is then added. A colour change reveals the presence of enzyme-
labelled antibody as well as its bound antigen. No colour change indicates that the 
antigen was not present. The assay is then quantified by measuring the amount of 
labelled antibody bound to the matrix, through the use of a colorimetric substrate. 
 
2.3.8 Determination of MAb Concentration by ELISA 
Wells of a 96-well immunlon 4 HXB microtitre plate [Sigma] were coated with anti-
mouse IgM (-chain specific) capture antibody [Sigma], 100 ng/well in 
carbonate/bicarbonate coating buffer (0.318 g/L Na2CO3, 0.586 g/L NaHCO3, pH 
9.6) overnight at 4°C.  Wells were washed four times with PBS and 0.1% (w/v) 
Tween 20 (PBST) and bocked with PBS and 5% FCS at 37°C for 1 hour. Well were 
then washed four times with PBST. Ten-fold serial dilutions of the MAb (1:1000 to 
1:25600) and two-fold serial dilutions of the corresponding IgM control [Sigma], in 
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the range 200-0.78 ng/ml were prepared in dilution buffer. Aliquots (100 l) of each 
MAb and standard serial dilution were added to triplicate wells of an appropriately 
coated microtire plate, incubated 60 minutes, 37°C, washed four times with PBST, 
and blot dried. The ELISA was then processed using goat anti-mouse IgM 
horseradish peroxidise (HRP) conjugated secondary antibody [Sigma]. The mean 
absorbance 450 nm for each standard serial dilution was calculated, corrected by 
subtracting the mean blank absorbance 450 nm for the non-specific binding of the 
HRP conjugated secondary antibody, and plotted against antibody concentration to 
produce a standard curve. Using the corrected mean absorbance 450 nm obtained for 
each MAb serial dilution, the MAb concentration was then determined from the 
standard curve and multiplied by the dilution factor to give the actual MAb 
concentration.  
 
2.4 Computer based analyses 
 
2.4.1 Statistical analysis 
Measurement data are presented as mean ± standard deviation (S.D) or standard error 
of the mean (S.E). Any significant differences between samples in different groups 
were confirmed by REML (residual estimate maximum likelihood) analysis taking 
into account that various factors were unbalanced. REML analysis was carried out 
using the Genstat 10
th
 edition software. When values of 100% were included in the 
analysis a non-parametric sign test was used for statistical analysis. Values of P<0.05 
were accepted as significant.  
 
2.4.2 Statistical power 
Throughout this thesis it was difficult to collect a large number of samples. In some 
cases only two samples could be collected, this meant that the sample population was 
not large enough to carry out statistical analysis. If the sample size is large then the 
estimate of the population mean will be more precise and the statistical power will be 
high. If the sample size is small then the statistical power will be low. Throughout 
this thesis the sample size is relatively small which means that the statistical power is 





2.4.3 Semi Quantitative analysis of Western blots 
An equal amount of brain homogenate (i.e. 5 µl) was also loaded and a loading 
control (alpha tubulin) was sometimes used to observe whether equal amounts of 
protein had been loaded. This was particularly important when comparing bands for 
different brain areas. 
 
Western blot images were scanned using the Kodak MI image station. Using the 
Kodak MI software a region of interest was selected covering all parts of the film, 
the lanes and bands were automatically detected. Following band location and fitting, 
the Kodak MI software calculated the net intensity determined by the number and 
intensity of pixels within the band area. For each Western blot image three separate 
exposures were taken at 1, 3 and 10 minute intervals. In some cases direct exposure 
of the membrane onto the Kodak MI scanner was carried out, however as only some 
of the images were calculated using this method, only values calculated indirectly 
from the film have been included in this thesis.  
  
In most cases the signal was saturated at the 10 minute exposure, this was indicated 
on the Kodak MI software when the peak of the over exposed band would become 
flat.  This is indicated in Figure 2.2 where the peak for unglycosylated PrP is flatter 
compared to the peak for the C1 band. The Kodak MI software, in built program 
therefore gave an estimate of the maximum intensity.  In cases where the signal was 
saturated the values were not included in the statistical analysis. By ignoring the 
bands that were saturated it is possible that the amount of full-length PrP or C1 
calculated is an underestimate of the real value.  
 
The net intensity was used for quantitative analysis of the bands. In cases of 
incomplete deglycosylation, these bands were included in the analysis along with any 
other additional fragments of PrP. A ratio between total PrP 
C
 and C1 was therefore 
calculated. The molecular weight for each band was also calculated using the Kodak 






Figure 2.2 Densitometry profile of Western blot of unglycosylated PrP (Un PrP) and 
the C1 fragment from uninfected sheep 
Example of PrP and C1 detected using anti-PrP monoclonal 6H4. Intensity of anti-PrP signal 
displayed on y-axis, relative distance from the top of gel on the x-axis. Area highlighted in 
yellow, was used for quantification of full-length PrP to C1 ratio. In cases where the signal 
was saturated, values were not included in the analysis. 
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2.4.4 Preparation of gel figures and nomenclature 
Original Western blot images were transferred to Photoshop element 5.0 (Adobe, 
2006) and greyscale mode applied. Images were cropped and labelled using the 
photoshop software. Where obvious gaps exist between different images these were 
taken from different gels and grouped together or in some cases they were non-
continous gel images). No manipulation of the original images was carried out. 
 
To explain the different sheep PrP genotypes, amino acid residue numbers refer to 
the ovine PrP sequence for example.  
VLRQ is V136 L141 R154 Q171 and ALRR is A136 L141 R154 R171 with V = 
valine, L = leucine, R = arginine and Q = glutamine. In general amino acids are 
described in standard one-letter code. Ovine PrP alleles are also shown in three-
codon standard nomenclature, e.g. VRQ is V136 R154 Q171. Genotypes in turn are 





Mice were bred and housed at the Neuropathogenesis Division, Roslin Institute, 
Edinburgh. All animal breeding and experimental work was carried out under Home 
Office legislation and approved by the local Ethics Committee. All transgenic 
animals have been approved by the Health and Safety Executive. 
 
2.5.2 Sheep 
Sheep were from the NPU flock, Compton flock, VLA and Moredun Research 
Institute. 
Animals with the following genotypes were used: 
ALRR/ALRR n= 6,  
ALHQ/ALRR n= 5,  
ALRQ/ALRR n= 12,  
AFRQ/ALRR n= 1,  




VLRQ/VLRQ n = 10,  
ALRQ/ALRQ n= 9,  
VLRQ/ALRQ n= 4 
VLRQ/AFRQ n=2.  
 
Table I in appendix I provides additional information for each animal within each 
genotype group. Sequences were established between codon 86 and codon 202. 
Three animals had a known additional polymorphism in codon 112 with genotypes 








2.5.3 Antibodies  
The primary antibodies used in this study are shown in Table 2.2 
 
Table 2.2 Primary antibodies used in Western blotting and for DELFIA assay 
















































































































2.5.4 Cell lines 
Cells were grown from individual cloning well plates or from vials from LN2 storage 
to 75cm
2
 flasks and frozen down to preserve the cell line for future characterisation 
studies (2.3.5). Various batches of cells from the same cell line were frozen on 
different days (Table 2.3). This was carried out so there was a back up in case 
something went wrong with the freezing process on a particular day. This was not the 
case for H3.2 which unfortunately had to be frozen on the same day but from 
different sources i.e. cloning plates and from the original vial from LN2 storage.   
 




Viability Vials Date 
H1.8 LN2 88% 6 at 2 x 10
6
 2/11/09 
H1.8 Cloning plate 91% 8 at 2 x 10
6
 3/11/09 
H1.8 LN2 87% 7 at 2 x 10
6
 27/10/09 
H3.2 Cloning plate 83% 2 at 2 x 10
6
 19/11/09 
H3.2 Cloning plate 86% 3 at 2 x 10
6
 19/11/09 
H3.2 LN2 88% 11 at 4 x 10
6
 19/11/09 
H3.3 Cloning plate 95% 6 at 2 x 10
6
 19/11/09 




The above table indicates what cell lines were frozen, what the original source was, the  
viability of the cells, how many vials were frozen and the date of the freezing batch. 
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Chapter 3 Optimisaton of experimental techniques 
 
3.1 Introduction 
In order to investigate the relative amount of full-length PrP
C 
and the C1 fragment in 
various tissues it is necessary to develop techniques that allow the protein to be 
visualised and quantified. Techniques for the detection of PrP
Sc
 from brain and 
peripheral tissue are well established but involve harsh methods that may degrade 
PrP
C
. Methods for the detection of PrP
C
 are less defined and are made complex 
because PrP
C
 is easily degradable. For example PrP
C
 is sensitive to the enzyme PK 
whereas PrP
Sc
 is partially resistant (Oesch et al., 1985). 
 





through the use of different detergents and proteases without the need for PK 
digestion. After treatment of prion infected human brain tissue with sarkosyl and 
deglycosylation using PNGase the soluble fraction contained small amounts of PrP
C
 
and an 18 kDa fragment assumed to be C1. The C1 fragment was also detectable in 
the insoluble PrP
Sc
 fraction of type-1, type-2 CJD and GSS brain samples as well as a 
fragment ranging from 20 kDa to 22.5 kDa in the various prion diseased models. 
This truncated fragment could be the C2 fragment which has previously been shown 
to be present in some CJD cases (Chen et al., 1995) and in mouse neuroblastoma 
cells infected with scrapie (Caughey et al., 1991). 
 
Successful detection of full-length PrP
C
 and the C1 fragment has previously been 
reported in a variety of species, e.g. sheep, humans, cows and mice (Chen et al., 
1995, Horiuchi et al., 1995, Jimenez-Huete et al., 1998, Gatti et al., 2002, 
Nieznanski et al., 2005, Laffont-Proust et al., 2006, Kuczius et al., 2007a,b). PrP
C
 
was also found in sheep and hamster peripheral tissues (Bendheim et al., 1992, 
Horiuchi et al., 1995, Moudjou et al., 2001). These studies used immunoprecipitation 
methods to detect PrP
C
 but did not investigate whether C1 was generated within the 
periphery as they omitted the deglycosylation step without which C1 at normal 




Within this section of the thesis methods have been modified with the specific aim of 
detecting PrP
C
 and the C1 fragment on a Western blot from brain (3.2.2-3.2.4) and 
peripheral tissues (3.2.6). Control experiments were carried out to ensure that the C1 
fragment is not an artefact produced by degradation of the protein. 
 
3.2 Optimisation of experimental techniques 
 
3.2.1 Detection of PrPSc from scrapie infected murine brain 
To confirm that the available Western blot protocol worked with antibody 6H4 
mouse brain tissue from experimentally infected animals was investigated for PrP
Sc
.  
Brain material was used from SV or VM mice infected with scrapie strains 22A, 87V 
and 135A. Figure 3.1 shows immunodetection of PrP
Sc
 after PK treatment with the di 
glycosylated band at 28 kDa, the monoglycosylated band at 23 kDa and the 
unglycosylated band at 18 kDa. After PK digestion unglycosylated PrP
Sc
 shifts to 19 
kDa. 
                                                         
   Figure 3.1 PrP
Sc
 detection from scrapie infected animals after PK treatment 
Western blot using anti-PrP monoclonal antibody 6H4 to detect PrP
Sc
 in mouse brain   
extracts. Lane 1 SV brain homogenate (10%) infected with 135A scrapie. Lane 2 VM brain 
homogenate (10%) infected with 87V scrapie. Lane 3 VM brain homogenate (10%) 
infected with 22A scrapie. 25 µl of a 1/1000 dilution of 10% brain homogenate was loaded 
for each sample. 0.5 µl of PK was added to each sample prior to electrophoresis. The 
diglycosylated form of PrP
Sc
 is at ~ 28 kDa, monoglycosylated PrP
Sc 
at ~ 23 kDa and 
unglycosylated PrP
Sc
 at ~19 kDa. This experiment was repeated twice (n = 2). 
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3.2.2 Detection of PrPC from uninfected mouse brain 
Brain tissue was collected from a wild type mouse, from a PrP null mouse and from a 
PrP hemizygote mouse (cross of null mouse with wildtype) that only has one copy of 
the PrP gene. This experiment was conducted to compare PrP
C
 detection limits using 
6H4. There is no protein in the sample from the null mouse which is expected. The 
signal for the di-glycosylated PrP
C
 fragment in the hemizygote (Figure 3.2, solid 
line) is considerably reduced compared with the wild-type (Figure 3.2). The faint 
middle band is most likely monoglycosylated PrP
C
. There are two unexpectedly 
strong bands in the hemizygote (Figure 3.2, bottom dashed lines). The top band may 
be unglycosylated PrP
C
 although it appears too strong relative to the diglycosylated 
band. The second band can as yet not be explained and is not normally seen in mouse 




Figure 3.2 Detection of PrP
C
 from wild type, hemizygote and null mouse brain 
Western blot using anti-PrP monoclonal antibody 6H4 to detect PrP
C
 from wild type, 
hemizygote and null mouse brain extracts. Lane 1, 10% mouse brain homogenate that 
only expresses one copy of the PrP gene (hemizygote). Lane 2, 10% mouse brain 
homogenate (wild type). Lane 3, 10% mouse brain homogenate that has had the PrP gene 
knocked out (null). 25 µl of a 1/100 dilution of 10% brain homogenate was loaded for each 
sample. Diglycosylated PrP
C
 is at ~ 35 kDa, monoglycosylated PrP
C
 at ~ 29 kDa and the 
unglycosylated PrP
C
 at ~ 25 kDa. This experiment was repeated twice (n = 2). 
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3.2.3 Detection of PrPC from uninfected ovine brain using two 
preparation methods 
For the detection of PrP
C
 from uninfected brain tissue two preparation methods were 
tested, one a simple lysis homogenate (2.1.1) the other including a sucrose gradient 
purification / enrichment step (2.1.2) and an assessment was made which preparation 
method was best for ovine brain tissue. Two different antibodies with different 
sensitivity for PrP
C
 were used for detection. This experiment verified that P4 was 
more sensitive than 6H4, but due to its epitope (aa93-99, Figure 3.11) P4 will not 
detect C1. In the comparison of the two methods the enrichment protocol is not as 





 can be detected using the simple homogenate at a higher dilution compared to 
the enrichment protocol (Figure 3.3). 
 
 
Figure 3.3 Immunodetection of PrP
C
 from uninfected ovine brain tissue using 
monoclonal antibodies 6H4 and P4 
Western blot using anti-PrP monoclonal antibodies 6H4 (A) and P4 (B) to detect PrP
C
 from 
uninfected ovine brain extracts. (A) Lane 1, 3, 5, 7 and 9 contain uninfected ovine brain 
tissue homogenate (10%) that was prepared using the lysis preparation method (2.1.1). 
Lanes 2, 4, 6, 8 and 10 contain uninfected ovine brain tissue homogenate (10%) that was 
prepared using the sucrose gradient purification method (2.1.2) (B) Lanes 1, 3, 5, 7 and 9 
contain uninfected ovine brain tissue homogenate (10%) that was prepared using the 
sucrose gradient purification method. Lanes 2, 4, 6 and 8 contain uninfected ovine brain 
tissue homogenate that was prepared using the lysis preparation method (2.1.1). Lanes 1 
and 2, 1/100 dilution of brain homogenate, lanes 3 and 4, 1/10000 dilution of brain 
homogenate, Lanes 5 and 6, 1/100000 dilution of brain homogenate, Lanes 7 and 8, 
1/1000000 dilution of brain homogenate and lanes 9 and 10, 1/10000000 dilution of brain 
homogenate. 20µl of each brain homogenate dilution was loaded. The diglycosylated band 
PrP
C
 is at ~ 35 kDa, monoglycoyslated PrP
C
 at ~ 29 kDa and unglycosylated PrP
C
 at ~ 25 
kDa. Each experiment was repeated twice (n = 2). 
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3.2.4 Detection of PrPC from uninfected ovine and murine brain tissue 
Brain homogenate from Cheviot sheep number 30 x 31, an animal confirmed to be 
clinically negative and negative for PrP
Sc
 was prepared using the lysis preparation 
method (2.1.1). A murine brain tissue sample from a 129/Ola mouse was used as a 
control to compare detection levels of PrP
C
 between ovine and murine tissues (Figure 





                                         
   
   Figure 3.4 Detection of PrP
C
 from uninfected ovine and murine brain tissue 
Western blot using anti-PrP monoclonal antibody 6H4 to detect PrP
C
 from uninfected ovine 
and murine brain tissue. Lane 1 contains 10% uninfected mouse brain homogenate (strain 
129/Ola). Lane 2 contains 10% ovine uninfected brain tissue homogenate (animal 30 x 31). 
20µl of a 1/100 dilution of 10% brain homogenate was loaded. The di-glycosylated band of 
PrP
C
 is at ~ 35 kDa, monoglycosylated PrP
C
 at ~ 29 kDa and unglycosylated PrP
C
 at 25 
kDa. This experiment was repeated twice (n = 2). 
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3.2.5 PrPC expression patterns in ovine brain regions 
To determine the relative expression levels of PrP
C
 among different brain regions to 
aid the decision on which brain region would be best for the analysis of PrP and C1,   
medulla, cerebellum, frontal cortex and thalamus brain homogenates were analysed. 
Examples of Western blot analysis and glycoform patterns can be observed in 
Figures 3.5-3.7.  
 
In Figure 3.5 there are higher signal intensities of PrP
C
 in all brain regions using 
antibody BC6. The diglycosylated form of PrP
C
 in cortex appears to run higher than 
other brain areas. In the cerebellum, cortex and thalamus there is lower molecular 
weight bands when antibody BC6 is used for detection. These bands may correspond 
to degradation products of glycosylated forms of the C1 fragment as the lowest 
molecular weight band in the cerebellum migrates at aproximately 18 kDa. 
                               
                          
Figure 3.5 PrP glycoform patterns from different brain areas of sheep 72 x 38 using   
monoclonal antibodies 6H4 and BC6 
Western blot using anti-PrP monoclonal antibodies 6H4 and P4 to detect PrP
C
 from the 
medulla, cerebellum, cortex and thalamus of an ARQ/ARR sheep. For each brain area 10 
µl of a 10% brain homogenate was loaded. The diglycosylated form of PrP
C
 is at ~ 36 kDa, 
monoglycosylated PrP
C
 at ~ 31 kDa and unglycosylated PrP
C
 at ~ 26 kDa. The 
diglycosylated band of PrP in the cortex appears to run higher than the other brain areas 
this is more noticeable when 6H4 is used for detection. This Western blot demonstrates 
that BC6 is the more sensitive antibody and that the most dominant glycoform for all brain 
regions is di-glycosylated PrP
C




In Figure 3.6 the signal intensities of PrP
C
 are higher in the cortex and medulla when 
antibody 6H4 is used for detection, whereas the signal intensities of PrP
C
 in the 
cerebellum and thalamus are higher when antibody P4 is used for detection. Only di-
glycosylated forms of PrP
C
 are observed in the cerebellum and thalamus after 6H4 
detection. Again the diglycosylated form of PrP
C
 in cortex appears to run higher than 
other brain regions, this might suggest that glycosylation within the cortex PrP
C
 is 
different from other brain regions. 
         
   Figure 3.6 PrP glycoform patterns from different brain areas of sheep 69 x 67  
   using tibodies 6H4 and P4.  
Western blot using anti-PrP monoclonal antibodies 6H4 and P4 to detect PrP
C
 from the 
medulla, cerebellum, cortex and thalamus of an ARQ/ARQ sheep. For each brain area 
10µl of a 10% brain homogenate was loaded. The diglycosylated form of PrP
C
 is at ~ 36 
kDa, monoglycosylated PrP
C
 at ~ 31 kDa and unglycosylated PrP
C
 at ~ 26 kDa. Again the 
diglycosylated band of PrP
C
 in the cortex appears to run higher than the other brain areas. 
This Western blot demonstrates that P4 is more sensitive than 6H4 and that the dominant 
glycoform for all brain regions is diglycosylated PrP
C
. This experiment was repeated twice 




In Figure 3.7 PrP
C
 signal intensities are highest for all brain regions when antibody 
P4 is used for detection. For all brain areas diglycosylated PrP
C
 is the most dominant 
glycycoform when antibody BC6, 6H4 and P4 is used for detection. However when 
antibody BE12 is used for detection unglycosylated PrP
C
 is the most dominant 
glycoform. The difference observed between the different antibodies may be 




Figure 3.7 PrP glycoform patterns from different brain areas of sheep 75 x 49 using 
monoclonal antibodies BC6, BE12, 6H4 and P4 
Western blots using anti-PrP monoclonal antibodies BC6, BE12, 6H4 and P4 to detect 
PrP
C
 from the medulla, cerebellum, cortex and thalamus of an ARR/ARR sheep. For each 
brain area 10 µl of a 10% brain homogenate was loaded. The diglycosylated form of PrP
C
 
is at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 31 kDa and unglycosylated PrP
C
 at ~ 26 kDa. 
The diglycosylated band of PrP
C
 in the cortex appears to run higher than the other brain 
areas. This Western blot demonstrates that antibody P4 is the most sensitive antibody and 
that the dominant glycoform for all brain regions is diglycosylated PrP
C
 except when BE12 
is used for detection. When BE12 is used for detection unglycosylated PrP
C
 is the 
dominant glycoform. This experiment was repeated twice (n = 2). 
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3.2.6 PrPC preparation methods for peripheral tissue 
As the level of PrP
C 
expression in sheep peripheral tissues is approximately twenty 
fold less than in the brain (Gossner et al., 2009) it was investigated whether PrP
C
 
could be detected from peripheral tissues using the crude 10% homogenate 
preparation method (2.1.1) without the need for purification or immunoprecipitation 
of the sample. Ovine spleen samples and murine small intestine samples were tested. 
We found that PrP
C
 could not be detected in ovine spleen using this method when 
monoclonal antibodies 6H4 and BC6 were used (Figure 3.8). 
 
Unspecific protein binding was detected in the murine small intestine samples 
(Figure 3.9) when BC6 was used which was confirmed with a sample from null 
mouse small intestine (Figure 3.9).  
 
                                         
Figure 3.8 Protein detected in ovine spleen homogenate using monoclonal antibody 
BC6 
Western blot using anti-PrP monoclonal antibody BC6 to detect PrP
C
 from sheep 63 x 57 
spleen homogenate. 2 µl, 4 µl and 8 µl of a 10% spleen homogenate was loaded. This was 
equivalent to 20, 40 and 80 µg of total protein as measured using the BCA protein assay. 
Unspecific binding of protein was detected at ~ 30 kDa. This experiment was repeated 




                                  
Figure 3.9 PrP detected in murine brain and intestinal tissue using monoclonal 
antibody BC6 
Western blot using anti-PrP monoclonal antibody BC6 to detect PrP
C
 in the 129/ola brain 
and 129/Ola intestine. 3 µl, 7 µl and 14 µl of 10% intestinal homogenate was loaded. This 
was equivalent to 20 µg and 40 µg of total protein. 4 µl of 10% 129/Ola brain homogenate 
was loaded. This was equivalent to 20 µg of total protein. 3 µl of 10% null brain and null 
intestinal homogenate was loaded. This was equivalent to 20 µg of total protein as 
measured using the BCA protein assay. 129/Ola brain was loaded as a positive control. 
The diglycosylated form of PrP
C
 is at ~ 26 kDa, monoglycosylated PrP
C
 at ~ 30 kDa and 
the unglycosylated PrP
C
 at ~ 38 kDa. Unspecific protein bands were detected at ~ 25 kDa 
which is slightly lower than the unglycosylated form of PrP
C
 of the 129/Ola control. This 




The next method that was tested for the detection of PrP
C 
in peripheral tissues was a 
purification protocol that had been cited previously (Mohri et al., 1992). This 
purification method involves the use of potassium chloride and a sucrose gradient 
(2.1.2). For this experiment ovine spleen samples were used, however PrP
C 
could not 
be detected using this method when monoclonal antibody 6H4 was used for detection 
(data not shown). As these methods were unsuccessful for detecting PrP
C
 from 
peripheral tissue, immunoprecipitation using a panel of monoclonal antibodies was 
investigated (Chapter 6).  
 
3.2.7 PNGase deglycosylation of PrPC 
Optimum conditions for the enzymatic deglycosylation of PrP
C
 in total brain 
homogenate were experimentally determined using commercially available PNGase 
enzyme. Initially 50 l of 10% brain homogenate was incubated with PNGase for 2 
hours at 37°C as recommended by the manufacturers; however these conditions did 
not allow for complete de-glycosylation of PrP
C
 although the truncated fragment C1 
was detectable (Figure 3.10 A). Decreasing the starting 10% brain homogenate to 25 
l and in some cases 12.5 l allowed for complete deglycosylation of the protein 
(Figure 3.10 B). 
 
In Figure 3.10 B there is a strong appearance of the C1 fragment band following 
deglycosylation although there appears to be no mono-glycosylated PrP
C
 in the 
untreated sample. It was previously assumed that prior to PNGase treatment, all of 
the glycosylated C1 is hiding within the monoglycosylated and unglycosylated full-
length PrP which becomes visible after deglycosylation. However this does not 
appear to be the case. One explanation may be that the PNGase reaction itself, may 
generate C1 because of contaminants. However this seems unlikely as the C1 
fragment does not appear in every PNGase treated sample, this is observed for sheep 




                             
   
   Figure 3.10 Western blots of PNGase treated ovine brain tissue 
Western blots using of PNGase deglycosylated PrP
C
 and undigested PrP
C
 in uninfected 
ovine brain material detected using anti-PrP monoclonal antibody 6H4. (A) 50 µl of a 10% 
brain homogenate was incubated for 2 hours at 37°C with 1000 units/ml of PNGase. 
Complete deglycosylation of the protein has not been successful as the di and mono 
glycosylated bands of PrP
C
 are still present. An extra band assumed to be the C2 fragment 
migrates around 20 kDa, and is indicated by * on the blot. (B) 25 µl of a 10% brain 
homogenate was incubated for 2 hours at 37°C with 1000 units/ml of PNGase. After 
altering PNGase conditions there is complete deglycosylation of the protein. 3 µl of 10% 
brain homogenate was loaded in each lane. The diglycosylated form of PrP
C
 is at ~ 38 
kDa, monoglycosylated PrP
C
 at ~ 35 kDa and unglycosylated PrP
C
 at ~ 26 kDa. The C1 
fragment is at ~ 18 kDa while the unidentified fragment (*) assumed to be C2 in (A) is at ~ 





3.3.1 Antibody mapping 
To visualise the C1 fragment on a Western blot an antibody with a C-terminal 
epitope (between codons 115-230) is required as the C1 fragment is N-terminally 
truncated. Throughout this thesis monoclonal antibody 6H4 has been used to detect 
full-length PrP and C1. To confirm that the fragment was indeed C1, 6H4 was 
stripped from the membrane and the membrane re-probed with N-terminal antibody 
P4. When the membrane is probed with 6H4 the C1 band is present, however when it 
is probed with P4 the C1 band is not present (Data not shown). This indicates that the 
C1 fragment does not contain the P4 epitope and is as expected N-terminally 
truncated.  
 
To investigate whether the amount of full-length PrP and C1 visualised on a Western 
blot could be influenced by the choice of antibody, BC6 was also used to detect full-
length PrP and the C1 fragment. BC6 gave a stronger signal for both full-length PrP 
and C1 when used at the same concentration as 6H4. The epitopes for antibodies 
6H4, P4 and BC6 is shown in Figure 3.11. 
 
 
    Figure 3.11 Antibody map 
Schematic representation of ovine PrP with the location of the epitopes used to generate 
and recognise the antibodies BE12, FH11, P4, 3F4, 6H4, BC6, 8H4, H1.8, H3.2 and H3.3. 
Location of the alpha cleavage site and the C1 fragment is shown. The epitope for 3F4 is 
only available for humans and hamster but because this antibody was used in this thesis it 
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3.3.2 Degradation experiments and storage conditions 
It is possible that C1 is also a degradation product of full-length PrP
C
 generated at the 
time of or shortly after post-mortem. It may also be generated when frozen tissue is 
thawed and during PNGase treatment. To investigate the effect of storage and 
handling conditions on the amount of full-length PrP and C1 in tissue samples, a 
number of control experiments were carried out. For most of the experiments in this 
thesis, tissue was taken from the outside of the brain material as this is the area that 
defrosts first and is also clearly recognisable as cortex.  
 
Tissue from the inside of a frozen sheep brain (frontal cortex) and tissue from the 
outside of the same frozen sheep brain were compared. After deglycosylation and 
Western blot analysis there was little difference in the amount of full-length PrP and 
C1. (Figure 3.12 lanes 1 and 2). This experiment was repeated twice with 
reproducible results. 
 
Although measures were taken to avoid post-mortem material being at room 
temperature for longer than necessary (as given by the procedure), material was not 
always frozen instantly. To test the effect of this, 0.2 g of tissue (not mazerated or 
homogenised) from a sheep brain (frontal cortex) was incubated at room temperature 
for 16 hours without the presence of protease inhibitors. This sample was 
deglycosylated along with tissue from the same animal that had not been subject to 
16 hours defrost. After Western blot analysis there was little difference in the amount 
of full-length PrP
C
 and C1 between the experimental and control tissue (Figure 3.12 
lanes 3 and 4). 
 
To test whether freeze thawing could influence the ratio between full-length PrP
C
 
and C1 the final control experiment involved taking 0.2 g brain tissue (frontal cortex) 
and subjecting it to four freeze thaw cycles (Tissue defrosted at room temperature 
and refrozen at -20°C). As a control, brain tissue from the same animal was used 
which was not subject to freeze thaw conditions. After deglycosylation and Western 
blot analysis there was little difference in the amount of full-length PrP
C
 and C1 




                                
 
   Figure 3.12 Ovine PrP
C 
degradation experiments (non-continous gel) 
Western blot of PNGase deglycosylated PrP
C
 in uninfected ovine brain material detected 
using anti-PrP monoclonal antibody 6H4. 25 µl of a 10% sheep brain homogenate was 
incubated for 2 hours at 37°C with 1000 units/ml of PNGase. Lane 1 contains a 
homogenate that was prepared from the inside of a sheep brain tissue. Lane 2 contains a 
homogenate that was prepared from the outside of the same sheep brain tissue as shown 
in lane 1. Lane 3 contains a homogenate that was prepared from brain tissue that was left 
at room temperature for 16hrs in the absence of protease inhibitors. Lane 4 contains a 
homogenate from the same animal shown in lane 3 but which was not left at room 
temperature for 16 hours. Lane 5 contains a brain homogenate that was subject to 4 x 
freeze thaw cycles. Lane 6 contains a brain homogenate from the same animal in lane 5 
that was not subject to 4 x freeze thaw cycles. 5 µl of a 10% brain homogenate was loaded 
for each sample. The unglycosylated form of PrP
C
 is at ~ 26 kDa and the C1 fragment at ~ 
18 kDa. This experiment was repeated twice (n = 2). 
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3.3.3 Distinguishing PrPC from PrPSc 
PrP
Sc
 can easily be distinguished from PrP
C
 when it is treated with proteinase K 
(PK).  PrP
Sc
 is partially resistant to this protease and when it is treated with 
Proteinase K it is truncated to leave a 19-30 kDa protein pattern. When PrP
C
 is 
treated in the same way the protein is completely digested. Thus Proteinase K is used 
to distinguish between infected and uninfected samples during immunoblotting as 
only PrP
Sc
 will be detected (Figure 3.13). In Figure 3.13 there appears to be four 
bands present, this is not usually the case as three bands corresponding to 
diglycoyslated, monoglycosylated and unglycosylated PrP are usally detectable. It is 
possible that one of the extra bands could be glycosylated C1. However, after longer 
exposure there appears only to be three bands present (Data not shown). 
 
             
   Figure 3.13 Ovine brain samples treated with and without proteinase K 
Western blot of ovine brain samples treated with and without proteinase K and detected 
using anti-PrP monoclonal antibody 6H4. Total ovine brain protein was treated for 1 hour 
with at 37°C with 5mg/ml of PK.  Samples were denatured at 100°C for 10 minutes and 
electrophoresis carried out. In the lanes indicated with +PK no PrP
Sc
 was detected. This 
indicates that these samples were uninfected. 1/100000 dilution of 10% brain homogenate 
was loaded for each sample. Diglycosylated PrP
C
 is at ~ 38 kDa, monoglycosylated PrP
C
 
at ~ 31 kDa and unglycosylated PrP
C





The main aim of this thesis is to analyse the amount of full-length PrP and the C1 
fragment in various tissues to examine their role on TSE susceptibility. This chapter 
describes the effort in optimising PrP preparation methods for the detection of full-
length PrP and truncated PrP fragment C1 and the essential controls to show that the 
experimental approach is sound.  
 
Two methods were used for the preparation of PrP
C
 from ovine and murine tissues 
(2.1.1-2.1.2). Results from (Figure and 3.3 A and B) show that the signal detection 
levels of PrP
C
 in ovine brain were stronger using the crude homogenate preparation 
method than the sucrose preparation method. The reason behind this may be that 
some of the PrP is degraded during the sucrose method as there is an enrichment and 
purification step used in this protocol.  Unfortunately, we were unable to detect PrP 
in ovine spleen and murine small intestine (Figures 3.8, 3.9) using the crude or 
purification method therefore immunoprecipitation experiments were carried out 
(Chapter 6). The C1 fragment was also successfully detected in ovine brain tissue 
after some modification of the protocol (Figure 3.10). 
 
The amount of PrP
C
 in different brain areas was also analysed along with the 
corresponding glycoform patterns (Figures 3.5-3.7). The main reason behind these 
experiments was to determine which brain area should be used in future experiments. 
All available antibodies detected diglycosylated PrP
C
 the most. Although BE12 did 
detect unglycosylated PrP
C
 as the dominant isoform this was in only one animal, and 
in other cases this antibody was not as sensitive as 6H4. The frontal cortex and the 
medulla gave the strongest signal when antibody 6H4 was used for detection. The 
frontal cortex was chosen for analysis in the ovine (Chapter 4) and murine (Chapter 
5) deglycosylation experiments as the frontal cortex was available for all animals 
used in the study.  
 
There is little difference in the level of PrP
C
 detection between ovine and murine 
brain samples when monoclonal antibody 6H4 is used (Figure 3.4). This was an 
important result as later experiments were carried out on murine models expressing 
 
 83
murine, ovine and bovine PrP (Chapter 5) therefore it was important to determine the 
normal levels of murine PrP
C
 before beginning these experiments.  
 
Results from the degradation experiments indicate that both full-length PrP and the 
C1 fragment are very stable as very little degradation is observed after four freeze 
thaw cycles when compared to the control sample (Figure 3.12). If degradation 
occurs it appears to be roughly equal for both full-length PrP and the C1 fragment. 
The importance of the freeze thawing experiments was to see if results could be 
influenced by certain storage and handling conditions of the tissue sample. Most of 
the tissue used in the experiments was taken fresh and frozen immediately at -70°C. 
However, archived tissue which had been frozen for a number of years was also 
used. This archived tissue is most likely to have been thawed previous to our 
experiments. The results indicate that freeze thawing of tissue samples does not lead 
to immediate degradation of either full-length PrP or C1 or spontaneous production 
of C1. These experiments indicate that our results have not been influenced by freeze 
thawing of sample tissue. We repeated this experiment twice on two separate 
samples which had not been subject to freeze thawing previously with reproducible 
results.  
 
By law, human brain samples can not be taken for a number of hours after death 
therefore to try and mimic human post-mortem conditions within the laboratory, 
tissue without the presence of protease inhibitors was left for 16 hours at room 
temperature. Remarkably there was little degradation compared to the control sample 
(Figure 3.12) which had not been left for 16 hours at room temperature. This is likely 
not to be the case when the tissue is homogenised. We repeated this experiment twice 
on two separate samples with reproducible results. Some lamb tissue was collected a 
number of hours after the animal had died. These control experiments indicate that 
these results may not be influenced as much by the conditions of the tissue as would 
have been predicted. Overall our degradation experiments indicate that PrP and the 
C1 fragment are relatively stable within tissues and are not easily degraded by 
various storage and handling conditions. These experiments also provide evidence 
that the C1 fragment is not a degradation product due to harsh handling and long 
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term storage conditions and is a true cleavage product. These data are also relevant 
when comparisons are made between the analysis of this thesis and publications on 
alpha cleavage.  
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Chapter 4 Alpha cleavage of PrP in ovine brain 
 
4.1 Introduction  
Sheep with different PRNP genotypes are differentially susceptible to scrapie 
disease. To investigate whether the amount of alpha cleavage correlates with scrapie 
disease, C1 as a percentage of total PrP
C
 was measured in sheep with different PRNP 
genotypes, and therefore different scrapie susceptibility.  
 
PRNP genotypes in sheep are grouped in accordance to their amino acids at codons 
136, 154 and 171 of ovine PrP. Polymorphisms at these three amino acid positions 
are known to confer resistance or susceptibility to scrapie (for more details see 
Chapter 1). Disease outbreaks appear to be dependent on allele frequency and breed 
as the VRQ and ARQ alleles confer different susceptibility when expressed in 
different sheep breeds. PRNP genetics also applies to incubation period differences. 
For example New Zealand Cheviot VRQ/VRQ sheep have shorter incubation periods 
compared to Cheviot sheep held at the Neuropathogenesis Division (NPD/NPU) 
Roslin, after experimental challenge with SSBP/1 (Houston et al., 2002b).  
 
Most available data allows the suggestion that polymorphisms that are within close 
structural proximity have similar effects on disease susceptibility. For example 
codons 136 and 171 are structurally close to each other (Haire et al., 2004) and are 
both associated with classical scrapie (Goldmann et al., 1990,1991a). Codons 141 
and 154 are even closer to each other and are both associated with atypical scrapie 
(Benestad et al., 2003, Moum et al., 2005, Colussi et al., 2008). As the alpha 
cleavage site is located within the unstructured region of PrP it is possible that this 
region is close to one or all of these polymorphisms which could therefore influence 
PrP processing by altering the enzyme binding site, making it more or less accessible 
to cleavage. 
 
At present there is insufficient data within the literature about the processing of alpha 
cleavage and its biological consequences. Previous studies of the proteolytic 
processing of PrP have used both in vivo and in vitro approaches. These studies have 
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been carried out on a variety of species, such as sheep, humans, cows, mice and pigs 
(Chen et al., 1995, Horiuchi et al., 1995, Jimenez-Huete et al., 1998, Gatti et al., 
2002, Nieznanski et al., 2005, Tveit et al., 2005, Laffont-Proust et al., 2006, Kuczius 
et al., 2007a,b).  
 
Residues 106-126 have been suggested to be involved in the conversion process of 
the prion protein (Forloni et al., 1993,1994, Gu et al., 2002). The C1 fragment 
contains only residues 115-126 of this domain; therefore it may be that cleavage 
within this region affects the ability of PrP
C
 to be an effective template for 
conversion to PrP
Sc
. To gain further understanding of the proteolytic processing this 
chapter presents the analysis between the levels of cleavage product (C1) in the 




4.2.1 Quantification of the C1 fragment as a percentage of total PrPC 
The quantification of C1 as a percentage of total PrP
C
 was calculated in the frontal 
cortex of sheep with different PRNP genotypes. This region was chosen for various 
reasons; firstly, this brain area was available for all sheep that were analysed; 
secondly, this area is always affected at the terminal disease time point (Jeffrey et al., 
2001). Thirdly, more PrP was consistently detected via immunoblotting in the frontal 
cortex compared to other brain regions (Chapter 3). 
 
Frontal cortex tissue was collected from sheep of two breeds (Cheviot and Poll 
Dorset) and seven PRNP genotypes (based on the codons 136, 154 and 171) (see 
Appendix 1, Table I). Each genotype group contained at least four animals. The 
largest group was the VRQ/VRQ genotype, which contained ten animals as it 
included both Poll Dorset and Cheviot sheep. Brain homogenates were prepared 
according to the PrP
C
 lysis preparation protocol (2.1.1) and deglycosylated using the 
enzyme PNGase. PrP
C
 and the truncated C1 fragment were detected by Western 
blotting using monoclonal antibody 6H4. For some samples the assay was repeated 
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with monoclonal antibody BC6. For each sheep at least two separate tissue 
extractions were prepared and each sample was assayed twice.  
  
After PNGase treatment to remove the carbohydrates, PrP
C
 was detected in most 
cases as two distinct bands, unglycosylated full-length PrP
C
 and unglycosylated C1. 
However, a band of around 20 kDa was present in some of the samples (Figure 4.2 
B, C; Figure 4.3 A, B and C), this was often but not always accompanied by some 
monoglycosylated full-length PrP
C
. The 20 kDa band may be present due to other 





C1 as a percentage of total detectable PrP
C
 was measured after deglycosylation. The 
total signals of PrP
C
 consisting of (full-length PrP
C
, C2 and the C1 fragment) and the 
C1 fragment was defined as 100% and C1 was calculated as a percentage of the 
combined signal. All results in this thesis will be shown as percentage of total 
detectable PrP
C
. The signal quantification was calculated as a percentage so that a 
direct comparison could be made to previously published data (Kuczius et al., 
2007a). Only the C1 fragment was measured as the N1 fragment that is generated in 
a 1:1 ratio with C1 was not detected with 6H4 or BC6 antibodies. It was also not 
detected in any of the samples when monoclonal antibody P4 was used suggesting a 
short half-life. Each sample was loaded with and without PNGase to show that 
glycosylated forms of PrP
C
 were present in each sample. However in many cases 
unglycosylated and monoglycosylated forms of PrP
C
 are not detected with 6H4.  
 
Based on Molecular weight calculations it can be assumed that the C1 fragment will 
migrate to the same position as unglycosylated PrP
C
 which could explain why the C1 
band is not detectable on its own. Alternatively, the C1 fragment itself may be di- 
mono and unglycosylated, each band under the detection limit becoming visible 
when after deglycosylation the band shift to the same position.  It has been observed 
in a few high expression models with antibody BC6 that di, mono and 




However, in cases where the unglycosylated band of PrP
C
 is not detected either, it is 
difficult to explain the absence of the glycosylated C1 fragment.  Although it is 
possible that C1 is produced during PNGase digestion, it is rather unlikely to be of 
importance as samples with undetectable C1 were observed regularily and prolonged 
incubation with PNGase did not increase C1 percentage (Table 4.1).  
 
The average percentage of C1 in all brain samples was around 20-30% with the 
exception of the ARQ/ARQ and VRQ/ARQ animals that had an average C1 
percentage of 16 and 17% respectively. Two Poll Dorest VRQ/ARQ animals had 0% 
C1, whereas New Zealand Cheviot VRQ/ARQ animals had up to 44% C1. After 
statistical analysis there was no significant difference between Poll Dorset and New 
Zealand Cheviots within this genotype group. Figure 4.4 shows a representation of 
the ratio between C1 and total PrP
C
 in relation to the different genotypes reflecting 
average results for each group. The mean percentage values C1 for all animals are 













 and C1 detected from ARR/ARR homozygotes using monoclonal 
antibody 6H4 
(A) Western blot of PNGase deglycosylated and undigested PrP
C
 in Cheviot sheep no. 014 
and no. 017 (ARR/ARR homozygotes). 5 µl of 10% brain homogenate was loaded in each 
lane. The majority of PrP
C
 is diglycosylated (lane 1, 3). Remaining monoglycosylated PrP
C
 
was occasionally seen after PNGase treatment (lane 2, 4, 6). (B) Western blot of PNGase 
deglycosylaed and undigested PrP
C
 in Cheviot sheep 030 (ARR/ARR homozygote). 5 µl of 
10% brain homogenate was loaded in each lane. (C) Western blot of PNGase 
deglycosylated and undigested PrP
C
 in Cheviot sheep no. 020 (ARR/ARR homozygote). 5 
µl of 10% brain homogenate was loaded in each lane. For Blot A-C the diglycosylated form 
of PrP
C
 was at ~ 35 kDa, monoglycosylated PrP
C
 at ~ 30 kDa, unglycosylated PrP
C
 at ~ 26 




      A      B 
 
 
      C                D 
 
 Figure 4.2 PrP
C
 and C1 detected from various heterozygote and homozygote 
  animals using monoclonal antibody 6H4 
(A) Western blot of PNGase deglycosylated and undigested PrP
C
 in Cheviot sheep no. 42 x 
05 (AHQ/ARR heterozygote) and no. 051 (ARR/ARR homozygote). The majority of PrP
C
 is 
diglycosylated. Remaining monoglycosylated PrP
C
 was occasionally observed after 
PNGase treatment (lane 1 and 5). (B) Western blot of PNGase deglycosylated and 
undigested PrP
C
 in Cheviot sheep no. 050 (AHQ/ARR heterozygote) and no. 47 x 66 
(AHQ/ARQ heterozygote).  An extra band above C1 (most likely to be the C2 fragment) can 
be visualised in these samples (Indicated by * on blot) this band migrates at ~ 20 kDa. (C) 
Western blot of PNGase degylcosylated and undigested PrP
C
 in cheviot sheep no. 63 x 51 
(AHQ/ARQ heterozygote) and no. 61 x 13 (ARQ/ARR heterozygote). An extra band above 
C1 (most likely to be the C2 fragment) can be visualised in these samples (Indicated by * 
on blot) this band migrates at ~ 20 kDa. (D) Western blot of PNGase degylcosylated and 
undigested PrP
C
 in New Zealand cheviot sheep no. Pg0109/02 (VRQ/ARQ heterozygote), 
no. Pg437/06 (VRQ/ARQ heterozygote) and no. Pg0675/08 (VRQ/ARQ heterozygote). For 
Western blots A-D the diglycosylated form of PrP
C
 is at ~ 36 kDa, monoglycosylated PrP
C
 
at ~ 31 kDa, unglycosylated PrP
C
 is at ~ 26 kDa and the C1 fragment at ~ 18 kDa. 5 µl of 
10% brain homogenate was loaded in each lane for Western blots A-D. Each experiment 
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 and C1 detected from VRQ/VRQ and ARQ/ARQ homozygotes using 
monoclonal antibody 6H4 
(A) Western blot of PNGase deglycosylated and undigested PrP
C
 in Poll Dorset sheep no. 
J212, no. J232 and no. J236. All these animals are VRQ/VRQ homozygotes. An extra 
band above C1 (most likely to be the C2 fragment) can be visualised in these samples 
(Indicated by * on blot). This band migrates at ~ 20 kDa. Unfortunately there is an air 
bubble in lane 9 on the C1 fragment; this result was not included in the overall analysis. (B) 
Western blot of PNGase deglycosylated and undigested PrP
C
 in Cheviot sheep no. 
Pg0877, no. Pg0856, Pg0416 and no. Pg0854. All these animals are ARQ/ARQ 
homozygotes. An extra band above C1 (most likely to be the C2 fragment) can be 
visualised in all samples (Indicated by * on the blot). This band migrates at ~ 20 kDa. (C) 
Western blot of PNGase deglycosylated and undigested PrP
C
 in Poll Dorset sheep no. 
J232, no. J225 and no. J212 and Cheviot sheep K285 and J374. All these animals are 
VRQ/VRQ homozygotes. An extra band above C1 (most likely to be the C2 fragment) can 
be visualised in all these samples (indicated by * on the blot). For Western blots A-C the 
diglycosylated form of PrP
C
 is at ~ 36 kDa, the monoglycosylated PrP
C
 at ~ 31 kDa, 
unglycosylated PrP
C
 at ~ 26 kDa and the C1 fragment at ~ 18 kDa. 5 µl of 10% brain 
homogenate was loaded in each lane for Western blots A-C. Each experiment was 





Figure 4.4 Representative Western blots of alpha cleavage profiles from various 
PRNP genotypes using monoclonal antibody 6H4 (montage of different gels) 
Western blot analysis of deglycosylated PrP
C
 from sheep brain tissue detected using 
monoclonal antibody 6H4. Full-length unglycosylated PrP
C
 was detected at ~26 kDa and 




Table 4.1 Densitometry data for animals used in genotype study (Frontal cortex) 
Genotype Animal no 






VRQ/VRQ J212 Poll Dorset 36:64 32:68 
VRQ/VRQ J225 Poll Dorset 41:59 39:61 
VRQ/VRQ J232 Poll Dorset 44:56 30:70 
VRQ/VRQ J236 Poll Dorset 37:63 28:72 
VRQ/VRQ J255 Poll Dorset 33:67 26:74 
VRQ/VRQ J368 Cheviot 23:77 21:79 
VRQ/VRQ J374 Cheviot 31:69 27:73 
VRQ/VRQ K295 Cheviot 31:69 28:72 
VRQ/VRQ K310 Cheviot 33:67 32:68 
VRQ/VRQ K320 Cheviot 36:64 35:65 
ARQ/ARQ 69 x 67 Cheviot 34:66 24:76 
ARQ/ARQ Pg0416 NZ Cheviot 23:77 18:82 
ARQ/ARQ Pg0433 NZ Cheviot 14:86 8:92 
ARQ/ARQ Pg0854 NZ Cheviot 21:79 19:81 
ARQ/ARQ Pg0856 NZ Cheviot 32:68 20:80 
ARQ/ARQ Pg0877 NZ Cheviot 24:76 22:88 
VRQ/ARQ H30 Poll Dorset 0:100 0:100 
VRQ/ARQ H41 Poll Dorset 12:88 3:97 
VRQ/ARQ H50 Poll Dorset 25:75 18:82 
VRQ/ARQ H84 Poll Dorset 0:100 0:100 
VRQ/ARQ Pg0109 NZ Cheviot 44:56 44:56 
VRQ/ARQ Pg0437 NZ Cheviot 43:57 28:72 
VRQ/ARQ Pg0675 NZ Cheviot 6:94 4:96 
VRQ/ARQ Pg0490 NZ Cheviot 27:73 26:74 
VRQ/ARQ Pg1226/04 NZ Cheviot 28:72 19:81 
AHQ/ARQ 47 x 66 Cheviot 32:68 23:77 
AHQ/ARQ 59 x 89 Cheviot 25:75 16:84 
AHQ/ARQ 63 x 51 Cheviot 26:74 22:78 
AHQ/ARQ 69 x 24 Cheviot 26:74 25:75 
AHQ/ARR 050 Cheviot 33:67 23:77 
AHQ/ARR 42 x 05 Cheviot 32:68 25:75 
AHQ/ARR 47 x 29 Cheviot 31:69 25:75 
AHQ/ARR 71 x 58 Cheviot 31:69 29:71 
ARQ/ARR 43 x 39 Cheviot 36:64 13:87 
ARQ/ARR 53 x 57 Cheviot 20:80 10:90 
ARQ/ARR 61 x 13 Cheviot 22:78 18:82 
ARQ/ARR 72 x 38 Cheviot 33:67 28:72 
ARQ/ARR 74 x 00 Cheviot 28:72 22:78 
ARR/ARR 014 Cheviot 17:83 12:88 
ARR/ARR 017 Cheviot 24:76 13:87 
ARR/ARR 022 Cheviot 33:67 23:77 
ARR/ARR 030 Cheviot 32:68 26:74 
ARR/ARR 051 Cheviot 26:74         26:74 
ARR/ARR 75 x 49 Cheviot 35:65 33:67 
 
Table showing densitometry data for all sheep used in genotype study. C1 is calculated as a 
ratio of total PrP
C
 and shown in the format C1: total PrP
C
. Each sample was tested twice 




These results show that PrP alpha cleavage occurs in all seven ovine genotypes that 
were analysed (Figure 4.4). VRQ homozygote animals contained the highest 
percentage of C1 when 6H4 was used for detection. To ensure that these results were 
not antibody specific monoclonal antibody BC6 was used on five VRQ/VRQ 
samples. Western blot detection with antibody BC6 resulted in similar C1 percentage 
values with 6H4 detection (Figure 4.5). High percentages of C1 were found in five 
Cheviot animals of the VRQ/VRQ genotype. To confirm that these results were not 
specific for this breed, five Poll Dorset VRQ/VRQ animals were collected and tested 
for the amount of C1.  These five Poll Dorset VRQ/VRQ sheep had C1 percentages 
which were comparable to the VRQ/VRQ Cheviot sheep.  
 
 
                             
   Figure 4.5 Alpha cleavage profiles from VRQ homozygote (montage of different gels) 
Lane 1 Western blot analysis of deglycosylated PrP
C
 from VRQ/VRQ sheep brain 
homogenate (10%) detected using monoclonal antibody 6H4. Lane 2 Western blot analysis 
of deglycosylated PrP
C
 from VRQ/VRQ sheep brain homogenate (10%) detected using 
monoclonal antibody BC6. Alpha tubulin was used as a loading control. 5 µl of 10% brain 
homogenate was loaded for each sample. Unglycosylated PrP
C
 was at ~ 26 kDa, the C1 
fragment at 18 kDa and the alpha tubulin loading control at ~ 55 kDa. This experiment was 
repeated twice (n = 2). 
 
 95
4.2.2 Statistical analysis (REML)  
Analysed data from Western blots were available for replicate samples of brain tissue 
from 44 healthy sheep (Table 4.1). The data were unbalanced in respect to some 
factors i.e. age, sex and breed therefore some comparisons between genotype could 
not be made within the same breed and sex group. It was possible to collect a more 
informative summary of the data by providing assumptions about certain effects. For 
example, all genotypes that were analysed are found in Cheviot and Poll Dorset 
sheep therefore the means for genotype adjusted for breed and sex were estimated on 
the condition that differences between genotypes are the same in all breeds and 
between males and females. 
 
These assumptions allow genotype differences to be estimated both directly from 
comparisons of observed means within breed/sex combinations and indirectly from 
comparisons of means between breed/sex comparisons. To fit a model that included 
age, breed and genotype the data was analysed using REML (residual maximum 
likelihood). A linear mixed model with random variation between animals and 
between repeat observations within animals was used to estimate means and standard 
errors of the C1 fragment. The parameters of the model were estimated using REML 
directive in Genital 10
th
 edition.  
 
Approximate statistical significance of differences between genotype means was 
evaluated using Student’s t distribution with 41 degrees of freedom, calculating t 
from the difference between any two genotype means and its corresponding standard 
error.  For example, ARR/ARR v. VRQ/VRQ gives t = (25.47-29.72)/6.78 = -0.63, 
p >0.53. Table of Means and corresponding standard errors can be observed in Table 
4.2. 
 
After statistical analysis between the genotype groups a significant difference was 
found between ARQ/ARQ homozygotes and VRQ/VRQ homozygotes (p<0.05) and 
between VRQ/ARQ heterozygotes and VRQ/VRQ homozygotes (p<0.01). A 





All differences between genotypes in the same breed and sex are not statistically 
significantly different from zero (p>0.05) except for the VRQ/ARQ v. VRQ/VRQ 
comparison in Poll Dorset females  p<0.01.  The mean for VRQ/ARQ in Poll Dorset 
females is strikingly low with 2 out of the 6 animals observed with zero C1.  The 
same comparison in Cheviot females is  p>0.22. 
 
The REML analysis was also used to estimate the variance of C1 between repeat 
observations on the same animal. The pooled variance of C1 between repeat 
observations on the same animal was calculated as 26.77 with a standard deviation of 
5.17. This is somewhat smaller than the standard deviation between observations 
made on different animals (of the same breed, sex, genotype and age) estimated to be 
8.95. 
 
Although a significant difference was found between VRQ/VRQ homozygotes and 
VRQ/ARQ heterozygotes and VRQ/VRQ homozygotes and ARQ/ARQ 
homozygotes no significant correlation was found between the amont of C1 and 
incubation period data (SSBP/1) after analysis of the genotype means R
2
 = 0.0058 
(Figure 4.6). This result therefore suggests that there is no linkage between the 




Table 4.2 C1 Mean percentage for each Genotype averaged equally over Breed and 
Sex adjusted to the mean age of 43 months 
----------------------------------------------------------------------------------------------------------------------- 
 
Genotype  AHQ/ARQ  AHQ/ARR  ARQ/ARQ  ARQ/ARR  ARR/ARR  VRQ/ARQ  VRQ/VRQ 
                     20.46         27.16          15.87         22.27          25.47         16.72          29.72 
 
Standard errors of differences between pairs 
 
Genotype AHQ/ARQ   1        * 
Genotype AHQ/ARR   2     6.40        * 
Genotype ARQ/ARQ   3     5.95     5.60        * 
Genotype ARQ/ARR   4     5.56     5.66     4.66        * 
Genotype ARR/ARR   5     5.96     5.75     5.58     5.11        * 
Genotype VRQ/ARQ   6     6.71     6.35     4.96     6.13     6.63        * 
Genotype VRQ/VRQ   7     7.21     6.49     5.15     6.53     6.78     4.64        * 




Table 4.3 Comparisons between Genotype means 
Mean vs Mean Approx.t Significant at p<0.05 
ARQ/ARQ  AHQ/ARQ -0.771 No 
ARQ/ARQ  ARQ/ARR -1.373 No 
ARQ/ARQ  ARR/ARR -1.722 No 
ARQ/ARQ  AHQ/ARR -2.017 No 
ARQ/ARQ  VRQ/VRQ -2.691 Yes (p<0.05) 
VRQ/ARQ  AHQ/ARQ -0.556 No 
VRQ/ARQ  ARQ/ARR -0.905 No 
VRQ/ARQ  ARR/ARR -1.321 No 
VRQ/ARQ   AHQ/ARR -1.645 No 
VRQ/ARQ   VRQ/VRQ -2.803 Yes (p<0.01) 
AHQ/ARQ   ARQ/ARR -0.326 No 
AHQ/ARQ   ARR/ARR -0.841 No 
AHQ/ARQ   AHQ/ARR -1.047 No 
AHQ/ARQ   VRQ/VRQ -1.285 No 
ARQ/ARR   ARR/ARR -0.627 No 
ARQ/ARR   AHQ/ARR -0.864 No 
ARQ/ARR   VRQ/VRQ -1.142 No 
ARR/ARR   AHQ/ARR -0.293 No 
ARR/ARR   VRQ/VRQ -0.626 No 




The relationship between C1 and incubation period 

































Figure 4.6 Correlation graph between mean percentage of C1 and incubation period 
with SSBP/1 
Mean percentage of C1, for each genotype group measured by densitometry and the 
incubation period for each genotype after incubation with SSBP/1. Each point represents one 
genotype group. This graph clearly shows that there is no correlation between the amount of 
C1 and incubation period.  
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4.2.3 Full-length PrP and C1 percentages in young animals (<1 year) 
As part of the genotype study, it was noted that three still born lambs had a higher 
percentage of C1 compared to adult sheep. To follow up this observation sheep with 
mixed genotypes from three different breeds (Cheviot, Poll Dorset and Suffolk) were 
divided into three age groups: 
I) 0-5 day old, n = 6, 
II) 100-320 day old, n = 5, 
III) adult sheep one year or older, n = 44 
 
The results for group (III) are presented under 4.2.1. The frontal cortex was 
homogenised and Western blotting was performed with antibody 6H4.  Statistics was 
carried out using REML. After statistical analysis there was no significant difference 
between the age of the animal and the percentage of C1 (p>0.05).  
 
However, the percentage of C1 in younger animals (0-5 day olds) was very low 
(Figure 4.7). In contrast animals in the 100-320 age group had much higher 
percentages of C1 which were comparable to animals in the one year and older age 
group (Figure 4.7 and Figure 4.8). Mean C1 percentage values for young animals are 




Table 4.4 Densitometry data for young sheep (Frontal cortex) 










ARQ/ARQ 6D 0-5 5:95 2:98 
ARQ/ARQ 2006E 0-5 15:85 7:93 
ARQ/ARQ 2016E 0-5 12:88 19:81 
AHQ/ARQ 82 x 15 0-5 14:86 11:89 
AHQ/ARR 81 x 80 0-5 9:91 5:95 
ARR/ARR 81 x 34 0-5 12:88 7:93 
ARQ/ARQ 97A 100-320 30:70 27:73 
ARQ/ARR 005D 100-320 5:95 3:97 
ARQ/ARR 021D 100-320 37:63 32:68 
ARQ/ARR 024D 100-320 21:79 21:79 
ARQ/ARR 013D 100-320 37:63 22:78 
 
Table showing densitometry data for young sheep. C1 is calculated as a ratio of total PrP
C
 
and shown in the format C1: total PrP
C
. Each sample was tested twice (shown as result 1 




                          
Figure 4.7 Representative Western blots of alpha cleavage profiles for lambs 0-5 
days and lambs 100-320 days (Cortex) detected using monoclonal antibody 6H4 
Western blot of PNGase deglycosylated and undigested PrP
C 
from lamb brain 
homogenate. Diglycosylated PrP
C
 detected at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 31 
kDa, unglycosylated PrP
C
 at ~ 26 kDa and the C1 fragment at ~ 18 kDa. 5 µl of 10% brain 
homogenate was loaded for each sample. 
 
 
                        
 
   Figure 4.8 PrP and C1 detected from frontal cortex of three Suffolk lambs animals 
   aged 100-320 days using monoclonal 6H4 
Western blot of PNGase deglycosylated and undigested PrP
C
 from Suffolk sheep no. 
021D, no. 013D and no. 97A. These animals are 100-320 days old. The diglycosylated 
form of PrP
C
 is at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 31 kDa, unglycosylated PrP
C
 at ~ 
26 kDa and the C1 fragment at ~ 18 kDa. 5 µl of 10% brain homogenate was loaded for 
each sample. This experiment was repeated twice (n = 2). 
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4.2.4 Full-length PrP and C1 in ovine brain regions 
PrP was prepared from medulla, thalamus and cerebellum to compare the percentage 
of C1 in these brain regions to the previously established values for frontal cortex. 
The medulla was chosen as this area is one of the first to accumulate PrP
Sc
 deposition 
during scrapie disease (Jeffrey et al., 2001). The thalamus and cerebellum are also 
targeted during scrapie pathogenesis and also chosen because these brain areas had 
previously been analysed  (Kuczius et al., 2007a). 
 
Brain tissue was sectioned from six animals that were one year or older (Table 4.5). 
There was no scope for investigating the effect of breed, sex, genotype or age on 
differences between brain areas as the 11 animals come from 10 different 
breed/sex/genotype/age combinations. Brain areas were compared on the assumption 
that breed/sex/genotype/age do not affect brain area differences. Repeat observations 
on the same animal/brain area was averaged to give at most one measure per animal 
per brain area and a non-parametric sign test used as many observation are at the 0% 
limit.  
 
After statistical analysis using a non-parametric sign test there was a significant 
difference in the percentage of C1 between the cortx and medulla (p<0.05) and 
thalamus and medulla (p<0.05) (Figure 4.12). Overall, the highest amount of C1 was 
found in the frontal cortex and thalamus and less so in the medulla and cerebellum 
(Figure 4.9 A and B, Figure 4.11, Figure 4.12).  
 
The variance was calculated for each individual animal for each brain region (Data 
not shown). A pooled estimate of variance was also calculated for each brain region 
(All animals). For the cerebellum the pooled estimate of variance was 4.4 with a 
standard deviation of 2.10. For the medulla the pooled estimate of variance was 3.6 
with a standard deviation of 1.90. For the cortex the pooled estimate of variance was 
10.17 with a standard deviation of 3.18. Finally the pooled estimate of variance for 
the thalamus was 10.35 with a standard deviation of 3.21. The Variance for the 




The percentage of C1 in these four brain regions were also analysed for newborn 
lambs (0-5 days old) and young lambs (100-320 days). Western blot results from the 
newborn lambs (0-5 days old) show very low percentages of C1 in the medulla, 
cerebellum and thalamus (Figure 4.10) which is comparable to the results that were 
seen in the frontal cortex using 6H4 (Figure 4.7, Figure 4.10). For two young lambs 
from the age group 100-320 days low percentages of C1 was observed in the medulla 
but higher percentages were observed in the thalamus (data not shown). Mean C1 
percentage values for animals used in the brain region study are located in Table 4.1 




                           
 
                                     
Figure 4.9 PrP
C
 and C1 detected in four areas of the sheep brain using monoclonal 
antibody 6H4 
(A) Western blot profile of PNGase deglycosylated and undigested PrP
C
 from Cheviot 
sheep no. 72 x 38. High percentage of full-length PrP and C1 is detectable within the 
thalamus (T), (lane 1, 2 and 4) and the cortex (C) (lane 6). Only full-length PrP
C
 is 
detectable in the cerebellum (Cb), (lane 3) and medulla (M), (lane 7). There is also a band 
above C1 (most likely to be C2) (lane 1, 4 and 6) indicated by * on the blot at 20 kDa. (B) 
Western blot profile of PNGase deglycosylated and undigested PrP
C
 from Cheviot sheep 
no. 71 x 58. Only a small percentage of C1 is detected in the medulla (M), (lane 1) and 
cerebellum (Cb), (lane 5) of this animal. The diglycosylated form of PrP
C
 is detected at ~ 
36 kDa, unglycosylated PrP
C
 at ~ 26 kDa and the C1 fragment at ~ 18 kDa. The 
monoglycosylated form of PrP
C
 is not detected in any of the undigested samples. 5 µl of 
10% brain homogenate was loaded for each sample. Both experiments were repeated 




           
Figure 4.10 Western blots of alpha cleavage profiles from various ovine brain areas 
from newborn lambs (0-5 days old) detected using monoclonal antibody 6H4 
(montage of different gels) 
Western blot profiles of PNGase deglycosylated PrP
C
 from Cheviot sheep no. 81 x 34, 81 x 
80, and 82 x 15. For sheep no. 81 x 34 only full-length PrP
C
 is detected in the cortex (Co), 
medulla (M) and cerebellum (Cb), (lanes 1-3). For animal no. 81 x 80 only full-length PrP
C
 
is detected in the cortex (Co) and cerebellum (Cb), (lane 4 and 5). Full-length PrP
C
 and 
some C1 detected are detected in the medulla (M) of animal 81 x 80, (lane 6). For animal 
no. 82 x 15 full-length PrP
C
 and C1 are detected in the cortex (Co) (lane 7). Full-length 
PrP
C
 only is detected in the cerebellum (Cb) (lane 8). The unglycosylated form of PrP
C
 is 
detected at ~ 26 kDa and the C1 fragment at ~ 18 kDa. 5 µl of 10% brain homogenate was 
loaded for each sample. 
         
           
Figure 4.11 Detection of full-length PrP
C
 and C1 in different brain regions using  
monoclaonal antibody 6H4  
Representative Western blot of alpha cleavage profiles from VRQ/VRQ homozygote 
animal J255. Full-length PrP
C
 and C1 were detected in the frontal cortex (Co), (Lane 1), 
cerebellum (Cb), (Lane 2), medulla (M), (Lane 3) and thalamus, (T) (Lane 4). The 
unglycosylated form of PrP
C
 is detected at ~ 26 kDa and the C1 fragment at ~ 18 kDa. 5 µl 
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Table showing densitometry data for brain region study. C1 is calculated as a ratio of total 
PrP
C
 and shown in the format C1: total PrP
C 
for each brain region tested. Each sample was 























Figure 4.12 Histogram of mean C1 % values for all ovine brain regions 
Error bars indicate the standard deviation for animals for each brain area. After analysis 
using non parametric sign test the mean amount of C1 in the frontal cortex and the mean 
amount of C1 in the thalamus is significantly different to that in the medulla (p<0.05). 
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4.2.5 Quantifying the amount of PrPC in four different regions of the 
sheep brain  
As PrP
C
 expression is important for the development of TSE disease, the amount of 
PrP
C
 in different areas of the sheep brain was quantified using the enhanced 
lanthanide fluoroimmunoassay (DELFIA
®
) with a previously established protocol. 
Five animals that had been used previously for protein detection by Western blot 
analysis were used for this quantitative ELISA. The DELFIA
®
 technique uses pairs 
of PrP specific antibodies to measure the amount of PrP in a sample. In this 
experiment capture antibody FH11 (epitope 54-57, Figure 3.11) which will only 
capture full-length PrP
C
 was used. The DELFIA
® 
assay conditions were not 
established to use antibodies that would detect C1 and full-length PrP. Antibody 8H4 
(epitope 175-185, Figure 3.11) labelled with lanthanide europium was used to detect 
bound PrP. For this assay the amount of PrP
C
 in an individual sample was 
determined using sheep recombinant PrP (ARQ allele) as a standard and assay buffer 
as a negative control.  
 
To confirm that these animals were uninfected, PrP
C 
was solubilised in 2M guanidine 
hydrochloride in which PrP
Sc
 is insoluble. After initial treatment with guanidine 
hydrochloride a pellet remained. This pellet was solubilised in 6M guanidine 
hydrochloride. PrP
Sc
 is soluble at this concentration and would be detectable if it was 
present. Total protein concentrations were carried out for each sample (2.1.3) before 
treatment with guanidine hydrochloride. All the samples that were used in the 
DELFIA
®
 assay were negative for PrP
Sc 
(Data not shown). For these experiments, the 
cortex, medulla, cerebellum and thalamus from five Cheviot sheep with mixed 
genotypes were analysed, each sample was assayed twice in duplicate.   
 
Statistical analysis was not performed because only five animals were used in this 
study. The results for all sheep tested are presented as histograms in Figure 4.13. 
Total PrP values for these animals take into account the C1 fragment by adding the 
mean percentage of C1 for each individual brain area using densitometry 
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Figure 4.13 Mean amount of soluble PrP
C
 (Including C1) detected by DELFIA
®
 and 
Western blot for four different regions of the ovine brain for individual animals 
PrP
C
 quantification in different brain regions is expressed in ng/mg of total protein for each 
tissue. Full-length PrP
C
 was measured using the DEFLIA
® 
and this was added to the mean 
amount of C1 which was measured from the Western blot results to get an estimate total 
PrP
C
 value (Full-length PrP
C
 + (Full-length PrP
C
 x % C1) = Total PrP
C
. Each sample was 
assayed in duplicate and the corresponding means calculated. Error bars indicate the 
standard deviation between repeats for each brain region for the DELFIA assay. In cases 
where no error bar is shown, exact replicate values were produced. Each sample was 
repeated twice n = 2.  
Sheep I ARR/ARR 
 
Sheep II VRQ/VRQ 
 
Sheep IV ARQ/ARQ Sheep III ARQ/ARR 





The overall distribution of PrP
C
 for all sheep was variable between each animal and 
between individual brain areas of the same animal (Figure 4.13). The least variation 
was observed for animal 75 x 49 with mean values of 4.1 ng/mg for the cortex, 4.9 
ng/mg for the medulla, 5.5ng/mg for cerebellum and 5.9 ng/mg for the thalamus. The 
most variation was observed for animal 71 x 58 with mean values of 3.1 ng/mg for 
the cortex, 6.5 ng/mg for the medulla, 11.7 ng/mg for the cerebellum and 8.1 ng/mg 
for the thalamus.  
 
For sheep 75 x 49 the highest amount of PrP was detected in the thalamus and lowest 
in the cortex. For sheep J225 the highest amount of PrP was detected in the medulla 
and lowest in the cortex. For sheep 72 x 38 the highest amount of PrP was detected 
in the cortex and lowest in the cerebellum. For sheep 69 x 67 the highest amount of 
PrP was detected in the medulla and the lowest in the cerebellum. And finally for 
sheep 71 x 58 the highest amount of PrP was detected in the cerebellum and lowest 
in the cortex. These results are very varied and are different to the Western blot 
results although the Western blot results were not quantitative (Table 4.1 and Table 
4.5). Results from the Western blots show strong PrP signals in the cortex and 
thalamus and lower signals for PrP in the cerebellum and medulla. The DELFIA
®
 
results are opposite for some of the sheep tested with higher amounts of PrP detected 




4.3.1 The association of PrPC alpha cleavage and PRNP genotype 
The presented analysis of 44 adult sheep shows that PrP alpha cleavage occurs in all 
seven genotypes that were tested. It appears that the VRQ homozygote animals have 
a significantly higher percentage of C1 than ARQ/ARQ and VRQ/ARQ, genotypes, 
under the premise that breed and sex have, if at all, only a minor effect on this 
biochemical process and that only animals over three months of age are compared 
(REML analysis). The effect of breed was tested as the VRQ/VRQ group contained 
both Cheviot and Poll Dorset animals, however, no statistical difference was 
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observed between these groups although, this may be due to the small number of 
animals in each group n= 5. The sex ratio of the animals used in the genotype study 
is almost 1:3 male to female with some female only genotype groups. It is highly 
unlikely that sex has an effect on alpha cleavage as no differences in PrP between the 
sexes in any species have been published. In this study the amount of C1 that was 
detected in young lambs (0-5 days old) occurred at very low and often immeasurable 
levels, however these measurements were not significantly different to the amount of 
C1 detected in adult sheep. This data is supported by Laffont-Proust et al., (2005) 
who show no correlation between age and the amount of C1 in human brain samples. 
Our results may have been influenced by the low sample size of the young lambs (n 
= 5). 
 
Although the REML analysis showed that there was a statistical significant 
difference between the amount of C1 between VRQ/VRQ homozygotes and 
ARQ/ARQ homozygotes and between VRQ/VRQ homozygotes and VRQ/ARQ 
heterozygotes, there is no correlation between the amount of C1 and incubation 
period with SSPB/1 scrapie (Figure 4.6). There was also no significant difference in 
the amount of C1 between the VRQ/VRQ homozygotes and the ARR/ARR 
homozygotes, which is the opposite end of the susceptibility range. This suggests the 
alpha cleavage does not play a major role in disease susceptibility.  
 
Measuring the percentage of total PrP
C
 and C1 by Western blot has been shown to be 
reproducible. However the issue of enzymatic cleavage needs further investigation. 
In many cases before deglycosylation only diglycosylated PrP
C
 was detectable and 
after deglycosylation the C1 was visible. It was previously thought that 
deglycosylation was required for the visualisation of the C1 fragment as the C1 
fragment migrates at the same size as unglycoyslated PrP
C
 only becoming visible 
after removal of the sugars. It may be that the enzyme PNGase F, which is used for 
the deglycosylation of PrP
C
 may be responsible for this cleavage, however this is 
unlikely as in some samples C1 was not always detectable after PNGase treatment. It 
may be that during PrP
C
 digestion with PNGase, some of PrP
C
 is lost during this 





 degradation does not occur after freeze thawing or after incubation of tissue at 
RT for 16 hours. It may be that degradation occurs more quickly with homogenates 
rather than fresh tissue.    
 
By contrast a DELFIA/ELISA based approach provides quantitative analysis but 
requires more optimisation and a minimum of three different antibodies would have 
been necessary to get the same end result as it has been shown that antibody 
characteristics can significantly influence the outcome (Frances Wiseman, personal 
communication). DELFIA/ELISA based assays would also not have differentiated 
easily between C1, and C2 or potentially other fragments which is a great advantage 
of the Western blot as shown in several examples in this thesis.  
 
The sequence of the PrP hydrophobic region around amino acid codons 106 –119 
was identical for all animals that were used in the genotype study. This suggests that 
differences in the amount of cleavage can not be explained by the PrP hydrophobic 
sequence. Oliveira-Martins et al., (2010) show that only large deletions within the 
106-119 domain of PrP impair the production of the C1 fragment substantially 
supporting the idea that the sequence although not necessarily the amino acid 
composition of the hydrophobic region is not essential for alpha cleavage. However, 
PrP primary sequence has been shown to be important for PrP alpha cleavage as 
human PrP
C
 showed an increase in C1 levels compared to mouse PrP
C
 in an in vitro 
study (Haigh et al., 2009). 
 
Overall our results indicate that PrP alpha cleavage either has no biological 
consequence on disease or incubation period or that this association with disease is 
much more subtle and may only explain specific agent-host combinations. More 
experimental data will be needed to clarify this issue. 
 
4.3.2 Comparisons with other studies of PrPC cleavage ratios  
Kuczius et al., (2007a) showed that the signal intensity of the C1 fragment was 
higher compared to full-length PrP
C
 in pooled and single sheep brain tissue samples 
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(Table 4.4). Our results differ fundamentally from Kuczius et al., (2007a) with full-
length PrP
C
 being dominant over the C1 fragment (Table 4.6) in all examined tissues. 
A direct comparison is difficult as different antibodies were used between the two 
studies. One might argue that the differences may be attributed to the use of different 
antibodies with their different epitopes as Kuczius et al., (2007a) showed differences 
with various antibodies in their study. Alternatively, their procedure or storage of 
samples may be more prone to preferential degradation of PrP
C
. It is also not 
apparent from their study what genotypes were tested, which may be very different 
from the ones tested here. 
 
4.3.3 PrPC fragments in relation to brain region 
Previous work using RT-PCR and Western blotting show that expression levels of 
PrP in sheep brain are highest in the frontal cortex and lower in the obex and 
thalamus (Tichopad et al., 2003, Diaz-San Segundo et al., 2006, Gossner et al., 
2009) although a study by Han et al., (2006) shows that PrP expression is highest in 
the obex. 
 
In our study we quantified PrP expression levels in four regions of the sheep brain 
using the DELFIA
®
 assay. Expression of PrP in certain brain areas may be correlated 
with the accumulation of PrP
Sc
 and the onset of disease. In our study we were limited 
to only five animals with varying PRNP genotypes. The DELFIA
®
 results suggest 
that there is some within and between animal differences between the amounts of 
PrP
C
 in the different brain areas. These differences may be due to varying expression 
levels of the enzyme responsible for the cleavage in these different brain areas. The 
results for the Western blot data and DELFIA
®
 do not correlate well together, 
however these differences may be due to differences in antibodies that were used in 
both assays. As an internal control ovine ARQ/ARQ recombinant PrP was used to 
produce a standard curve, in which all our samples fell within the linear range.  
 
When the results are compared to data by others the amount of PrP
C
 detected in our 
animals are within the same range as results by Moudjou et al., (2001). In the study 
by Moudjou et al., (2001) the amount of PrP detected was between 3-5 ng/mg of 
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total protein whereas the amount of PrP detected in our quantification was between 
2-12 ng/mg of total protein. Differences observed between our results may be due to 
the differences between the DELFIA
®
 assay and the standard ELISA methods used 
by Moudjou et al., (2001) although similar principles apply. The antibodies used in 
our DELFIA
® 
was also different to the antibodies used by Moudjou et al., (2001). It 
is known from previous studies that the pairing of antibodies in the DEFLIA assay 
can affect results (Frances Wiseman, personal communication).  
 





. After analysing the percentage of C1 in animals with 
varying degrees of susceptibility to scrapie it seems unlikely that the amount of C1 is 
directly involved in scrapie disease.  
 
 
Table 4.6 Dominant PrP forms detected in sheep brain tissue 
Study Antibodies Brain region Dominant PrP form 













Love et al., 2009 data 












Chapter 5 Alpha cleavage in PrP transgenic mouse models 
  
5.1 Introduction 
PrP transgenic mice have been used extensively in prion research to address 
questions about pathology (Bueler et al., 1992, Manson et al., 1994, Moore et al., 
1995) transmission (Bruce et al., 1994, Scott et al., 1999), PrP glycosylation 
(Cancellotti et al., 2005) and about the normal function of PrP (Sakaguchi et al., 
1996, Moore et al., 1999). As yet transgenic mice have not been used to study PrP 
alpha cleavage.  
 
As shown in chapter 4, alpha cleavage can occur at a relative high level of almost 
50% of total PrP in sheep cortex. Two different transgenic models were available to 
investigate the relationship between the amount of PrP that is produced in a tissue, 
the sequence of PrP and the level of PrP alpha cleavage. The first model is 
represented by highly over-expressing transgenic mice Tg20, Tg338 and KB6. The 
second model represents moderately over-expressing transgenic mice with different 
PrP protein variants, such as KB5, KVRQ and KARQ.  
 
Tg20 mice express murine PrP at ten-times the level of wild type mice. These mice 
are very susceptible to mouse scrapie and have an incubation period of ~ 63 days 
compared to 149 days for wild type mice (Brandner et al., 1996, Fischer et al., 1996). 
Tg338 mice are transgenic for the VRQ allele of ovine PrP on a mouse PrP
0/0 
background. The PrP expression levels in the brains of Tg338 mice are 8-to-10 fold 
that in sheep (Le Dur et al., 2005). These mice are also susceptible to scrapie and 
have short incubation times compared to sheep with the same genotype (Vilotte et 
al., 2001, Le Dur et al., 2005, Thackray et al., 2008). Line KB6 expresses a bovine 
PrP variant with six octapeptide repeats (Goldmann et al., 1991b) at about 6 times 
the level of normal mouse brain. KB5 mice express a bovine PrP variant with five 




Lines KVRQ and KARQ were chosen as these two models express ovine VRQ and 
ARQ alleles respectively, at 1-2x level of normal brain. The last four mouse lines 
were derived from founders provided by Prof G. Telling, University of Kentucky. All  
four lines are on mouse PrP
0/0 
background. Unpublished data for the KARQ and 
KVRQ transgenic mice by Hunter and colleagues (Roslin Institute) show that the 
relationship between incubation period and PrP genotype are equivalent to what has 
been described for sheep (Goldmann et al., 1994, Houston et al., 2002a). This 
suggests that these mice are a good scrapie disease model, but it remains to be seen 
whether they are a good model for PrP
C
 biology, e.g. alpha cleavage. 129/Ola mice 
that express murine PrP at normal level were used as base line control. 
 
Another very different PrP-transgenic model that was used to investigate principles 
of PrP
C
 cell biology was mice deficient in PrP glycosylation. These mice are gene 
targeted and carry mutations at the first, second or both Asn-linked glycosylation 
sites of PrP. They are referred to as G1 (codon 180 Thr), G2 (codon 196 Thr) and G3 
(codon 180 Thr + codon 196 Thr) mice (Cancellotti et al., 2005, Tuzi et al., 2008). 
The substitution of asparagine with threonine at position 180 in the G1 mice and at 
position 196 in the G2 mice will only allow the production of mono- and 
unglycosylated PrP. G3 mice with the threonine substitution at positions 180 and 196 
only produce unglycosylated forms of PrP (Cancellotti et al., 2005, Tuzi et al., 
2008). 
 
In G1 and G2 mice, PrP is localised at the cell membrane (Cancellotti et al., 2007) 
and in G3 mice it is found mainly within the golgi apparatus (Cancellotti et al., 
2007). These models therefore provide a means of investigating cellular pathways 
and the role of glycosylation on alpha cleavage of PrP.  
 
This chapter analyses whether cleavage can occur in various transgenic models with 






5.2.1 Detection of C1 in ovine PrP expressing transgenic mice  
Brain homogenates from transgenic mice from lines KVRQ and KARQ, expressing 
ovine PrP variants VRQ and ARQ, respectively were analysed by Western blotting 
and C1 as a percentage of total PrP
C
 was measured by densitometry. Presence of the 
VRQ and ARQ alleles were confirmed by direct sequencing of PCR products (2.2.7). 
Figure 5.1 (A and B) show C1 cleavage profiles from two KARQ and two KVRQ 
transgenic mice.  
 
 
       A       B 
 
 
Figure 5.1 PrP and C1 detected from KARQ and KVRQ transgenic mice using 
monoclonal antibody 6H4  
(A) Western blot of PNGase deglycosylated and undigested PrP
C 
of two KARQ transgenic 
mice. PrP
C
 is mostly diglycosylated (lane 4), control buffer only (lane 5). C1 is present in all 
PNGase treated samples (Lane 1, 2 and 3). Animal 1 (lane 1, 3 and 4), animal 2 (lane 2). 
Some remaining mono and diglycosylated PrP
C
 can be seen in lanes 1-3. (B) Western blot 
of PNGase deglycosylated and undigested PrP
C 
of two KVRQ transgenic mice. Animal 1 
(lane 1 and 2), animal 2 (lane 3 and 4). PrP
C
 is most diglycosylated. C1 is present in both 
PNGase treated samples. The diglycosylated form of PrP
C
 is at ~ 36 kDa, 
monoglycosylated PrP
C
 at ~ 31 kDa, unglycosylated PrP
C
 at ~ 26 kDa and the C1 fragment 
at ~ 18 kDa. 5 µl of 10% brain homogenate was loaded for each sample. Each experiment 




Tg338 mice were analysed by Western blot and C1 as a percentage of total PrP
C 
was 
measured by densitometry. Cleavage profiles from Tg338 mouse brain homogenates 
with antibody 6H4 are shown in Figure 5.2A.  This profile proves that alpha cleavage 
does occur in these transgenic mice but at much higher percentage than in KVRQ 
and KARQ mice (Figure 5.1A and B). When 20µg of total protein is loaded (Figure 
5.2A, lane 2) there is also another truncated fragment at approximately 20kDa that is 
visible in substantial amounts. This fragment could be glycosylated C1, the C2 
fragment or a mixture of both. However, when the amount of total protein from the 
Tg338 homogenate was reduced from 20g/ml to 10g/ml to achieve complete 
PNGase digestion the amount of the 20kDa band is reduced compared to the 
previous preparation (Figure 5.2A, lane 4, 6). As expected C1 as a percentage of total 
PrP
C
 does not change when 10g of protein is loaded and all glycosylation has been 
removed from PrP (Figure 5.2A, lane 4, 6). Using antibody P4 that will recognise C2 
but not C1, two bands are detected suggesting that they are full-length PrP
C
 and the 
C2 fragment, respectively (Figure 5.2B). 
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   A 
   
 
   B 
   
   Figure 5.2 PrP and C1 detected from Tg338 mouse brain homogenate 
(A) Western blot profile of Tg338 mouse brain homogenate treated (lane 2, 4, 6) and 
untreated (lane 3, 5, 7) with PNGase and detected with monoclonal antibody 6H4. 
Molecular weight marker loaded in lane 1. C1 is detected in PNGase positive samples 
along with an extra band (most likely to be C2) (indicated by *) at ~ 20kDa. 20 µg of total 
protein loaded (lane 2, 3) and 10 µg of total protein loaded (4, 5, 6, 7). (B) Western blot 
profile of Tg338 mouse brain homogenate detected using P4. Molecular weight marker 
loaded in lane 1. C2 fragment (*) which is detected at ~ 20 kDa is only detected in PNGase 
treated samples. 20 µg of total protein loaded for each sample. The diglycosylated form of 
PrP
C
 is detected at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 32 kDa, unglycosylated PrP
C
 at 




In a serial dilution series Tg338 mouse brain homogenate was diluted 1:125 which 
resulted in a signal similar or slightly less than the level of a normal mouse brain at a 
1:5 dilution (Figure 5.3, lanes 5 and 6). This suggests that there is a 15-25 fold 
difference in the levels of PrP between the over expressing mice and the non 
transgenic mice (Figure 5.3).  
 
Full-length PrP mean percentage values and densitometry data for all ovine PrP 












Figure 5.3 Dilution series of PrP
C
 in Tg338 and non-transgenic 129/Ola mouse brain   
homogenate using monoclonal antibody BC6 
Western blot of PrP
C
 from frontal cortex homogenate (10%). The dilution values for the   
10% brain homogenate from Tg338 and 129/Ola mice are indicated. Molecular weight 
marker loaded in lane 1. Colour standard loaded in lane 2. 20 µl of 10% brain homogenate 
was loaded for each sample. The diglycosylated form of PrP
C
 is detected at ~ 38 kDa, 
monoglycosylated PrP
C
 at ~ 32 kDa, unglycosylated PrP
C
 at ~ 26 kDa and the C1 fragment 




5.2.2 Detection of C1 in murine PrP expressing transgenic mice 
Observations similar to the Tg338 mice were seen for murine PrP transgenic Tg20 
mice which also over-express PrP. Figure 5.4 show C1 cleavage profiles from Tg20 
and 129/Ola brain homogenates. Alpha cleavage does occur in these transgenic 
mouse models, with the percentage of C1 much greater in the Tg20 mice compared 
to the 129/Ola.  
 
The ratio of total PrP
C
/C1 produced in the 129/Ola mice (Figure 5.4, lane 1, 3) is 
equivalent to the ratios of total PrP
C
/C1 produced in the KVRQ (Figure 5.1B, lane 1, 
3) and KARQ (Figure 5.1A, lane 1, 2, 3) which also express approximately normal 
protein levels. The percentage of C1 produced in the Tg20 is similar to the 
percentage of C1 produced in the Tg338 mice (Table 5.1). An extra band of 
approximately 20kDa which is thought to be the C2 fragment is also seen in the Tg20 
mice (Figure 5.4, lane 5, 6). This band is also observed in the over-expressing ovine 
PrP mouse line (Figure 5.2 A).  
 
Densitometry data for transgenic mice (C1 expressed as a percentage of total PrP
C
) 
for all ovine and murine PrP transgenic mice and 129/Ola mice can be found in Table 
5.1. Densitometry measurements were also taken for the C2 band for Tg338, and 
Tg20 mice, Densitometry data for C1, C2 and Full-length PrP (FL PrP
C
) can be 
found in Table 5.2. C1 was measured as a percentage of C2 and Full length PrP
C
 i.e 
(C1 /C1+C2+ Full length PrP
C * 
100). For Tg338 and Tg20 mice the amount of C1 









 and C1 detected from 129/Ola and Tg20 mice brain homogenates      
using monoclonal antibody 6H4 
  (A) Western blot of PNGase deglycosylated and undigested PrPC of two 129/Ola mice. 
PrP
C
 is mostly diglycosylated (lane 2, 4). C1 is present in all PNGase samples (lane 1, 3). 
(B) Western blot of PNGase deglycosylated and undigested PrP
C
 of two Tg20 mice. C1 is 
present in all the PNGase samples (lane 5, 6). An extra band can be seen in the PNGase 
samples (most likely to be C2) (lane 5, 6) indicated by * on the blot. This band is at ~ 20 
kDa. Some remaining mono-glycosylated PrP
C
 can be seen in lane 5, 6. Diglycosylated 
PrP
C
 is at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 31 kDa, unglycosylated PrP
C
 at ~ 26 and 
the C1 fragment at ~ 18 kDa. 5 µl of 10% brain homogenate was loaded for each sample. 
This experiment was repeated twice (n = 2). 
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5.2.3 Detection of C1 in bovine PrP expressing transgenic mice 
Bovine PrP transgenic mice KB6 mice that over-express PrP with six octapeptide 
repeats and KB5 mice that express PrP at normal levels with five octapeptide repeats 
were analysed by Western blotting and C1 as a percentage of total PrP
C
 was 
measured by densitometry. C1 cleavage profiles from KB6 and KB5 mice are 
presented in Figure 5.5 (A and B). These profiles show that alpha cleavage does 
occur in these transgenic mouse models although the percentage of C1 is more in the 
KB6 mice compared to the KB5 mice (Figure 5.7).   
 
The percentage of C1 in the KB6 mice is equivalent to the percentage of C1 found in 
the other over expressing transgenic mice Figure 5.6 (A, B and C). The percentage of 
C1 found in the KB5 mice is equivalent to other transgenic mice expressing normal 
levels of PrP and equivalent to wild type mice Figure 5.6 (A, B and C). The C2 band 
is also visible in the KB6 model. Representative Western blots for all transgenic 
mouse models are shown in Figure 5.6 (A, B and C). Densitometry data for 
transgenic mice (C1 expressed as a percentage of total PrP
C
) for all KB5 and KB6 
mice can be found in Table 5.1. Densitometry measurements were also taken for the 
C2 band for KB6 mice, Densitometry data for C1, C2 and Full-length PrP (FL PrP
C
) 
can be found in Table 5.2. C1 was measured as a percentage of C2 and Full length 
PrP
C
 i.e (C1 /C1+C2+ Full length PrP
C * 
100). For KB6 mice the amount of C1 was 




          A      B     




 and C1 detected from KB6 and KB5 mice brain homogenates using 
monoclonal antibody 6H4 
(A) Western blot of PNGase deglycosylated and undigested PrPC of one KB6 mouse. PrPC 
is mostly diglycosylated. The C1 fragment is present in the PNGase sample (lane 1). An 
extra band can be seen in the PNGase sample (most likely to be C2) (lane 1) indicated by 
* on the blot. This band migrates at ~  20 kDa. Some remaining monoglycosylated PrP
C
 
can also be seen in lane 1. (B) Western blot of PNGase deglycosylated and undigested 
PrP
C
 of one KB5 mouse. The C1 fragment is present in the PNGase sample (lane 3). 
Diglycosylated PrP
C
 is at ~ 38 kDa, monoglycosylated PrP
C
 at ~ 31 kDa, unglycosylated 
PrP
C
 at ~ 26 kDa and the C1 at ~ 18 kDa. 5 µl of 10% brain homogenate was loaded for 























Figure 5.6 Representative Western blots of PrP and C1 from transgenic mouse brain   
homogenates using monoclonal antibody 6H4  
(A, B and C) Western blot of deglycosylated PrP
C
 from mouse brain tissue. Protein bands 
were detected as full-length unglycosylated PrP
C
 (~30 kDa) and the C1 fragment at (~18 
kDa) using antibody 6H4. An increase in levels of C1 was observed in the over expressing 
KB6, Tg338 and Tg20 mouse models. A band at ~ 20 kDa most likely to be the C2 
fragment indicated by * on the blot was present in higher quantities in the over-expressing 
transgenic models. 5 µl of 10% brain homogenate was loaded for each sample. 
























KVRQ  2x 
Mouse 1 5:95 5:95 
Mouse 2 14:86 11:89 
Mouse 3 22:78 21:79 
Mouse 4 20:80 15:85 
KARQ 2x 
Mouse 1 11:89 10:90 
Mouse 2 21:79 18:82 
Mouse 3 15:85 14:86 
Mouse 4 13:87 12:88 
KB5  2x 
Mouse 1 11:89 7:93 
Mouse 2               9:91 7:93 
KB6  6x 
Mouse 1 34:66 30:70 
Mouse 2 35:65 34:66 
Tg20  10x 
Mouse 1 29:71 25:75 
Mouse 2 23:77 21:79 
Tg338  8x 
Mouse 1  43:57 31:69 
Mouse 2 27:73 25:75 
129/Ola  1x 
Mouse 1 9:91 8:92 
Mouse 2 10:90 10:90 
 
Table showing densitometry data for all transgenic mice. C1 is calculated as a ratio of total 
PrP
C
 and shown in the format C1:C1 :(Full length PrP
C
+C2) Each sample was tested twice 
(shown as result 1 and result 2). Western blots performed with 6H4.
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Table showing densitometry data for all transgenic mice (ratio of C1:C2:Full length 
PrP
C
).Each sample was tested twice (shown as result 1 and result 2). In some cases the C2 


















KB6 1 6x Mouse 1 34:27:39 30:12:58 6x 
KB6 2 6x Mouse 2 35:19:46 34:18:48 6x 
Tg20 1 8x Mouse 1 29:0:27 25:13:62 10x 
Tg20 2 8x Mouse 2 23:17:60 21:0:79 10x 
Tg338 1 10x Mouse 1 43:0:57 31:17:52 8x 
Tg338 2 10x Mouse 2 27:19:54 25:21:54 8x 
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5.2.4 Comparison between the amount of PrPC in over expressing 
Tg338 mice and normal PrP expressing KVRQ and KARQ mice  
To quantify how much prion protein is produced in PrP over-expressing mice, the 
amount of PrP
C
 in the brains of over-expressing ovine PrP transgenic Tg338 mice 
and normal expressing ovine PrP transgenic KARQ and KVRQ mice were compared 




In this experiment capture antibody FH11, which will only capture full-length PrP, 
was used as before. Antibody (8H4) labelled with lanthanide europium was used to 
detect bound PrP. (For detailed methodology see section 2.3.4 and 2.1.11.4). For this 
assay the amount of PrP
C
 in an individual sample was determined using sheep 
recombinant PrP (ARQ allele) as a standard. Assay buffer was used as a negative 
control. 129/Ola mice could not be used as direct control because mouse recombinant 
PrP would be required as a standard to obtain accurate measurements. For these 
experiments each animal was assayed twice in duplicate.  
 
The results for all transgenic mice tested are presented as a table 5.3. PrP values for 
these animals take into account the C1 fragment by adding the mean percentage of 
C1 for each individual transgenic line, using densitometry measurements from the 
Western blot results. The amount of protein loaded was not controlled as not enough 
tissue was available for this assay; therefore a total protein assay was not carried out. 
Instead 50 µl of a 10% w/v brain homogenate was loaded for each sample. The 
values are given as ng/ml as this corresponds to the value given for the standard 
curve.  
 
Results from the DELFIA
®
 indicate that Tg338 mice express approximately 10 x 
more PrP than KVRQ and KARQ mice, which is less than the calculated values for 
the Western blot quantification (Figure 5.3). The DELFIA
®
 results for the KARQ 
and KVRQ mice were similar with a mean value of 0.7 ng/ml and 0.4 ng/ml, 
respectively. Because only two or three animals were used in this study per group 




Table 5.3 PrP values (including C1) detected by DELFIA
® 
detected for ovine PrP 
transgenic mice 
Transgenic line (PrP ng/ml) 
KVRQ 1 0.3, 0.4 
KVRQ 2 0.5, 0.5 
KVRQ 3 0.1, 0.3 
KARQ 1 0.5, 0.6 
KARQ 2 0.6, 0.8 
Tg338 1 5.0, 5.3 




 quantification is expressed in ng/ml. Full-length PrP
C
 was measured using the DEFLIA
® 
and this was added to the mean amount of C1 which was measured from the Western blot 
results to get an estimate total PrP
C
 value (Full-length PrP
C
 + (Full-length PrP
C
 x % C1) = 
Total PrP
C
. Each sample was assayed in duplicate and the corresponding means calculated. 
Each sample was repeated twice n = 2. KVRQ group contained 3 mice (n = 3), ARQ group 
contained two mice (n = 2) and the Tg338 group contained two mice (n = 2).  
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5.2.5 Detection of C1 in PrP glycosylation deficient mice 
To investigate whether glycosylation of PrP is important for alpha cleavage, PrP-
glycosylation deficient mice were analysed. The presence of the mutant and wild 
type alleles were confirmed by PCR (2.2.5). Visual inspection of Western blots 
suggests that the electrophoretic mobility of mono-glycosylated PrP differs between 
G1 and G2 mice (Figure 5.9 B and C) this has been shown previously (Cancellotti et 
al., 2005).  
 
Without deglycosylation PrP truncated fragments were observed in the G1, G2 and 
G3 mice when 6H4 was used for detection (Figure 5.7A, lanes 2, 3, 4 and Figure 
5.7B, lanes 3, 4, 7, 8). When BC6 (epitope 147-155, Figure 3.11) was used for 
detection PrP truncated fragments were also observed in the 129/Ola controls as well 
as the G1, G2 and G3 mice (Figure 5.7 C, lanes 5 and 9). The PrP truncated fragment 
observed in the G3 mice is predicted to be the C1 fragment. The PrP truncated 
fragments observed in the G1, G2 and 129/Ola mice are predicted to be C1 with one 
or two carbohydrates attached. The PrP truncated band in the G1 mice (Figure 5.7A, 
lane 1 and Figure 5.7 C, lane 2 and 6) is positioned at a slightly higher molecular 
weight compared to the G2 mice this would correspond to the mono-glycosylated 
form of PrP.  
 
When brain homogenates from the PrP-glycosylation deficient mice are fully 
deglycosylated with PNGase the complete content of C1 fragment is revealed in the 
G1, G2 and G3 mice (Figure 5.8A, lanes 5, 6, 7 and Figure 5.8B, lane 2, 8). 
However, when 6H4 is used for detection after deglycosylation sometimes C1 is 
present (Figure 5.8B, lane 3) and other times C1 is not present (Figure 5.8A, lanes 
11-13).  
 
In conclusion the C1 fragment is processed in all three PrP glycosylation deficient 
mice. This suggests that the carbohydrates are not required for alpha cleavage. 
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Figure 5.7 Western blot profiles of PrP glycosylation deficient mice  
(A) This blot demonstrates the difference in the electrophoretic mobility of monoglycosylated 
PrP
C
 from G1 and G2 transgenic mice. In the G1 and G2 mice there is an extra lower 
molecular weight band present at ~ 35 kDa and 34 kDa. In the G3 mice there is also an extra 
lower molecular weight band that is equivalent in size to the C1 fragment at ~ 18 kDa. PrP
C
 
was detected using monoclonal antibody 6H4. (B) This blot highlights the same aspects as 
blot A however there is no extra molecular weight band in the G1 mice. Only the C1 band is 
observed in the G3 mice. PrP
C
 was detected using monoclonal antibody 6H4. (C) Membrane 
in (B) was stripped and re-probed using monoclonal antibody BC6. This blot shows that 
there are lower molecular weight bands seen in the G1, G2 and 129/ola control mice at ~ 20 
and 18 kDa as well as the G3 mice. 5 µl of 10 % brain homogenate was loaded for each 
sample. Each experiment was repeated twice (n = 2). 
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Figure 5.8 Western blot profiles of PNGase deglycosylated total brain proteins from 
PrP glycosylation deficient mice detected using monoclonal antibodies BC6 and 
6H4   
(A) The C1 fragment is present in the PNGase positive and negative samples (lane 2-7) 
when BC6 is used for detection. An extra band is observed in the PNGase negative 
samples for G1 and G2 mice (lane 2, 3). The C1 fragment is not present in the PNGase 
positive samples (lane 11, 12, 13) when 6H4 is used for detection. (B) The C1 fragment is 
present in the PNGase positive and negative samples (lane 2, 3, 4, 5) for G2 and 129/Ola 
mice when BC6 is used for detection. The C1 fragment is present in the PNGase positive 
samples (lane 8, 10) for G2 and 129/Ola mice when 6H4 is used for detection.  5 µl of 10% 
brain homogenate was loaded for each lane (A and B). Monoglycosylated PrP
C
 detected at 
24-25 kDa, unglycosylated PrP
C
 at 26 kDa, C1 band at ~ 18 kDa and another lower 








Our results from the various transgenic mouse lines show that alpha cleavage occurs 
in all PrP transgenic mice. The primary sequence of PrP does not appear to 
significantly affect the processing of this cleavage. There are 25 amino acid 
differences within the coding region of PrP between sheep and mice. Only one of 
these changes is close to the alpha cleavage site, this change is found at codon 112 
where methionine in sheep is replaced for leucine in mice at the equivalent position 
(codon 108). As there is little difference between the primary PrP sequence between 
mice and sheep within the alpha cleavage region it may not be surprising that alpha 
cleavage occurred in these transgenic mice. One can therefore conclude that all these 
mouse lines are useful models for alpha cleavage. However, the KB6 mice which 
have six octapeptide repeats had more C2 compared to the KB5 mice which have 
only five octapeptide repeats. As beta cleavage occurs within the octapeptide region, 
the amount of octapeptides may have an effect on beta cleavage. 
 
Interestingly a recent paper by Oliveira-Martins et al., (2010) suggests that the amino 
acid sequence near the cleavage site of PrP is not critical for alpha cleavage. This 
group showed that alpha cleavage occurred in a variety of cell lines which was only 
disrupted when large areas of the central domain were deleted. These results show 
that the central domain of PrP is important but the protease which may be 
responsible for this cleavage is not overly dependent on sequence specificity. It may 
be that other domains of PrP may be important for alpha cleavage.  
 
A study by Haigh et al., (2009) show that the primary sequence of PrP around the 
alpha cleavage site is important for proteolytic processing as cells expressing mouse 
PrP produced significantly more C1 compared to cells expressing human PrP.  
Studies on Alzheimer’s disease report that the distance from the membrane may be 
more important for protease activity rather than the amino acid sequence of the 
protein (Sisodia et al., 1990, Maruyama et al., 1991 Novak, 2004). The experiments 
presented here indicate that there is no reduction between cleavage of mouse and 
sheep PrP sequence.Therefore sequence appears to be less relevant for alpha 




Transgenic mice that over-expressed PrP showed an increase in the percentage of C1 
compared to wild type mice and mice that expressed close to normal levels of PrP.  
Interestingly over-expressing mice have shorter incubation periods compared to wild 
type mice, however it is currently impossible to separate the possible effect of C1 
levels from the well established dosage effect of full-length prion protein. In a recent 
paper Huang et al., (2007) showed that over-expression of PrP in Tg mice lead to a 
myopathy that correlates with high levels of C1. These results suggest that an 
increase in C1 may be detrimental and may also have an influence on scrapie disease 
susceptibility. However, Tg338 mice are healthy up to 600 days of age (Hunter et al., 
personal communication) and no abnormalities in muscle tissue have been reported.  
 
KVRQ mice are not the best model of VRQ sheep when considering alpha cleavage. 
In relative terms sheep with the VRQ/VRQ genotype produce more C1 as a 
percentage of total PrP
C
 than the KVRQ transgenic mouse line, however only 4 
animals were used per group. KARQ and Tg338 mice provide a much better 
representation of alpha cleavage when compared to ARQ/ARQ and VRQ/VRQ 
sheep. However, as Tg338 mice over-express PrP they are compromised models for 
that reason.  
 
Results from the DELFIA
®
 analysis showed that Tg338 mice express 10 times more 
PrP compared to KVRQ and KARQ mice, however this result was less than the 25x 
difference that was quantified via Western blotting (Figure 5.3). As Western blot 
analysis is only semi-quantitative it is likely that this result was an overestimate and 
that the DELFIA
®
 result provided a more accurate measurement. Interestingly Tg338 
mice have been previously quoted to have 8-10 fold more PrP compared to a normal 
sheep, however the amount of PrP detected in the Tg338 in this study was more 
equivalent to the levels detected in a sheep (4.2.7) although direct comparisons 
cannot be made as the total amount of protein loaded in the DELFIA
®
 assay was not 
controlled. However, as the levels of PrP
C
 detected in the KARQ and KVRQ were 
relatively equal it can be assumed that a higher degree of accuracy was achieved with 
the DELFIA
®




The data presented here also show that all three PrP-glycosylation deficient mice 
produce the C1 fragment. Antibody 6H4 did not consistently detect C1 in the PrP-
glycosylation deficient mice. The percentage of C1 produced in PrP-glycosylation 
deficient mice was more than 50% of the total PrP
C
 signal Figure 5.8 (A and B) when 
BC6 was used for detection. When BC6 was used for the detection of C1, 129/Ola 
mice had equivalent levels of C1 as the PrP-glycosylation deficient mice (Figure 5.8 
B).  
 
PrP Truncated fragments were observed in G1, G2 and 129/Ola mice when BC6 was 
used for detection Figures 5.7 C lanes 1, 3, 5, 6, 7, 9, Figure 5.8 A lanes 2, 3, 6 and 
Figure 5.8 B lanes 2, 3, 4, 5. Truncated forms were also observed in G1 and G2 mice 
with 6H4 (Figures 5.7 A lane 2, 3, Figure 5.7 B lane 3, 7). The truncated fragments 
in the glycosylation deficient mice are likely to reflect glycosylated forms of C1 and 
possibly C2 as these fragments were not observed in the G3 mice.  
  
In conclusion, the carbohydrates are not required for PrP alpha cleavage as G3 mice 
which have the glycosylation sites abolished were able to cleave C1 efficiently. It is 
known that the trafficking of PrP
C
 is altered in G3 mice as PrP
C
 is mainly localised 
internally within the Golgi (Cancellotti et al., 2005) but it appears that the alpha 
cleavage is independent of reaching the plasma membrane or recycling. Although 
subtle effects on alpha cleavage cannot be excluded from these experiments 
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Chapter 6 Detection of the alpha cleavage fragment C1 in ovine and 
murine peripheral tissues using novel monoclonal antibodies 
 
6.1 Introduction 
In previous chapters PrP
C 
and the C1 fragment have been successfully detected from 
ovine and murine brain samples using a simple lysis extraction (2.1.1). However, this 
method was not successful for the detection of PrP
C
 from peripheral tissues even 
after a purification step was added to the extraction method (2.1.2). Within the 
literature PrP
C
 has been detected from many murine peripheral tissues but the 
number of studies that have detected PrP
C
 from ovine peripheral tissues are limited. 
In the few studies that have been able to detect PrP
C
 from ovine peripheral tissue, 
immunoprecipitation methods have been used to concentrate levels of PrP
C
 (Horiuchi 
et al., 1995, Moudjou et al., 2001) before detection by Western blotting.  
 
As well as detecting PrP
 
by Western blotting Moudjou et al., (2001) also quantified 
the amount of PrP from peripheral tissues using solid phase EIA methodology. This 
group found consistently high levels of PrP expression in the lung, heart and skeletal 
muscle in three different ovine PrP genotypes. These quantification results were 
supported by their Western blot data that showed high levels of PrP detection for 
these tissues, although much less compared to the brain control (Moudjou et al., 
2001). Interestingly ARQ/VRQ animals contained the highest PrP expression levels 
for five out of the nine peripheral tissues tested. However, a link between genotype 
and quantification levels of PrP could not be investigated fully as only a small 
number of animals were used in this study.  
 
Unfortunately neither Horiuchi et al., (1995) or Moudjou et al., (2001) examined the 
presence of C1 in these tissues. In order to expand upon C1 data that had already 
been collected for ovine brain tissue various peripheral tissues were also tested for 
the presence of the C1 fragment. It is of interest to investigate the percentage of C1 
in peripheral tissues to see if alpha cleavage is processed in the same way in different 
tissue types and to see if the percentage of alpha cleavage varies accordingly.
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In an attempt to concentrate PrP from peripheral tissues immunoprecipitation was 
carried out using three different IgM (IgM κ) monoclonal antibodies. Antibodies were 
kindly supplied by (M. Jones, Blood Transfusion Service Scotland). Antibodies that 
were chosen for immunoprecipitation of PrP
C 
were (IgM) H1.8, H3.2 and H3.3. The 
epitopes of these antibodies are directed against the C-terminal end of PrP (Figure 
3.11, Figure 6.1). The epitopes of these antibodies were the main reason that these 
antibodies were chosen, so that the amount of full-length PrP and C1 in peripheral 
tissues could be compared. Antibody 6H4 which had previously been used for 
Western blotting was not used for immunoprecipitation as other groups had shown 
that 6H4 gave poor results for the immunoprecipitation of PrP
C
 (unpublished data). A 
novel IgG antibody (BC6, Kind gift from Sandra McCutcheon, Roslin Institute) 












 (Jones et al., 2009) from human 
brain tissue. Because this antibody had been able to precipitate PrP
C
 from human 
tissue it was hoped that it would be able to immunoprecipitate PrP
C
 from ovine 





 by Western blotting (Jones et al., 2009). For previous results of these 
antibodies for immunoprecipitation and Western blotting see Table 6.1 (A, B and C).  
 
The IgM antibodies were produced by Michael Jones and his group at the Blood 
Transfusion Service, Scotland. The IgM antibodies were raised against human 
platelets (Jones et al., 2005). By raising these antibodies against human platelets it 
was hoped that they may be useful in the development of a blood-screening assay for 
PrP. PrP null mice were used to overcome the problem of immune tolerance 
(Andrievskaia et al., 2006, Jones et al., 2009). However, the animal spleens (B-
lymphocytes) were fused together with a myleoma cell that did express PrP, although 
at very low levels (Kim et al., 2003, Jones et al., 2009). For each fusion the mouse 
chosen received a final intravenous boost of 50 mg pHuPrP in phosphate-buffered 
saline (PBS) and was sacrificed 4 days later (Jones et al., 2009).  The effect of this 
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PrP expression is unknown but may have some effect on antibody production and 
stability of the cell lines. 
 
Hybridoma supernatants were routinely screened for the production of antibody 
binding to pHuPrP by ELISA. Hybridoma cell lines producing anti-pHuPrP 
antibodies were single cell cloned, expanded, and cryopreserved according to 
standard procedures (Jones et al., 2009). 
. 
Ovine and murine tissue was available for the characterisation of these antibodies. 
These antibodies provide the potential of visualising PrP
C
 and C1 on a Western blot 
from uninfected peripheral tissues and also provide data to compare against 













H1.8 Weak Weak 
H3.2 Yes Yes 
H3.3 No Yes 
  












H1.8 No No No No No No 
H3.2 Weak No No No No No 
H3.3 No No No No No No 
 
Table 6.1 C 
MAb RecMoPrP Normal brain- PK Scrapie brain + PK 
H1.8 Yes Yes Yes 
H3.2 Yes Yes Yes 
H3.3 Yes Yes Yes 
 




. Data from (Jones et al., 
2009).  Immunoprecipitation data for MAb H1.8, H3.2 and H3.3 which were tested on 
Alzheimer’s control brain (PrP
C
), and vCJD brain with PK digestion (PrP
Sc





 by Western blotting. Data from V. McLoughlin, M.Phil thesis 
(2009). Western blot data for MAb H1.8, H3.2 and H3.3 which were tested on normal platelet 
lysate (NPL), normal activated platelet supernatant (NAPS), Variant Creutzfeldt Jacob 





by Western blotting. Data from V. McLoughlin, M.Phil thesis (2009). Western blot data for 
MAb H1.8, H3.2 and H3.3, which were tested on recombinant mouse PrP (RecMoPrP), 



























Figure 6.1 PrP epitopes for MAbs H1.8, H3.2 and H3.3 
Bold letters indicate amino acid change. Glycosylation site present at amino acid 196. This 
work was undertaken by Victoria McLoughlin (Data was taken from her M.Phil).  
H1.8         147-166      
Human  DRYYRENMHRYPNQVYYRPM 
Ovine  --------Y----------V  
Ovine  ----H---Y----------V 
Murine --------Y----------V 
 
H3.2         157-176   
Human  YPNQVYYRPMDEYSNQNNFV   
Ovine  ---------V-Q--------  
Ovine  ---------V-R-------- 
Murine ---------V-Q-------- 
 
H3.3 186-205 (Glycosylation site at 196) 
Human  HTVTTTTKGENFTETDVKMM 






6.2 Results  
 
6.2.1 Single cell cloning to stabilise cell lines 
In the first attempt to revive the monoclonal cell lines H3.3 and H3.2 problems were 
encountered as they were dying shortly after they were removed from LN2 storage. 
Whereas H3.3 cells grew quickly after another fresh batch was taken out of LN2 
storage,  H3.2 cells took  approximately 3 months to grow  To support cell growth 
mixed thymocyte media (MTM) and R20 was added to the cells when they were in 
25cm
2 
flasks and in 96 well plates. MTM media provides the cells with extra growth 
factors (Micklem et al., 1987). These cell lines were previously frozen down without 
a cell viability count and never re-grown, so the amount of viable cells may have 
been initially low, however it is likely that the cell lines are unstable.  
 
Single cell cloning of H1.8, H3.2 and H3.3 from flasks at 5 cells/well and 1 cell/well 
was carried out to clone more stable cell lines. Colony counts and screening of 
cloning plates by ELISA was also carried out. Figure 6.2 shows an ELISA result for 
cell line H1.8 for the production of IgM antibody. Cells from the 1 cell/well cloning 
plates were grown up to 75cm
2
 flasks, and then they were frozen down for future 
characterisation studies. One vial from each cell line and each frozen batch was taken 





















































































































































































































































































































































































































































6.2.2  Quantification of purified IgM isotype monoclonal antibodies by 
ELISA 
Purification of all three IgM antibodies was carried out using ammonium sulphate 
and quantification of the final IgM concentration was undertaken using a simple 
ELISA. Two fold serial dilutions of mouse IgM standard (Sigma) [200ng/ml to 
1.56ng/ml] were prepared along with serial dilutions of the MAb [1:1000 to 
1:256000]. The mean absorbance (450nm) for each standard was plotted against the 
corresponding IgM concentration to produce a standard curve from which the IgM 
concentration of the test sample was determined. The total IgM concentration for 
each antibody can be seen in Table 6.2.  
   
 Table 6.2 Total IgM concentration for cell line H1.8, H3.2 and H3.3 





Summary of all MAbs grown up in vitro from LN2 frozen stocks. The names of the IgM MAbs 
are described in the first column, followed by the antibody concentration of the MAb (mg/ml). 
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6.2.3 Immunoprecipitation of PrP from vCJD and normal human brain  
homogenate using IgM MAbs H1.8, H3.2 and H3.3 
The three IgM MAbs and a non-PrP related IgM isotype control were evaluated for 
their ability to immunoprecipitate PrP
C
 from uninfected human brain and PrP
Sc
 from 
vCJD infected brain (Figure 6.3). Human samples were used a control to confirm 
previous published results and to ensure that the antibodies were working correctly. 
MAb H3.2 immunoprecipitated from both brain homogenates, suggesting that this 
MAb recognises both normal and prion disease associated forms of HuPrP (Figure 
6.3, lanes 1 and 2). MAb H3.3 only immunoprecipitated from non-PK digested vCJD 
brain, suggesting that this MAb displays selectivity towards abnormal disease 
associated PrP (Figure 6.3, lane 4). Neither MAb H1.8 nor the IgM control appeared 
to immunoprecipate any forms of PrP (Data not shown); these results support 
published work by Jones et al., (2009). 
 
A lower truncated fragment at ~ 16 kDa was visible in both uninfected and infected 
samples (Figure 6.3, lanes 1, 2 and 4). This lower molecular fragment was not 
observed or mentioned in the previous publication (Jones et al., 2009). Even though 
protease inhibitors are used in the preparations of brain homogenates it could be 
possible that this truncated fragment is degradation of PrP
C
 caused by post-mortem 
lysis of the brain tissue. The storage and handling conditions of this particular brain 
sample was unknown.  It is also possible that this fragment may also be a novel 
truncated fragement of PrP. 
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Figure 6.3 Western blotting of PrP
C 
immunoprecipitated from uninfected human 
brain homogenate and PrP
Sc
 from vCJD infected human brain homogenate  
Uninfected (lanes 1 and 3) and vCJD infected (lanes 2 and 4), human brain homogenates 
(10%) without proteinase K (PK) treatment were incubated with anti-PrP antibodies H3.2 
and H3.3 coupled to magnetic beads Immunoprecipitated PrP
C
 was detected by antibody 
3F4. 20 µl of immunoprecipitate was loaded for each sample. The diglycosylated form of 
PrP was present at ~ 36 kDa, monoglycosylated PrP at ~ 31 kDa and unglycosylated PrP 
at ~ 26 kDa.  An unidentified truncated fragment migrates at ~ 16 kDa. This experiment 
was repeated twice (n = 2). 
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6.2.4  Immunoprecipitation of PrP from scrapie infected ovine brain 
and uninfected ovine brain  
The three IgM MAbs and a non-PrP related IgM isotype control were also evaluated 
for their ability to immunoprecipitate PrP
C
 from uninfected ovine brain and PrP
Sc
 





, however only di and unglycosylated forms 
of PrP were detectable (Figure 6.4 lane 1 and 2). MAb H3.3 immunoprecipitated 
only unglycosylated PrP (Figure 6.4 lane 3). This result suggests that H3.2 
recognised both normal and prion disease associated forms of Ovine PrP and that 
H3.3 only recognises normal Ovine PrP. Neither MAb H1.8 nor the IgM control 
immunoprecipated any forms of PrP (Data not shown).
 
 
These results were repeated but this time antibody BC6 was used for detection. This 
IgG antibody shares the same epitope as 6H4. Although 6H4 and BC6 have the same 
PrP sequence, they may have different conformations for PrP.  In the first experiment 
H1.8, H3.2 and H3.3 immunoprecipitated PrP
C
 from ovine ARQ/ARQ brain 
homogenate (Figure 6.5A, lanes 4, 6 and 8). Only H3.3 immunoprecipitated PrP
Sc
 
from scrapie infected ovine ARQ/ARQ brain homogenate (Figure 6.5A, lane 9). The 
IgM control did not immunoprecipitate any form of PrP. The genotype of the 
homogenate used in the 6H4 experiment (Figure 6.4) was unknown so; these results 
may be due to genotypic differences. This experiment was repeated, this time all 
three MAbs immunoprecipitated PrP
C 
(Figure 6.5B, lanes 3-5). PrP
Sc
 was not 
immunoprecipitated by any of the antibodies (Figure 6.5B, lanes 7-9).  
 
To follow up the idea that there may be some genotypic differences uninfected 
ARR/ARR brain homogenate was incubated with H1.8, H3.2 and H3.3 and PrP 
detected by Western blot using BC6 (Figure 6.6). All three MAbs 
immunoprecipitated PrP
C 
(Figure 6.6, lanes 3, 5 and 7). As a negative control 
dynabeads were incubated in the presence of brain homogenate but in the absence of 




                                  
 
Figure 6.4 Western blot of PrP
C
 immunoprecipitated from uninfected ovine brain 
homogenate and PrP
Sc
 immunoprecipitated from scrapie infected ovine brain 
homogenate  
Uninfected (Lanes 1 and 3) and scrapie infected (Lanes 2 and 4) ovine brain homogenates 
(10%) without proteinase K (PK) treatment were incubated with anti-PrP antibodies (H3.2 
and H3.3) coupled to magnetic beads. Blank lanes indicate sample buffer only. 
Immunoprecipitated PrP was detected by antibody 6H4. 20 µl of immunoprecipitate was 
loaded for each sample. The diglycosylated form of PrP present at ~ 36 kDa, 
monoglycosylated PrP at ~ 31 kDa, unglycosylated PrP
 
~ at 26 kDa.  This experiment was 














Figure 6.5 Western blot of PrP
C
 immunoprecipitated from uninfected ovine brain 
homogenate and PrP
Sc
 immunoprecipitated from scrapie infected ovine brain 
homogenate 
(A) Uninfected and scrapie infected brain homogenates (10%) from ARQ/ARQ 
homozygotes. Uninfected (lanes 2, 4, 6 and 8) and scrapie infected (lanes 3, 5, 7 and 9). 
(B) Uninfected and scrapie infected brain homogenates (10%) from ARQ/ARQ 
homozygotes. Uninfected (lanes 3, 4 and 5) and infected (lanes 7, 8 and 9). Ovine brain 
homogenates without proteinase K (PK) treatment were incubated with anti-PrP antibodies 
(H1.8, H3.2 and H3.3) coupled to magnetic beads. Magnetic beads (Dynabeads) were 
incubated as a negative control in the presence of brain homogenate. Blank lanes indicate 
sample buffer only. Immunoprecipitated PrP was detected using monoclonal antibody 
BC6. 20 µl of immunoprecipitate was loaded for each sample. The diglycosylated form of 
PrP
 
was present at ~ 36 kDa, monoglycosylated PrP at ~ 31 kDa and unglycosylated PrP 











     
                        
 
 
Figure 6.6 Western blot of PrP
C
 immunoprecipitated from uninfected ovine brain 
homogenate from an ARR/ARR homozygote  
Uninfected (Lanes 3, 5 and 7) ovine brain homogenates (10%) were incubated with anti-
PrP antibodies (H1.8, H3.2 and H3.3) coupled to magnetic beads. Blank lanes indicate 
sample buffer only. Magnetic beads (Dynabeads) were incubated as a negative control in 
the presence of brain homogenate but in the absence of anti-PrP antibody. 
Immunoprecipitated PrP was detected by antibody BC6. 20 µl of immunoprecipitate was 
loaded for each sample. The diglycosylated form of PrPC was present at ~ 36 kDa, 
monoglycosylated PrP
C
 at ~ 31 kDa, unglycosylated PrP
C
 at ~ 26 kDa.  This experiment 









 was successfully immunoprecipitated from the brain of uninfected sheep the 
next experiment investigated whether PrP
C
 could be immunoprecipitated from the 
mesenteric lymph node (MLN). Mesenteric lymph node was chosen as this 
peripheral tissue is infected during scrapie infection and was available for the same 
animals used in the brain analysis. Messenger RNA expression within lymph node 
has been calculated to be equivalent to levels within certain areas of the brain 
(Moudjou et al., 2001), therefore it may be possible to imunoprecipitate PrP
C
 from 
this tissue.   
 
After incubation and precipitation with anti-PrP antibodies (H1.8, H3.2 and H3.3) 
PrP was not detected in the MLN by Western blotting (Figure 6.7, lanes 4, 6 and 8). 
A brain sample was used as a positive control and as expected PrP was detected after 
immunoprecipitation with all three MAbs (Figure 6.7, lanes 5, 7 and 9). As a 
negative control MLN and brain homogenates were incubated in the presence of a 
non PrP related IgM antibody. Unexpectedly the IgM control immunoprecipitated 
PrP
C
 from the brain sample (Figure 6.7, lane 3); this suggests that non-PrP related 
antibodies may be capable of immunoprecipitating PrP, this has been observed 
previously for PrP
Sc
 (Morel et al., 2004) or that occasionally PrP
C
 when present at 
high concentrations can adhere to the beads or other material and can be carried over 
through the washes. The IgM control was negative for the MLN sample (Figure 6.7, 
lane 2).  
 
To investigate whether PrP was not detected in the MLN due to low levels of starting 
material a repeat of this experiment was carried out by increasing the starting 
concentration of the material of the MLN from 1mg/ml to 10mg/ml. After an 




                            
Figure 6.7 Western blot of PrP
C
 immunoprecipitated from uninfected ovine brain 
homogenate and PrP
C
 immunoprecipitated from uninfected ovine MLN  
Uninfected brain (B) and MLN (M) was from an ARR/ARR homozygote. Brain (Lanes 3, 5, 
7 and 9) and MLN (Lanes 2, 4, 6 and 8) homogenates (10%) were incubated with anti-PrP 
antibodies (H1.8, H3.2 and H3.3) coupled to magnetic beads or a corresponding IgM 
isotype (non-prion related). Immunoprecipitated PrP was detected by antibody BC6. 20 µl 
of immunoprecipitate was loaded for each sample (Brain and MLN). The diglycosylated 
form of PrP
C 
was present at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 31 kDa and 
unglycosylated PrP
C
 at ~ 26 kDa for brain samples only. No PrP
C





As IgM antibodies H1.8, H3.2 and H3.3 were unable to immunoprecipitate PrP
C
 
from the mesenteric lymph node IgG antibody BC6 was used for 
immunoprecipitation of PrP
C
 ovine MLN and ovine brain as a control. Unfortunately, 
after immunoprecipitation of normal sheep brain, scrapie sheep brain and ovine 
mesenteric lymph node there was a lot of unspecific staining (Figure 6.8 A). No 
unspecific staining was observed when dynabeads were incubated in the presence of 
normal brain (Figure 6.8 A, lane 10) and normal MLN (Figure 6.8 A, lane 11) but in 
the absence of BC6.  
 
Antibody BC6 was also incubated as a control in the presence of lysis buffer only 
and unspecific staining was observed in this sample (Figure 6.8 A, lane 9). Therefore 
the unspecific binding must be related to either the capture (BC6) or the detector 
antibody (P4). To determine whether the unspecific staining was due to the capture 
or detector antibody the membrane was stripped of the detector antibody and the 
membrane re-probed with the secondary antibody only (Figure 6.8 B). The Western 
blot image in Figure 6.8 B shows that after stripping of the detector antibody (P4) 
most of the unspecific staining remains. This suggests that the capture antibody BC6 
is responsible for the unspecific staining. 
 
In an attempt to eliminate the unspecific staining and to see if PrP could be detected, 
BC6 which is used at a concentration of 1mg/ml for immunoprecipitation was diluted 
(1:10 and 1:20) before it was used for immunoprecipitation. The Western blot image 
in Figure 6.8 C shows that unspecific binding is reduced compared to Figure 6.8 A 
and B but BC6 is unable to immunoprecipitate PrP
C
 from ovine brain and MLN and 
PrP
Sc
 from scrapie infected ovine brain. In conclusion, IgG antibody BC6 was unable 
























Figure 6.8 Western blots of PrP
C
 immunoprecipitated from uninfected ovine brain 
homogenate, MLN homogenate and PrP
Sc
 immunoprecipitated from scrapie infected 
brain homogenate 
(A) Uninfected brain (Un Br) (lanes 3 and 4), scrapie infected brain (In Br) (lanes 5 and 6) 
and MLN (lanes 7 and 8) were incubated with anti-PrP antibody BC6 coupled to magnetic 
beads (Dynabeads). Magnetic beads (Dynabeads) were incubated as a negative control in 
the presence of brain homogenate (lane 10) and in the presence of MLN (lane 11) but in 
the absence of anti-PrP antibody. Protein was detected using monoclonal antibody P4. (B) 
The Western blot in (A) was stripped using restore stripping reagent and re-probed with 
secondary antibody only. (C) Repeat of blot (A) but a 1:10 (lanes 3, 5, 7, 9 and 11) and 
1:20 (lanes 4, 6, 8 and 10) dilution of BC6 was carried out before immunoprecipitation. 10 
µl of immunoprecipitate was loaded for each sample. This experiment was carried out 
once (n = 1). 
A        B 
           
C 
         
  
 155
6.2.6  Immunoprecipitation of deglycosylated PrP and C1 from 
uninfected mesenteric lymph node  
Deglycosylation experiments on PrP
C
 immunoprecipitated from ovine ARQ/ARQ 
mesenteric lymph node (MLN) were carried out in the hope of detecting the C1 
fragment from this peripheral tissue. Brain tissue was also deglycosylated as a 
positive control. Treatment of PrP
C 
with PNGase resulted in simplifying the PrP
C
 
profile into one or two bands. The top band corresponds to unglycosylated PrP
C
 and 
the bottom band migrates at the same size as the C1 fragment. Figure 6.9 (lanes 5, 7 
and 9) shows that H1.8, H3.2 and H3.3 are able to immunoprecipitate PrP
C
 and the 
C1 fragment from brain tissue after deglycosylation, although the bands for the C1 
fragment are very faint. A band at the same size as the unglycosylated form of PrP is 
present in the MLN after immunoprecipitation with H1.8, H3.2 and H3.3 (Figure 6.9, 
lanes 6, 8 and 10) but the C1 fragment is not detectable. There is also a band in the 
IgM control for both brain and MLN homogenates (Figure 6.9, lanes 2 and 3). This 
band is slightly higher than the band for unglycosylated PrP therefore it is likely that 
this band is not PrP.   
 
The experiment was repeated with homogenates from an ARR/ARR homozygote 
animal. Figure 6.10 (lanes 5, 7 and 9) shows that H1.8, H3.2 and H3.2 are able to 
immunoprecipitate PrP
C
 and the C1 fragment from the brain after deglycosylation. 
Antibody H1.8 immunoprecipitated the most C1 although complete deglycosylation 
has not occurred and an extra band is seen above the C1 band (indicated by * on 
blot). A doublet is also seen for immunoprecipitation of PrP
C
 from the brain with 
antibody H3.2 and H3.3 (Figure 6.10, lanes 9 and 7). All three MAbs were unable to 
precipitate PrP
C
 and C1 from the MLN (Figure 6.10, lanes 6, 8 and 10). There are 
two bands in the IgM control for brain and one band in the IgM control for MLN 
(Figure 6.10, lanes 2 and 3).  
 
In conclusion, it appears that H1.8, H3.2 and H3.3 can immunoprecipitate PrP
C
 and 
the C1 fragment from the brain of uninfected sheep although the intensity of PrP 
signal can vary between animals and between the different antibodies. These three 
antibodies do not precipitate unglycosylated PrP
C


























Figure 6.9 Sensitivity of PrP
C
 from the brain and MLN to treatment with 
PNGase F 
A) Normal sheep brain homogenate (B) (10%) (lane 3, 5, 7 and 9) and MLN (M)  
homogenate (10%) (4, 6, 8, and 10) from ARQ/ARQ homozygote was treated with 
PNGase F and were incubated with anti-PrP antibodies (H1.8, H3.2 and H3.3) or to 
a corresponding IgM isotype (Non-PrP related) coupled to magnetic beads. Blank 
lane indicates sample buffer only. Immunoprecipitated PrP
C
 and C1 were detected 
by Western blot with monoclonal antibody BC6. B) Enlargement of image in A. This 
image has been highlighed by a box to emphasise the size difference between 
bands in lane 3 and 4 compared to other bands in the image. The unglycosylated 
PrP band (lanes 5-10) migrates at ~ 25 kDa while a band of ~ 26 kDa is observed in 
lanes 3 and 4. The C1 band migrates at ~ 18 kDa. 20µl of immunoprecipitate was 
loaded for each sample (Brain and MLN). This experiment was carried out once (n = 
1). 
   A                      
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Figure 6.10 Sensitivity of PrP
C
 from the brain and MLN to treatment with 
PNGase F 
A) Normal sheep brain homogenate (10%) (lane 3, 5, 7 and 9) and MLN 
homogenate (10%) (lane 4, 6, 8 and 10) from ARR/ARR homozygote was treated 
with PNGase F and were incubated with anti-PrP antibodies (H1.8, H3.2 and H3.3) 
or to a corresponding IgM isotype (Non-PrP related) coupled to magnetic beads. 
Blank lane indicates sample buffer only. Immunoprecipitated PrP
C
 and C1 were 
detected by Western blot with BC6. A band above the C1 fragment (most likely to be 
the C2 fragment) is indicated by * on the blot B) Enlargement of image in A. This 
image has been highlighted by a box to emphasise the doublet band observed in 
lanes 5, 7 and 9. Unglycosylated PrP
C
 migrates at ~ 25 kDa the doublet band 
observed in lane 5, 7 and 9 migrates at ~ 27 kDa, Band indicated by * migrates at ~ 
20 kDa while the C1 band migrates at ~ 18 kDa. 20µl of immunoprecipitate was 
loaded for each sample (Brain and MLN). This experiment was carried out once (n = 
1). 
A 
                       
B 
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6.2.7  Immunoprecipitation of PrP from uninfected murine tissues and 
ME7 infected brain  
As MAbs H1.8, H3.2 and H3.3 were unable to immunoprecipitate PrP
C 
from ovine 
peripheral tissues we decided to investigate whether PrP
C
 could be detected from the 
periphery of Tg338 mice. These antibodies were first tested for their ability to 
immunoprecipitate murine PrP
C
. All three IgM MAbs successfully 
immunoprecipitated PrP
C
 from 129/Ola mouse brain homogenate (Figure 6.11 lane 
1, 2 and 3) after detection with antibody BC6. As PrP
C
 was successfully detected 
from a 129/Ola brain homogenate it was thought that Tg338 (over-expressing ovine 
Tg mice) could be used as a model for detecting ovine PrP
C
 within peripheral tissues. 
In the next set of experiments Tg338 brain and liver were incubated with MAbs 
H1.8, H3.2 and H3.3 and 129/Ola brain used as a positive control. Proteins were 




was successfully detected from Tg338 brain and 129/Ola brain homogenates as 
expected (Figure 6.12, lanes 3-8) after immunoprecipitation with H1.8, H3.2 and 
H3.3. PrP
C
 was detected from Tg20 brain after immunoprecipitation with H1.8 only 
(Figure 6.15, lane 9). A band was detected in the Tg338 liver lanes for all three 
antibodies (Figure 6.12, lanes 9-11; Figure 6.13, lanes 9-11,) at approximately 25 
kDa however as this band migrated slightly lower than unglycosylated PrP
C
 it would 
suggest that this band is IgM light chain and not PrP. An attempt was also made to 
immunoprecipitate PrP
C
 from Tg338 spleen homogenate however this was 
unsuccessful and only unspecific staining was detected (Figure 6.14, lanes 1-3 and 
Figure 6.15, lanes 3-5). 
 
To investigate whether MAbs H1.8, H3.2 and H3.3 can immunoprecipitate PrP
Sc 
from murine brain tissue these antibodies were incubated with ME7 infected C57/B 
mouse homogenate. After three immunoprecipitation attempts none of the IgM 
antibodies was able to immunoprecipitate PrP
Sc
 from scrapie infected mouse brain 
homogenate (Figure 6.13, lanes 3-5; Figure 6.14, lanes 4-6 and Figure 6.15, lanes 6-
8). Table 6.3-Table 6.6 provide a summary of the immunoprecipitation results for 




In conclusion, MAbs H1.8, H3.2 and H3.3 only immunoprecipitated from uninfected 
murine brain homogenate, suggesting that these MAbs display selectivity towards the 
normal isoform of PrP. H1.8, H3.2 and H3.3 were unable to immunoprecipitate PrP
C
 
from over-expressing transgenic spleen and liver which suggests that the expression 
level of these tissues were too small or the confirmation of PrP
C
 in these tissues does 




                                      
Figure 6.11 Immunoprecipitation of PrP
C 
from 129/Ola brain homogenate (10%) 
Uninfected 129/Ola brain homogenate (10%) was incubated with anti-PrP antibodies (H1.8, 
H3.2 and H3.3) coupled to magnetic beads and analysed by Western blot. Blank lanes 
indicate sample buffer only. Immunoprecipitated PrP
C
 was detected by antibody BC6. The 
diglycosylated form of PrP
C
 was at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 30 kDa and 
unglycosylated PrP
C




                             
Figure 6.12 Western blot of PrP
C
 from brain and liver immunoprecipitates 
Uninfected murine brain homogenate (10%) (Lanes 3-5), Tg338 brain homogenate (10%) 
(lanes 6-8) and Tg338 liver homogenate (10%) (lanes 9-11) were incubated with anti-PrP 
antibodies (H1.8, H3.2 and H3.3) coupled to magnetic beads. Blank lane indicates sample 
buffer only. Immunoprecipitated PrP was detected by antibody BC6. The diglycosylated form 
of PrP
C
 was at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 30 kDa and unglycosylated PrP
C
 at ~ 
25 kDa. 20µl of immunoprecipitate was loaded for each sample (brain and liver). This 




                          




brain and liver immunoprecipitates 
ME7 infected C57/B brain homogenate (10%) (lanes 3-5) uninfected Tg338 brain 
homogenate (10%) (lanes 6-8) and uninfected Tg338 liver homogenate (10%) (lanes 9-11) 
were incubated with anti-PrP antibodies (H1.8, H3.2 and H3.3) coupled to magnetic beads. 
Immunoprecipitated PrP
C
 was detected by antibody BC6. The diglycosylated form of PrP
C
 
migrated at ~ 36 kDa. No PrP
Sc
 was detected in the ME7 infected brain homogenate (lanes 
3-5) and no PrP
C
 detected in the Tg338 liver homogenate (lanes 9-11). 20µl of 
immunoprecipitate was loaded for each sample (brain and liver). This experiment was 




                        




brain and spleen immunoprecipitates 
Uninfected Tg338 spleen homogenate (10%) (lanes 1-3), ME7 infected C57/B mouse brain 
homogenate (10%) (lanes 4-6) and uninfected 129/Ola mouse brain homogenate (10%) 
(lanes 7-9) were incubated with anti-PrP antibodies (H1.8, H3.2 and H3.3) coupled to 
magnetic beads. Immunoprecipitated PrP
C
 was detected by antibody BC6. Blank lane 
indicates sample buffer only. The diglycosylated form of PrP
C
 migrated at ~ 36 kDa, 
monoglycosylated PrP
C
 at ~ 30 kDa and unglycosylated PrP
C
 at ~ 25 kDa. No PrP
C
 was 
detected in the spleen of Tg338 mouse (lane 1-3), and no PrP
Sc
 was detected in the ME7 
infected brain homogenate (lanes 4-6). 20 µl of immunoprecipitate was loaded for each 




                          




spleen and brain immunoprecipitates  
Uninfected Tg338 spleen homogenate (10%) (lanes 3-5), ME7 C57/B mouse brain 
homogenate (10%) (lanes 6-8) and uninfected Tg20 brain homogenate (10%) (lanes 9-11) 
were incubated with anti-PrP antibodies (H1.8, H3.2 and H3.3) coupled to magnetic beads. 
Immunoprecipitated PrP
C
 was detected by antibody BC6. The diglycosylated form of PrP
C
 
migrated at ~ 36 kDa, monoglycosylated PrP
C
 at ~ 30 kDa and unglycosylated PrP
C
 at ~ 25 
kDa. No PrP
C
 was detected in the spleen of Tg338 mouse (lane 1-3), and no PrP
Sc
 was 
detected in the ME7 infected brain homogenate (lanes 4-6). 20µl of immunoprecipitate was 
loaded for each sample (brain and spleen). This experiment was carried out once (n = 1).
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Immunoprecipitation data for MAb H1.8, H3.2 and H3.3 which were tested on uninfected    
ovine brain (PrP
C 
Brain), uninfected mesenteric lymph node (PrP
C
 MLN) and scrapie infected 




Table 6.4 Immunoprecipitation of wild type murine PrP
C
 and murine PrP
Sc
 








H1.8 Yes No 
H3.2 Yes No 
H3.3 Yes No 
 
Immunoprecipitation data for MAb H1.8, H3.2 and H3.3 which were tested on uninfected 
murine brain (PrP
C 





Table 6.5 Immunoprecipitation of murine PrP
C
 from Tg338 and Tg20 mouse models 





















 Brain (10x) 
H1.8 Yes No No Yes 
H3.2 Yes No No No 
H3.3 Yes No No No 
 
Immunoprecipitation data for MAb H1.8, H3.2 and H3.3 which were tested on uninfected 
Tg338 brain, Tg338 liver, Tg338 spleen and Tg20 brain.   
MAb used for 
immunoprecipitation 








H1.8 Yes No No 
H3.2 Yes No Yes 
H3.3 Yes No Yes 
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MAb used for 
Immunoprecipitation 






H1.8 No No 
H3.2 Yes Yes 
H3.3 Yes Yes 
 
Immunoprecipitation data for MAb H1.8, H3.2 and H3.3 which were tested on uninfected 
human brain homogenate (PrP
C
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6.3 Discussion 
The aim of this part of the study was to concentrate PrP
C
 from peripheral tissues 
using immunoprecipitation techniques. IgM antibodies H1.8, H3.2 and H3.3 were 
chosen for immunoprecipitation of PrP from ovine and murine tissues. IgM 
antibodies are normally difficult to use in immunoprecipitation due to their 
pentameric structure and also because they do not bind well to protein A or protein 
G. To overcome these problems IgM antibodies were purified using ammonium 
sulphate and anti-IgM dynabeads (Invitrogen) were used in the immunoprecipitation 
reactions. 
 
As a control ovine brain homogenate was used to observe whether these antibodies 
could immunoprecipitate PrP
C
 as these antibodies had never been tested for 
immunoprecipitation on ovine tissue previously. The brain was used as PrP 
expression in the brain is much greater than in peripheral tissues (Han et al., 2006, 
Gossner et al., 2009). PrP
C
 was successfully immunoprecipitated from ovine brain 
tissue using H1.8, H3.2 and H3.3 from as little as 1 mg starting material. 
Unfortunately PrP
C
 could not be precipitated from ovine mesenteric lymph node by 
any of the IgM MAbs. The reason for the MLN being negative for PrP may be due to 
low protein expression within the tissue or it may be that PrP conformation within 
the MLN may not allow these antibodies to bind to the native protein. It is likely that 
the starting material of the MLN was at too low (10 mg) a concentration as Moudjou 
et al., (2001) used 50mg of tissue to detect PrP in various peripheral tissues and 
Horiuchi et al., (1995) required 200mg of tissue to detect PrP in lymph node. 
Increasing the loading concentration of the MLN was not investigated further due to 
time constraints and limited tissue availability.  
 
In one case two bands were observed in ovine brain homogenates after 
deglycosylation and one band observed in the MLN homogenate (Figure 6.10). It can 
be speculated that the two bands observed in the brain samples correspond to 
unglycosylated PrP and C1, and the one band observed in the MLN is unspecific 
protein. Another possibility is that the band observed in all MLN is IgM light chain 
although IgM heavy chain was not present. It is also possible that the top band 
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observed in the doublet for brain samples is unglycosylated PrP and unglycosylated 
PrP in the MLN runs at a slightly lower molecular weight.  Although this control was 
not carried out in this experiment, dynabeads incubated in the presence of the IgM 
antibodies only, does not produce any reaction which suggests that the band observed 
in the MLN is not IgM light chain and is unspecific protein. If there had been more 
time it would have been possible to use an anti-light chain antibody to be confirm 
these results. Therefore in conclusion it is unknown whether C1 is present in the 
MLN or as more experiments would need to be carried out to confirm this and due to 
time restraints this was not possible. It is likely that C1 is produced in many 
peripheral tissues as ADAMs that are thought to be responsible for PrP alpha 
cleavage are widely expressed within the periphery (Novak, 2004). It is however 
possible that PrP and ADAM proteases may not interact at the cellular level within 
certain peripheral tissues.  
 
As a way of trying to precipitate PrP
C
 from ovine peripheral tissues, over-expressing 
ovine, transgenic mice (Tg338) were used as a model. Unfortunately, PrP
C
 was not 
detected from Tg338 spleen or liver but was detected from Tg338 brain. Not being 
able to immunoprecipitate PrP
C
 from the liver was expected as other groups have 
shown that the PrP
C 
MRNA in the liver is expressed at very low levels (Horiuchi et 
al., 1995, Moudjou et al., 2001). These results indicate that PrP
C
 may not be 
expressed in the liver as PrP
C
 could not be detected in our over-expressing transgenic 
mouse model.  
 
MAbs H1.8, H3.2 and H3.3 only immunoprecipitated PrP from uninfected murine 
brain homogenate, suggesting that these MAbs displays selectivity towards the 
normal form of PrP. H1.8, H3.2 and H3.3 were unable to immunoprecipitate PrP
Sc
 
from ME7 infected mouse brain, although this experiment was only carried out once 
(n = 1).  
 
If there had been more time it would have been beneficial to test these IgM 
antibodies for the detection of PrP
C
 by Western blotting and used an IgG antibody 
for immunoprecipitation. IgG antibody BC6 was tested for immunoprecipitation of 






 from ovine brain and mesenteric lymph nodes with unsuccessful results 
when P4 was used for detection by Western blotting.  
 
In conclusion, the detection of PrP fragmentss within peripheral tissues may provide 
further understanding about the biochemistry and function of PrP. Unfortunately, 
full-length PrP
C
 and the C1 fragment was not detected in the peripheral tissues of 
ovine sheep and ovine transgenic mouse models. Initial characterization of these 
three IgM antibodies suggests that there are some interesting properties associated 
with these antibodies that can be further investigated in future characterisation 
studies. 
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Chapter 7 Final discussion  
 
7.1 Alpha cleavage and TSE disease 
The main aim of this study was to investigate the role of alpha cleavage in scrapie 
disease susceptibilbility with the idea that total full-length PrP
C
, total C1 and the 
ratio between full-length PrP
C
 and C1 may be linked to differences in scrapie 
susceptibility. 
 
A significant difference in the amount of C1 was observed between some of the 
genotypes after REML analysis, although the amount of C1 did not correlate with 
incubation period with SSBP/1. There was also no significant difference between the 
percentage of C1 between the highly susceptible VRQ/VRQ and resistant ARR/ARR 
animals; this suggests that the amount of alpha cleavage in these animals does not 
play a major role in defining disease susceptibility. The data presented here is 
supported by in vitro data from (Sabuncu et al., 2005) who show that VRQ and ARR 
variants do not display significant differences in the amount of C1 production. Their 
conclusion that resistance to infection was most likely not due to differences in alpha 
cleavage but may be associated with differences in solubility between the two 
variants may be applicable to sheep.  
 
The percentage of C1 varied depending on the brain region in sheep (Chapter 4). The 
percentage of C1 was higher in the cortex and thalamus than the cerebellum and 
medulla. If  ADAM proteases are responsible for alpha cleavage it may be that these 
proteases are expressed at different levels within different brain areas, a clue that 
could become important in the search for an enzyme or enzymes responsible for 
alpha cleavage. The cerebellum and medulla consistently produced lower 
percentages of C1 across five different genotypes making genotype much less of a 
factor that modulates alpha cleavage in different brain areas. In terms of scrapie 
pathogenesis the frontal cortex is the last area to accumulate PrP after injection with 
SSBP/1 scrapie and this area shows the most C1. This result would fit in with the 
model that more C1 is protective. On the other hand, the cerebellum shows almost no 
pathology but has very little C1.  
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As only roughly defined areas of the brain were taken for this analysis future studies 
should consider to collect more precise sections of the brain. This may require 
different collection methods for sheep brain tissue. It may then be possible to 
correlate areas of high or low C1 with strain targeting. Currently within the TSE  
genetics group full-length PrP
C
 and C1 levels are being quantified in seven areas of 
the sheep brain (Lauren Campbell, personal communications). 
 
Neural cells taken from the cerebellum of Tg338 transgenic mice and maintained in 
cell culture produced a high percentage of C1 (Cronier et al., 2004). As Tg338 mice 
are highly over-expressing PrP mice it is possible that as a consequence more C1 is 
produced in all or some brain areas. This has already been shown to be the case in 
the frontal cortex of Tg338 mice in vivo (Chapter 5). The dominance of C1 over full- 
length PrP
C
 produced in these cells is contradictory to our in vivo data that shows 
dominance for full-length PrP
C
. However as these two systems are very different it is 
difficult to compare results. Variation in protein detection via Western blotting can 
be caused by the use of different antibodies (Kuczius et al., 2007a,b)  but it is equally 
possible that differences between various studies arise from the handling and storage 
of samples.  
 
The possibility that other codons within the open reading frame of PrP may influence 
alpha cleavage and disease susceptibility can not be ruled out. All of the animals 
used in the genotype study were sequenced between codons 86 and 202. As the 
animals were mostly derived from closed flocks for which fairly complete data exist 
about all polymoprhisms it is very unlikely that any of the animals used had 
additional sequence variation in the unsequenced PrP regions. No additional 
polymorphisms were found in these animals with the exception of codons 112 and 
141. The frequency of these two polymorphism – keeping the 136 position constant- 
was too low to study disease association with alpha cleavage.   
 
Naturally occurring polymorphisms do exist around the alpha cleavage site in sheep 
but are not likely  to have a major effect on C1 production as Oliveira-Martins et al., 
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(2010) suggest based on their in vitro models. Data by Oliveira-Martins et al., (2010) 
also showed that point mutations within the hydrophobic domain have some effect 
on alpha cleavage, but do not completely abolish the production of the C1 fragment. 
It appears that the size of the central domain is more important than the amino acid 
sequence for PrP alpha cleavage; this has been shown by Wegner et al., (2002) and 
Oliveira-Martins et al., (2010). 
 
It is probable that other regions of PrP may be important for alpha cleavage and not 
just the sequence directly around the alpha cleavage site.  It may be that the proteases 
responsible for alpha cleavage are dependent on the distance from the cell membrane 
rather than sequence specificity (Novak, 2004). Sequences further C-terminal of the 
alpha cleavage site would be potential candidates but they have not yet been studied 
for their effects on C1 processing and function. It has been hypothesised that PrP 
catalyses its own release from full-length PrP and can function as an -secretase 
(Abdulla, 2001). This theory proposes that two histidines at codon 96 and 111 
participate in a metalloprotease assembly which is then able to initiate cleavage. 
There is no evidence from the experimental data in this thesis to support the 
hypothesis that PrP is able to cleave itself. Crucially, data from Oliveira-Martins et 
al., (2010) show that alpha cleavage still occurs after histidines  at codons 96 and 111 
are changed to glutamic acid or deleted which argues against the self cleavage 
model.  
 
The hydrophobic domain of PrP has been subject to debate as to whether or not this 
area is involved in conversion. Transgenic mice with particular deletions within the 
hydrophobic region of PrP (Baumann et al., 2007, Li et al., 2007, Shmerling et al., 
1998) develop a neurodegenerative condition different from TSE disease. This 
condition can be reversed with the re-introduction of wild type PrP. This suggests 
that the central domain of PrP may provide some protection against 
neurodegeneration. However the transmembrane region 1 (TM1) which is located 
within the central domain of PrP can predispose the protein to take up alternative 
pathogenic topologies (Hegde et al., 1998a, Stewart & Harris, 2005). 
 
    
 172
The sheep samples studied here contained animals of various ages and the 
association of age with alpha cleavage was investigated. The percentage of C1 
detected in new born lambs (aged 0-5 days) was much less than in young lambs aged 
100-320 days and in adult sheep. The percentage of C1 detected in the 100-320 days 
old lambs was ~30%, which is equivalent to the percentage found in adult sheep. 
This suggests that there may be a very early developmental effect as the percentage 
of C1 increased between a few days of age and a few hundred days of age. It appears 
that PrP is expressed first followed by expression of the alpha cleavage enzyme. This 
suggests that the enzyme that is responsible for alpha cleavage is independent from 
PrP, countering the argument for self-cleavage.  Knowledge of this delay in the alpha 
cleavage activity could help to characterise the enzyme.  
 
In terms of disease there appears to be an association with age and susceptibility to 
disease, for example most cases of variant Creutzfeld Jacob disease occur in young 
adults (Ghani et al., 2003) most cattle that developed BSE were infected as young 
calves (Arnold & Wilesmith, 2004) and it has been suggested that young lambs are 
more susceptible than adults to natural scrapie infection (Diaz et al., 2005). 
However, this rule does not apply to every species as neonatal mice are more 
resistant to scrapie infection than adult mice (Ierna et al., 2006) although this has 
been attributed to lack of spleen development in the neonatal mice. As milk has been 
shown to be infectious (Konold et al., 2008)  and as there is a low percentage of C1 
in new born lambs then the likelihood of natural infection may be higher as there is 
more available full-length PrP. However, this effect does not last long as the 
percentage of C1 increases dramatically in weaned animals.  
 
To follow on from the data collected on uninfected animals it might be of interest to 
evaluate levels of cleavage in TSE infected models to see if there is any correlation 
between the amount of alpha cleavage and PrP
Sc
 accumulation. In conclusion the 
association between the percentage of C1, susceptible genotypes and ultimately 
susceptibility to scrapie is not strong and may only play a minor part in disease 
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7.2 Normal function of alpha cleavage 
As well as investigating the role of the C1 fragment in terms of disease susceptibility 
this thesis has also been interested in the mechanisms and function behind this 
proteolytic event. The cellular location of PrP alpha cleavage has previously  been 
shown to occur in a late compartment of the Golgi as there was a reduction in the 
amount of C1 after blocking the exit of PrP from the endoplasmic reticulum 
(Walmsley et al., 2009). Here, PrP glycosylation mice were used as a model to gain 
further understanding about the cellular location of PrP cleavage. G3 mice were of 
particular interest as a model because PrP is located intracellularly within the Golgi 
apparatus of these mice (Cancellotti et al., 2005). PrP in the G1 and G2 mice is 
located on the cell surface (Cancellotti et al., 2005) but cellular trafficking may also 
be impaired in these mice. C1 was detected in all three PrP-glycosylation deficient 
mice which suggest that cleavage must occur within the Golgi compartment. The 
ratios of full-length PrP to C1 in these G-mice were very similar to the 129/Ola 
wildtype mice which indicate that N-glycosylation is neither essential nor 
detrimental for alpha cleavage. It also suggests that unglycosylated PrP follows 
similar pathways as glycosylated PrP through the Golgi compartment.   
 
Throughout this thesis the effects of the C1 fragment have been investigated. Over-
expression of the C1 fragment displays pro apoptotic function (Sunyach et al., 2007). 
The C1 fragment has also been linked to MAPK signalling pathways (Haigh et al., 
2009). The corresponding N1 fragment may also be of importance as it has been 
shown to have neuroprotective properties as it protects cells against staurosporine 
induced apoptosis and down regulates p53 transcription (Sunyach et al., 2007). 
Unfortunately we were unable to detect N1 via Western blotting; it may be that 
during preparation of brain material N1 is more prone to degradation. However, one 
can be certain that the amount of N1 produced is equal to the amount of C1 produced 
as these fragments are produced from the same cleavage event.  
 
The metalloproteases ADAM 9 (Cisse et al., 2005), 10 (Endres et al., 2009), 17 
(TACE) (Cisse et al., 2005, 2007, 2008) and more recently ADAM 23 (Costa et al., 
2009) have been suggested to mediate production of the C1 and N1 fragments within  
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the Golgi apparatus (Shyng et al., 1995). ADAM 17 and ADAM 10 have also been 
shown to be involved in cleavage of the APP (Alzheimer’s precursor protein) 
(Buxbaum et al., 1998). However, despite some evidence of ADAM involvement in 
cleavage of the prion protein the direct mechanisms of these proteases are still 
undefined and should form a basis for future work in sheep PrP biology.  
 
There are other similarities between the cleavage of PrP
C
 and APP, for example both 
cleavage of PrP
C
 and APP occurs within a toxic domain of the protein. C-terminal 
fragments of PrP
C
 that include the 106-126 sequence can cause neurotoxicity in 
cultured neurones (Ettaiche et al., 2000, Haik et al., 2000). Alpha cleavage of the 
prion protein disrupts this region which may provide some protection against 
toxicity. Cleavage of APP within the A region of APP prevents the formation of the 
A toxic peptide. Both these cleavage events are thought to occur by alpha 




The APP protein can also be cleaved by Beta-secretase 1 enzyme (BACE-1), which 
allows the release of the toxic A peptide. In 2007 Parkin and co-workers reported 
that overexpression of PrP
C
 in human neuroblastoma cells lead to a decrease in A, 
whilst PrP
C
 silencing lead to an increase in A production (Parkin et al., 2007, Kellet 
et al., 2009). It was noted further that the effect of PrP
C 
on A production was due to  
inhibition of BACE-1 and therefore a decrease in the amount APP cleavage. This 
group found that the N-terminal region of PrP
C 
and localisation on lipid rafts are 
required for PrP
C
 to have an inhibitory effect on BACE-1 (Kellet et al., 2009). It has 
been suggested that PrP
C
 may interact via glycosaminoglycans (such as heparin) with 
binding sites on BACE1, which may restrict the access of BACE-1 to APP (Araki 
2010, Kellet et al., 2009). This group concluded that PrP
C
 is protective against 
Alzheimer’s disease as it reduces the formation of A peptides. In terms of 
therapeutics the aim has been to diminish beta-amyloid production by secretases 
inhibition although this has not been as successful as it has been hoped. As alpha 
cleavage of PrP
C
 reduces the amount of full-length PrP
C
 it may be possible that this 
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Cleavage of the prion protein can also occur when the cell is subject to oxidative 
stress (McMahon et al., 2001, Watt et al., 2005). This cleavage is termed  cleavage 
and occurs within the octapeptide repeat region which allows the hydrophobic region 
of PrP
C
 to remain intact. Unlike the N1 and C1 fragments the C2 and N2 fragments 
of  cleavage are not associated with pro or anti apoptotic function (Sunyach et al., 
2007). It can be speculated that these fragments may be produced in response to 
disease as there is evidence that a fragment of similar size to C2 is protease resistant 
(Owen et al., 2007) and may therefore be involved in prion conversion. Although C2 
can not be created out of C1 it is possible that C1 could be produced by C2. This 
suggests that some interaction may occur between these two fragments which may be 
related to disease susceptibility. 
 
In PrP overexpressing mice the C2 fragment was observed. The KB6 mice that over-
express PrP
C
 with six octapeptide repeats had consistently more C2 on average than 
all other PrP
C
 overexpressing mice (Table 5.2). The KB6 mice also had more C2 
than normal expressing KB5 mice with five octapeptide repeats (data not shown). It 
may be that the increase in C2 in the KB6 mice is due to the over-expression of PrP, 
or it may be due to the amount of octapeptide repeats. As beta cleavage occurs within 
the octapeptide repeats it may be worth investigating the effect that these repeats 
have on cleavage. 
 
7.3 Alpha cleavage in transgenic mice 
Alpha cleavage of PrP has been shown to occur in a variety of species and this study 
has proven that it is active in transgenic mice expressing murine, ovine and bovine 
PrP at various levels.  Transgenic mice that over-express PrP show an increase in the 
percentage of C1 when compared to wild type mice. These mice can live until old 
age without any adverse phenotypic effects therefore it is unlikely that an increase in 
C1 is detrimental to these mice (Hunter, unpublished observations). However, 
(Huang et al., 2007) show that over-expression of PrP in the muscle leads to a 
primary myopathy which correlates with high percentage of C1. This group suggests 
that the myopathy seen in these mice are due to activation of p53 signalling pathways 
which may be triggered by C1 over-production (Sunyach et al., 2007, Guillot-Sestier 
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et al., 2009, Liang et al., 2009). However, in these models it is impossible to 
distinguish whether the cell-toxicity is associated with an increase in full-length PrP
C
 
or an increase in C1.   
 
Over-expressing transgenic mice generally have shorter incubation periods compared 
to mice expressing normal levels of PrP. Transgenic mice expressing ovine PrP 
(KARQ and KVRQ) have similar incubation periods compared to ARQ and VRQ 
sheep after injection with SSBP/1 (Hunter, unpublished observations). Therefore 
these mice appear to be a good model for prion disease in the normal host. In terms 
of alpha cleavage KVRQ mice are not a good model for alpha cleavage as a lower 
percentage of C1 was seen in these mice compared to VRQ sheep (Chapter 4). Tg338 
and KARQ are better models for alpha cleavage as they mimic what happens in the 
natural host (Chapter 4). It is difficult to compare KB6 and KB5 mice to the natural 
host as alpha cleavage levels in cattle were not investigated.  
 
When immunoprecipitation was carried out on Tg338 spleen PrP
C
 could not be 
detected via Western blotting (Chapter 6). The spleen has been shown to be involved 
in neuroinvasion as removal of the spleen results in increased incubation periods in 
scrapie mouse models (Fraser & Dickinson, 1978, Kimberlin & Walker, 1989b). 
PrP
Sc 
also regularly accumulates in the spleen tissue during classical scrapie infection 
(van Keulen et al., 1996). DELFIA
® 
measurements from the brains of Tg338 mice 
show that there is a 10 fold increase in the amount of PrP detected compared to 
KARQ and KVRQ mice that express normal levels of PrP. Assuming that PrP 
expression in the brain is 8-10 fold compared to wild type mice then the levels of PrP 
in the spleen should be equivalent to levels of PrP
C
 in a wild type mouse brain. This 
does not appear to be the case. In order to measure PrP protein levels in these tissues 
a DELFIA
®
 assay could be carried although the sensitivity of the DEFFIA
®
 assay 
may not be good enough for measuring PrP in peripheral tissues.  
 
7.4 Final conclusions 
The work presented here suggests that the PrP fragment C1 is not a significant 
determinant of TSE susceptibility. There may be some minor influence of PrP gene 
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polymorphisms on the production of the C1 fragment but this is not strong enough to 
modulate disease susceptibility. The C1 fragment does not appear to be associated 
with genetic variation of the PrP protein sequence as alpha cleavage occurred in mice 
expressing ovine, bovine and murine PrP sequence. PrP gene expression appears to 
be associated with the levels of C1 and possibly C2 production as PrP over-
expressing transgenic mice containing the ovine, bovine and murine sequence show a 
higher percentage of C1 and C2. 
 
The regulation of the C1 fragment is totally unknown but it appears from the data 
that PrP genetics is not associated with modulation of the C1 fragment. It is still 
unclear whether C1 takes part in the disease specific processes leading to PrP
Sc
 
deposition and partial protease resistance. However, the percentage of C1 in 
uninfected tissue does not appear to be associated with differences in disease 
susceptibility and can not be correlated with incubation periods in sheep. It is 
possible that the percentage of C1 changes during infection which may be an 
important modulator of susceptibility. This remains to be investigated for sheep.  




Abdulla, Y. H. (2001). A plausible function of the prion protein: conjectures and a 
hypothesis. Bioessays 23, 456-62. 
Agrimi, U., Nonno, R., Dell'Omo, G., Di Bari, M. A., Conte, M., Chiappini, B., 
Esposito, E., Di Guardo, G., Windl, O., Vaccari, G. & Lipp, H. P. (2008). 
Prion protein amino acid determinants of differential susceptibility and 
molecular feature of prion strains in mice and voles. PLoS Pathog 4, 
e1000113. 
Aguzzi, A., Sigurdson, C. & Heikenwalder, M. (2007). Molecular Mechanisms of 
Prion Pathogenesis. Annu Rev Pathol. 
Alfa Cisse, M., Louis, K., Braun, U., Mari, B., Leitges, M., Slack, B. E., Fisher, A., 
Auberger, P., Checler, F. & Vincent, B. (2008). Isoform-specific contribution 
of protein kinase C to prion processing. Mol Cell Neurosci 39, 400-10. 
Alper, T., Haig, D. A. & Clarke, M. C. (1966). The exceptionally small size of the 
scrapie agent. Biochem Biophys Res Commun 22, 278-84. 
Alper, T., Cramp, W. A., Haig, D. A. & Clarke, M. C. (1967). Does the agent of 
scrapie replicate without nucleic acid? Nature 214, 764-6. 
Andreoletti, O., Berthon, P., Marc, D., Sarradin, P., Grosclaude, J., van Keulen, L., 
Schelcher, F., Elsen, J. M. & Lantier, F. (2000). Early accumulation of 
PrP(Sc) in gut-associated lymphoid and nervous tissues of susceptible sheep 
from a Romanov flock with natural scrapie. J Gen Virol 81, 3115-26. 
Andrievskaia, O., McRae, H., Elmgren, C., Huang, H., Balachandran, A. & Nielsen, 
K. (2006). Generation of antibodies against bovine recombinant prion protein 
in various strains of mice. Clin Vaccine Immunol 13, 98-105. 
Andrievskaia, O., Algire, J., Balachandran, A. & Nielsen, K. (2008). Prion protein in 
sheep urine. J Vet Diagn Invest 20, 141-6. 
Arnold, M., Meek, C., Webb, C. R. & Hoinville, L. J. (2002). Assessing the efficacy 
of a ram-genotyping programme to reduce susceptibility to scrapie in Great 
Britain. Prev Vet Med 56, 227-49. 
 
    
 179
Arnold, M. E. & Wilesmith, J. W. (2004). Estimation of the age-dependent risk of 
infection to BSE of dairy cattle in Great Britain. Prev Vet Med 66, 35-47. 
Atarashi, R., Moore, R. A., Sim, V. L., Hughson, A. G., Dorward, D. W., Onwubiko, 
H. A., Priola, S. A. & Caughey, B. (2007). Ultrasensitive detection of scrapie 
prion protein using seeded conversion of recombinant prion protein. Nat 
Methods 4, 645-50. 
Austbo, L., Espenes, A., Olsaker, I., Press, C. M. & Skretting, G. (2007). Increased 
PrP mRNA expression in lymphoid follicles of the ileal Peyer's patch of 
sheep experimentally exposed to the scrapie agent. J Gen Virol 88, 2083-90. 
Baron, T. G., Madec, J. Y., Calavas, D., Richard, Y. & Barillet, F. (2000). 
Comparison of French natural scrapie isolates with bovine spongiform 
encephalopathy and experimental scrapie infected sheep. Neurosci Lett 284, 
175-8. 
Baron, T., Biacabe, A. G., Arsac, J. N., Benestad, S. & Groschup, M. H. (2007). 
Atypical transmissible spongiform encephalopathies (TSEs) in ruminants. 
Vaccine 25, 5625-30. 
Baumann, F., Tolnay, M., Brabeck, C., Pahnke, J., Kloz, U., Niemann, H. H., 
Heikenwalder, M., Rulicke, T., Burkle, A. & Aguzzi, A. (2007). Lethal 
recessive myelin toxicity of prion protein lacking its central domain. EMBO J 
26, 538-47. 
Baylis, M. & Goldmann, W. (2004). The genetics of scrapie in sheep and goats. Curr 
Mol Med 4, 385-96. 
Beck, J. A., Campbell, T. A., Adamson, G., Poulter, M., Uphill, J. B., Molou, E., 
Collinge, J. & Mead, S. (2008). Association of a null allele of SPRN with 
variant Creutzfeldt-Jakob disease. J Med Genet 45, 813-7. 
Beekes, M. & McBride, P. A. (2000). Early accumulation of pathological PrP in the 
enteric nervous system and gut-associated lymphoid tissue of hamsters orally 
infected with scrapie. Neurosci Lett 278, 181-4. 
Beekes, M. & McBride, P. A. (2007). The spread of prions through the body in 
naturally acquired transmissible spongiform encephalopathies. FEBS J 274, 
588-605. 
    
 180
Belt, P. B., Muileman, I. H., Schreuder, B. E., Bos-de Ruijter, J., Gielkens, A. L. & 
Smits, M. A. (1995). Identification of five allelic variants of the sheep PrP 
gene and their association with natural scrapie. J Gen Virol 76 ( Pt 3), 509-
17. 
Bendheim, P. E., Brown, H. R., Rudelli, R. D., Scala, L. J., Goller, N. L., Wen, G. 
Y., Kascsak, R. J., Cashman, N. R. & Bolton, D. C. (1992). Nearly ubiquitous 
tissue distribution of the scrapie agent precursor protein. Neurology 42, 149-
56. 
Benestad, S. L., Sarradin, P., Thu, B., Schonheit, J., Tranulis, M. A. & Bratberg, B. 
(2003). Cases of scrapie with unusual features in Norway and designation of 
a new type, Nor98. Vet Rec 153, 202-8. 
Benestad, S. L., Arsac, J. N., Goldmann, W. & Noremark, M. (2008). 
Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. 
Vet Res 39, 19. 
Bergstrom, A. L., Cordes, H., Zsurger, N., Heegaard, P. M., Laursen, H. & Chabry, 
J. (2005). Amidation and structure relaxation abolish the neurotoxicity of the 
prion peptide PrP106-126 in vivo and in vitro. J Biol Chem 280, 23114-21. 
Billinis, C., Panagiotidis, C. H., Psychas, V., Argyroudis, S., Nicolaou, A., 
Leontides, S., Papadopoulos, O. & Sklaviadis, T. (2002). Prion protein gene 
polymorphisms in natural goat scrapie. J Gen Virol 83, 713-21. 
Bolton, D. C., McKinley, M. P. & Prusiner, S. B. (1982). Identification of a protein 
that purifies with the scrapie prion. Science 218, 1309-11. 
Borchelt, D. R., Taraboulos, A. & Prusiner, S. B. (1992). Evidence for synthesis of 
scrapie prion proteins in the endocytic pathway. J Biol Chem 267, 16188-99. 
Bossers, A., Harders, F. L. & Smits, M. A. (1999). PrP genotype frequencies of the 
most dominant sheep breed in a country free from scrapie. Arch Virol 144, 
829-34. 
Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., 
Marino, S., Weissmann, C. & Aguzzi, A. (1996). Normal host prion protein 
necessary for scrapie-induced neurotoxicity. Nature 379, 339-43. 
Brockes, J. P. (1999). Topics in prion cell biology. Curr Opin Neurobiol 9, 571-7. 
    
 181
Brotherston, J. G., Renwick, C. C., Stamp, J. T., Zlotnik, I. & Pattison, I. H. (1968). 
Spread and scrapie by contact to goats and sheep. J Comp Pathol 78, 9-17. 
Brown, D. R., Qin, K., Herms, J. W., Madlung, A., Manson, J., Strome, R., Fraser, P. 
E., Kruck, T., von Bohlen, A., Schulz-Schaeffer, W., Giese, A., Westaway, 
D. & Kretzschmar, H. (1997). The cellular prion protein binds copper in vivo. 
Nature 390, 684-7. 
Brown, D. R., Wong, B. S., Hafiz, F., Clive, C., Haswell, S. J. & Jones, I. M. (1999). 
Normal prion protein has an activity like that of superoxide dismutase. 
Biochem J 344 Pt 1, 1-5. 
Brown, D. R. (2000). Altered toxicity of the prion protein peptide PrP106-126 
carrying the Ala(117)-->Val mutation. Biochem J 346 Pt 3, 785-91. 
Brown, K. L., Stewart, K., Ritchie, D. L., Mabbott, N. A., Williams, A., Fraser, H., 
Morrison, W. I. & Bruce, M. E. (1999). Scrapie replication in lymphoid 
tissues depends on prion protein-expressing follicular dendritic cells. Nat 
Med 5, 1308-12. 
Brown, K. L., Wathne, G. J., Sales, J., Bruce, M. E. & Mabbott, N. A. (2009). The 
effects of host age on follicular dendritic cell status dramatically impair 
scrapie agent neuroinvasion in aged mice. J Immunol 183, 5199-207. 
Bruce, M. & Fraser, H. (1975). Amyloid plaques in the brains of mice infected with 
scrapie: morphological variation and staining properties. Neuropathology and 
Applied Neurobiology 1, 189-202. 
Bruce, M. E. & Dickinson, A. G. (1987). Biological evidence that scrapie agent has 
an independent genome. J Gen Virol 68 ( Pt 1), 79-89. 
Bruce, M. E. & Fraser, H. (1991). Scrapie strain variation and its implications. Curr 
Top Microbiol Immunol 172, 125-38. 
Bruce, M. E., McBride, P. A., Jeffrey, M. & Scott, J. R. (1994). PrP in pathology and 
pathogenesis in scrapie-infected mice. Mol Neurobiol 8, 105-12. 
Bruce, M., Will, R., Ironside, J., McConnell, I., Drummond, D., Suttie, A., 
McCardle, L., Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H. & 
Bostock, C. (1997). Transmissions to mice indicate that 'new variant' CJD is 
caused by the BSE agent. Nature 389, 498-501. 
    
 182
Bruce, M. E., Brown, K. L., Mabbott, N. A., Farquhar, C. F. & Jeffrey, M. (2000). 
Follicular dendritic cells in TSE pathogenesis. Immunol Today 21, 442-6. 
Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H. P., DeArmond, S. J., 
Prusiner, S. B., Aguet, M. & Weissmann, C. (1992). Normal development 
and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 
356, 577-82. 
Burgess, S. T., Shen, C., Ferguson, L. A., O'Neill, G. T., Docherty, K., Hunter, N. & 
Goldmann, W. (2009). Identification of adjacent binding sites for the YY1 
and E4BP4 transcription factors in the ovine PrP (Prion) gene promoter. J 
Biol Chem 284, 6716-24. 
Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O'Callahan, J., Slunt, H. H., Price, D. 
L. & Sisodia, S. S. (1998). Alzheimer amyloid protein precursor in the rat 
hippocampus: transport and processing through the perforant path. J Neurosci 
18, 9629-37. 
Cancellotti, E., Wiseman, F., Tuzi, N. L., Baybutt, H., Monaghan, P., Aitchison, L., 
Simpson, J. & Manson, J. C. (2005). Altered glycosylated PrP proteins can 
have different neuronal trafficking in brain but do not acquire scrapie-like 
properties. J Biol Chem 280, 42909-18. 
Cancellotti, E., Barron, R. M., Bishop, M. T., Hart, P., Wiseman, F. & Manson, J. C. 
(2007). The role of host PrP in Transmissible Spongiform Encephalopathies. 
Biochim Biophys Acta 1772, 673-80. 
Capucchio, M. T., Guarda, F., Isaia, M. C., Caracappa, S. & Di Marco, V. (1998). 
Natural occurrence of scrapie in goats in Italy. Vet Rec 143, 452-3. 
Capucchio, M. T., Guarda, F., Pozzato, N., Coppolino, S., Caracappa, S. & Di 
Marco, V. (2001). Clinical signs and diagnosis of scrapie in Italy: a 
comparative study in sheep and goats. J Vet Med A Physiol Pathol Clin Med 
48, 23-31. 
Cartoni, C., Schinina, M. E., Maras, B., Nonno, R., Vaccari, G., Di Baria, M. A., 
Conte, M., Liu, Q. G., Lu, M., Cardone, F., Windl, O., Pocchiari, M. & 
Agrimi, U. (2005). Identification of the pathological prion protein allotypes in 
scrapie-infected heterozygous bank voles (Clethrionomys glareolus) by high-
    
 183
performance liquid chromatography-mass spectrometry. J Chromatogr A 
1081, 122-6. 
Castilla, J., Saa, P., Hetz, C. & Soto, C. (2005). In vitro generation of infectious 
scrapie prions. Cell 121, 195-206. 
Caughey, B., Race, R. E., Ernst, D., Buchmeier, M. J. & Chesebro, B. (1989). Prion 
protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J 
Virol 63, 175-81. 
Caughey, B., Raymond, G. J., Ernst, D. & Race, R. E. (1991). N-terminal truncation 
of the scrapie-associated form of PrP by lysosomal protease(s): implications 
regarding the site of conversion of PrP to the protease-resistant state. J Virol 
65, 6597-603. 
Caughey, B., Kocisko, D. A., Raymond, G. J. & Lansbury, P. T., Jr. (1995). 
Aggregates of scrapie-associated prion protein induce the cell-free conversion 
of protease-sensitive prion protein to the protease-resistant state. Chem Biol 
2, 807-17. 
Checler, F. & Vincent, B. (2002). Alzheimer's and prion diseases: distinct 
pathologies, common proteolytic denominators. Trends Neurosci 25, 616-20. 
Chen, S. G., Teplow, D. B., Parchi, P., Teller, J. K., Gambetti, P. & Autilio-
Gambetti, L. (1995). Truncated forms of the human prion protein in normal 
brain and in prion diseases. J Biol Chem 270, 19173-80. 
Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., LaCasse, R., 
Raymond, L., Favara, C., Baron, G., Priola, S., Caughey, B., Masliah, E. & 
Oldstone, M. (2005). Anchorless prion protein results in infectious amyloid 
disease without clinical scrapie. Science 308, 1435-9. 
Cisse, M. A., Sunyach, C., Lefranc-Jullien, S., Postina, R., Vincent, B. & Checler, F. 
(2005). The disintegrin ADAM9 indirectly contributes to the physiological 
processing of cellular prion by modulating ADAM10 activity. J Biol Chem 
280, 40624-31. 
Cisse, M. A., Sunyach, C., Slack, B. E., Fisher, A., Vincent, B. & Checler, F. (2007). 
M1 and M3 muscarinic receptors control physiological processing of cellular 
prion by modulating ADMA17 phosphorylation and activity. Journal of 
Neuroscience 27, 4083-4092. 
    
 184
Cisse, M. A., Louis, K., Braun, U., Mari, B., Leitges, M., Slack, B. E., Fisher, A., 
Auberger, P., Checler, F. & Vincent, B. (2008). Isoform-specific contribution 
of protein kinase c to prion processing. Molecular and Cellular Neuroscience 
39, 400-410. 
 
Collinge, J., Whittington, M. A., Sidle, K. C., Smith, C. J., Palmer, M. S., Clarke, A. 
R. & Jefferys, J. G. (1994). Prion protein is necessary for normal synaptic 
function. Nature 370, 295-7. 
Collinge, J. (2001). Prion diseases of humans and animals: their causes and 
molecular basis. Annu Rev Neurosci 24, 519-50. 
Collins, S., Lawson, V. & Masters, C. (2004). Transmissible spongiform 
encephalopathies. Lancet 363, 51-61. 
Colussi, S., Vaccari, G., Maurella, C., Bona, C., Lorenzetti, R., Troiano, P., 
Casalinuovo, F., Di Sarno, A., Maniaci, M. G., Zuccon, F., Nonno, R., 
Casalone, C., Mazza, M., Ru, G., Caramelli, M., Agrimi, U. & Acutis, P. L. 
(2008). Histidine at codon 154 of the prion protein gene is a risk factor for 
Nor98 scrapie in goats. J Gen Virol 89, 3173-6. 
Come, J. H., Fraser, P. E. & Lansbury, P. T., Jr. (1993). A kinetic model for amyloid 
formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U 
S A 90, 5959-63. 
Costa, M. D., Paludo, K. S., Klassen, G., Lopes, M. H., Mercadante, A. F., Martins, 
V. R., Camargo, A. A., Nakao, L. S. & Zanata, S. M. (2009). Characterization 
of a specific interaction between ADAM23 and cellular prion protein. 
Neurosci Lett 461, 16-20. 
Cronier, S., Laude, H. & Peyrin, J. M. (2004). Prions can infect primary cultured 
neurons and astrocytes and promote neuronal cell death. Proc Natl Acad Sci 
U S A 101, 12271-6. 
Crozet, C., Flamant, F., Bencsik, A., Aubert, D., Samarut, J. & Baron, T. (2001). 
Efficient transmission of two different sheep scrapie isolates in transgenic 
mice expressing the ovine PrP gene. J Virol 75, 5328-34. 
Crozet, C., Beranger, F. & Lehmann, S. (2008). Cellular pathogenesis in prion 
diseases. Vet Res 39, 44. 
    
 185
Cuille, J. & Chelle, P. L. (1939). Transmission experimentale de la tremblante a la 
chevre. Comptes rendus de l'Academie des sciences. La vie des sciences 208, 
1058-1060. 
Deleault, N. R., Lucassen, R. W. & Supattapone, S. (2003). RNA molecules 
stimulate prion protein conversion. Nature 425, 717-20. 
Deleault, N. R., Harris, B. T., Rees, J. R. & Supattapone, S. (2007). Formation of 
native prions from minimal components in vitro. Proc Natl Acad Sci U S A 
104, 9741-6. 
Diaz-San Segundo, F., Salguero, F. J., de Avila, A., Espinosa, J. C., Torres, J. M. & 
Brun, A. (2006). Distribution of the cellular prion protein (PrPC) in brains of 
livestock and domesticated species. Acta Neuropathol 112, 587-95. 
Diaz, C., Vitezica, Z. G., Rupp, R., Andreoletti, O. & Elsen, J. M. (2005). Polygenic 
variation and transmission factors involved in the resistance/susceptibility to 
scrapie in a Romanov flock. J Gen Virol 86, 849-57. 
Dickinson, A. G., Young, G. B., Stamp, J. T. & Renwick, C. C. (1965). An analysis 
of natural scrapie in Suffolk sheep. Heredity 20, 485-503. 
Dickinson, A., Stamp, J. T. & Renwick, C. C. (1974). Maternal and lateral 
transmission of scrapie in sheep. J Comp Pathol 84, 19-25. 
Dickinson, A. (1976). Scrapie in sheep and goats. Front Biol 44, 209-41. 
Dickinson, A. & Outram, G. W. (1988). Genetic aspects of unconventional virus 
infections: the basis of the virino hypothesis. Ciba Found Symp 135, 63-83. 
Didier, A., Gebert, R., Dietrich, R., Schweiger, M., Gareis, M., Martlbauer, E. & 
Amselgruber, W. M. (2008). Cellular prion protein in mammary gland and 
milk fractions of domestic ruminants. Biochem Biophys Res Commun 369, 
841-4. 
Diringer, H., Beekes, M., Ozel, M., Simon, D., Queck, I., Cardone, F., Pocchiari, M. 
& Ironside, J. W. (1997). Highly infectious purified preparations of disease-
specific amyloid of transmissible spongiform encephalopathies are not devoid 
of nucleic acids of viral size. Intervirology 40, 238-46. 
Elfrink, K., Oilesch, J., Stohr, J., Willbold, D., Riesner, D. & Geruert, K. (2008). 
Structural changes of membrane-anchored native PrPC. Proc Natl Acad Sci 
USA 105, 10815-19. 
    
 186
Elsen, J. M., Amigues, Y., Schelcher, F., Ducrocq, V., Andreoletti, O., Eychenne, F., 
Khang, J. V., Poivey, J. P., Lantier, F. & Laplanche, J. L. (1999). Genetic 
susceptibility and transmission factors in scrapie: detailed analysis of an 
epidemic in a closed flock of Romanov. Arch Virol 144, 431-45. 
Endres, K., Mitteregger, G., Kojro, E., Kretzschmar, H. & Fahrenholz, F. (2009). 
Influence of ADAM10 on prion protein processing and scrapie infectiosity in 
vivo. Neurobiol Dis 36, 233-41. 
Ettaiche, M., Pichot, R., Vincent, J. P. & Chabry, J. (2000). In vivo cytotoxicity of 
the prion protein fragment 106-126. J Biol Chem 275, 36487-90. 
Farquhar, C. F., Somerville, R. A. & Bruce, M. E. (1998). Straining the prion 
hypothesis. Nature 391, 345-6. 
Fioriti, L., Quaglio, E., Massignan, T., Colombo, L., Stewart, R. S., Salmona, M., 
Harris, D. A., Forloni, G. & Chiesa, R. (2005). The neurotoxicity of prion 
protein (PrP) peptide 106-126 is independent of the expression level of PrP 
and is not mediated by abnormal PrP species. Mol Cell Neurosci 28, 165-76. 
Fischer, M., Rulicke, T., Raeber, A., Sailer, A., Moser, M., Oesch, B., Brandner, S., 
Aguzzi, A. & Weissmann, C. (1996). Prion protein (PrP) with amino-
proximal deletions restoring susceptibility of PrP knockout mice to scrapie. 
EMBO J 15, 1255-64. 
Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O. & 
Tagliavini, F. (1993). Neurotoxicity of a prion protein fragment. Nature 362, 
543-6. 
Forloni, G., Del Bo, R., Angeretti, N., Chiesa, R., Smiroldo, S., Doni, R., Ghibaudi, 
E., Salmona, M., Porro, M., Verga, L. & et al. (1994). A neurotoxic prion 
protein fragment induces rat astroglial proliferation and hypertrophy. Eur J 
Neurosci 6, 1415-22. 
Foster, J. D., McKelvey, W. A., Mylne, M. J., Williams, A., Hunter, N., Hope, J. & 
Fraser, H. (1992). Studies on maternal transmission of scrapie in sheep by 
embryo transfer. Vet Rec 130, 341-3. 
Foster, J. D., Parnham, D. W., Hunter, N. & Bruce, M. (2001). Distribution of the 
prion protein in sheep terminally affected with BSE following experimental 
oral transmission. J Gen Virol 82, 2319-26. 
    
 187
Foster, J., McKenzie, C., Parnham, D., Drummond, D., Chong, A., Goldman, W. & 
Hunter, N. (2006). Lateral transmission of natural scrapie to scrapie-free New 
Zealand sheep placed in an endemically infected UK flock. Vet Rec 159, 633-
4. 
Fraser, H. & Dickinson, A. G. (1967). Distribution of experimentally induced scrapie 
lesions in the brain. Nature 216, 1310-1. 
Fraser, H. & Dickinson, A. G. (1968). The sequential development of the brain lesion 
of scrapie in three strains of mice. J Comp Pathol 78, 301-11. 
Fraser, H. & Dickinson, A. G. (1970). Pathogenesis of scrapie in the mouse: the role 
of the spleen. Nature 226, 462-3. 
Fraser, H. & Dickinson, A. G. (1978). Studies of the lymphoreticular system in the 
pathogenesis of scrapie: the role of spleen and thymus. J Comp Pathol 88, 
563-73. 
Fraser, H., Brown, K. L., Stewart, K., McConnell, I., McBride, P. & Williams, A. 
(1996). Replication of scrapie in spleens of SCID mice follows reconstitution 
with wild-type mouse bone marrow. J Gen Virol 77 ( Pt 8), 1935-40. 
Fraser, J. R. (2002). What is the basis of transmissible spongiform encephalopathy 
induced neurodegeneration and can it be repaired? Neuropathol Appl 
Neurobiol 28, 1-11. 
Fuhrmann, M., Bittner, T., Mitteregger, G., Haider, N., Moosmang, S., Kretzschmar, 
H. & Herms, J. (2006). Loss of the cellular prion protein affects the Ca2+ 
homeostasis in hippocampal CA1 neurons. J Neurochem 98, 1876-85. 
Gajdusek, D. C. & Zigas, V. (1957). Degenerative disease of the central nervous 
system in New Guinea; the endemic occurrence of kuru in the native 
population. New England Journal of Medicine 257, 974-978. 
Gasset, M., Baldwin, M. A., Lloyd, D. H., Gabriel, J. M., Holtzman, D. M., Cohen, 
F., Fletterick, R. & Prusiner, S. B. (1992). Predicted alpha-helical regions of 
the prion protein when synthesized as peptides form amyloid. Proc Natl Acad 
Sci U S A 89, 10940-4. 
Gatti, J. L., Metayer, S., Moudjou, M., Andreoletti, O., Lantier, F., Dacheux, J. L. & 
Sarradin, P. (2002). Prion protein is secreted in soluble forms in the 
    
 188
epididymal fluid and proteolytically processed and transported in seminal 
plasma. Biol Reprod 67, 393-400. 
Georgsson, G., Sigurdarson, S. & Brown, P. (2006). Infectious agent of sheep scrapie 
may persist in the environment for at least 16 years. J Gen Virol 87, 3737-40. 
Ghani, A. C., Ferguson, N. M., Donnelly, C. A. & Anderson, R. M. (2003). Factors 
determining the pattern of the variant Creutzfeldt-Jakob disease (vCJD) 
epidemic in the UK. Proc Biol Sci 270, 689-98. 
Ghetti, B., Tagliavini, F., Giaccone, G., Bugiani, O., Frangione, B., Farlow, M. R. & 
Dlouhy, S. R. (1994). Familial Gerstmann-Straussler-Scheinker disease with 
neurofibrillary tangles. Mol Neurobiol 8, 41-8. 
Giese, A., Groschup, M. H., Hess, B. & Kretzschmar, H. A. (1995). Neuronal cell 
death in scrapie-infected mice is due to apoptosis. Brain Pathol 5, 213-21. 
Glatzel, M., Giger, O., Braun, N. & Aguzzi, A. (2004). The peripheral nervous 
system and the pathogenesis of prion diseases. Curr Mol Med 4, 355-9. 
Godec, M. S., Asher, D. M., Kozachuk, W. E., Masters, C. L., Rubi, J. U., Payne, J. 
A., Rubi-Villa, D. J., Wagner, E. E., Rapoport, S. I. & Schapiro, M. B. 
(1994). Blood buffy coat from Alzheimer's disease patients and their relatives 
does not transmit spongiform encephalopathy to hamsters. Neurology 44, 
1111-5. 
Goldmann, W., Hunter, N., Foster, J. D., Salbaum, J. M., Beyreuther, K. & Hope, J. 
(1990). Two alleles of a neural protein gene linked to scrapie in sheep. Proc 
Natl Acad Sci U S A 87, 2476-80. 
Goldmann, W., Hunter, N., Benson, G., Foster, J. D. & Hope, J. (1991a). Different 
scrapie-associated fibril proteins (PrP) are encoded by lines of sheep selected 
for different alleles of the Sip gene. J Gen Virol 72 ( Pt 10), 2411-7. 
Goldmann, W., Hunter, N., Martin, T., Dawson, M. & Hope, J. (1991b). Different 
forms of the bovine PrP gene have five or six copies of a short, G-C-rich 
element within the protein-coding exon. J Gen Virol 72 ( Pt 1), 201-4. 
Goldmann, W. (1993). PrP gene and its association with spongiform 
encephalopathies. Br Med Bull 49, 839-59. 
    
 189
Goldmann, W., Hunter, N., Smith, G., Foster, J. & Hope, J. (1994). PrP genotype and 
agent effects in scrapie: change in allelic interaction with different isolates of 
agent in sheep, a natural host of scrapie. J Gen Virol 75 ( Pt 5), 989-95. 
Goldmann, W., Martin, T., Foster, J., Hughes, S., Smith, G., Hughes, K., Dawson, 
M. & Hunter, N. (1996). Novel polymorphisms in the caprine PrP gene: a 
codon 142 mutation associated with scrapie incubation period. J Gen Virol 77 
( Pt 11), 2885-91. 
Goldmann, W., Chong, A., Foster, J., Hope, J. & Hunter, N. (1998). The shortest 
known prion protein gene allele occurs in goats, has only three octapeptide 
repeats and is non-pathogenic. J Gen Virol 79 ( Pt 12), 3173-6. 
Goldmann, W., O'Neill, G., Cheung, F., Charleson, F., Ford, P. & Hunter, N. (1999). 
PrP (prion) gene expression in sheep may be modulated by alternative 
polyadenylation of its messenger RNA. J Gen Virol 80 ( Pt 8), 2275-83. 
Gossner, A. G., Bennet, N., Hunter, N. & Hopkins, J. (2009). Differential expression 
of Prnp and Sprn in scrapie infected sheep also reveals Prnp genotype 
specific differences. Biochem Biophys Res Commun 378, 862-6. 
Green, K. M., Browning, S. R., Seward, T. S., Jewell, J. E., Ross, D. L., Green, M. 
A., Williams, E. S., Hoover, E. A. & Telling, G. C. (2008). The elk PRNP 
codon 132 polymorphism controls cervid and scrapie prion propagation. J 
Gen Virol 89, 598-608. 
Gretzschel, A., Buschmann, A., Langeveld, J., & Groschup, M.H. (2006). 
Immunological characterisation of abnormal prion protein from atypical 
scrapie cases in sheep using a panel of monoclonal antibodies. J Gen Virol 
87, 3715-3722. 
Griffith, J. S. (1967). Nature of the Scrapie Agent: Self-replication and Scrapie. 
Nature 215, 1043-1044. 
Gu, Y., Fujioka, H., Mishra, R. S., Li, R. & Singh, N. (2002). Prion peptide 106-126 
modulates the aggregation of cellular prion protein and induces the synthesis 
of potentially neurotoxic transmembrane PrP. J Biol Chem 277, 2275-86. 
Guentchev, M., Groschup, M. H., Kordek, R., Liberski, P. P. & Budka, H. (1998). 
Severe, early and selective loss of a subpopulation of GABAergic inhibitory 
    
 190
neurons in experimental transmissible spongiform encephalopathies. Brain 
Pathol 8, 615-23. 
Guillot-Sestier, M. V., Sunyach, C., Druon, C., Scarzello, S. & Checler, F. (2009). 
The alpha-secretase-derived N-terminal product of cellular prion, N1, 
displays neuroprotective function in vitro and in vivo. J Biol Chem 284, 
35973-86. 
Hadlow, W. J. (1959). Scrapie and kuru. The Lancet 274, 289-290. 
Hagenaars, T. J., Melchior, M. B., Bossers, A., Davidse, A., Engel, B. & van 
Zijderveld, F. G. (2010). Scrapie prevalence in sheep of susceptible genotype 
is declining in a population subject to breeding for resistance. BMC Vet Res 6, 
25. 
Haigh, C. L., Lewis, V. A., Vella, L. J., Masters, C. L., Hill, A. F., Lawson, V. A. & 
Collins, S. J. (2009). PrPC-related signal transduction is influenced by 
copper, membrane integrity and the alpha cleavage site. Cell Res 19, 1062-78. 
Haigh, C. L., Marom, S. Y. & Collins, S. J. (2010). Copper, endoproteolytic 
processing of the prion protein and cell signalling. Front Biosci 15, 1086-104. 
Haik, S., Peyrin, J.M., Lins, L., Rosseneu, M.Y., Brasseur, R., Langeveld, J.P., 
Tagliavlin, F., Deslys, J.D., Lasmezas, C. & Dormont, D. (2000). 
Neurotoxicity of the putative transmembrane domain of the prion protein.  N 
eurobiol Dis 7 (6pt B) 644-56. 
Haire, L. F., Whyte, S. M., Vasisht, N., Gill, A. C., Verma, C., Dodson, E. J., 
Dodson, G. G. & Bayley, P. M. (2004). The crystal structure of the globular 
domain of sheep prion protein. J Mol Biol 336, 1175-83. 
Halliday, S., Houston, F. & Hunter, N. (2005). Expression of PrPC on cellular 
components of sheep blood. J Gen Virol 86, 1571-9. 
Han, C. X., Liu, H. X. & Zhao, D. M. (2006). The quantification of prion gene 
expression in sheep using real-time RT-PCR. Virus Genes 33, 359-64. 
Harmey, J. H., Doyle, D., Brown, V. & Rogers, M. S. (1995). The cellular isoform of 
the prion protein, PrPc, is associated with caveolae in mouse neuroblastoma 
(N2a) cells. Biochem Biophys Res Commun 210, 753-9. 
    
 191
Harris, D. A., Huber, M. T., van Dijken, P., Shyng, S. L., Chait, B. T. & Wang, R. 
(1993). Processing of a cellular prion protein: identification of N- and C-
terminal cleavage sites. Biochemistry 32, 1009-16. 
Harris, D. A. (1999). Cellular biology of prion diseases. Clin Microbiol Rev 12, 429-
44. 
Harris, D. A. (2003). Trafficking, turnover and membrane topology of PrP. Br Med 
Bull 66, 71-85. 
Hartsough, G. R. & Burger, D. (1965). Encephalopathy of mink. I. Epizootiologic 
and clinical observations. J Infect Dis 115, 387-92. 
Hegde, R. S., Mastrianni, J. A., Scott, M. R., DeFea, K. A., Tremblay, P., Torchia, 
M., DeArmond, S. J., Prusiner, S. B. & Lingappa, V. R. (1998a). A 
transmembrane form of the prion protein in neurodegenerative disease. 
Science 279, 827-34. 
Hegde, R. S., Voigt, S. & Lingappa, V. R. (1998b). Regulation of protein topology 
by trans-acting factors at the endoplasmic reticulum. Mol Cell 2, 85-91. 
 
Hill, A. F., Antoniou, M. & Collinge, J. (1999). Protease-resistant prion protein 
produced in vitro lacks detectable infectivity. J Gen Virol 80 ( Pt 1), 11-4. 
Hooper, N. M. & Turner, A. J. (2008). A new take on prions: preventing Alzheimer's 
disease. Trends Biochem Sci 33, 151-5. 
Hope, J., Wood, S. C., Birkett, C. R., Chong, A., Bruce, M. E., Cairns, D., 
Goldmann, W., Hunter, N. & Bostock, C. J. (1999). Molecular analysis of 
ovine prion protein identifies similarities between BSE and an experimental 
isolate of natural scrapie, CH1641. J Gen Virol 80 ( Pt 1), 1-4. 
Hopp, P., Omer, M. K. & Heier, B. T. (2006). A case-control study of scrapie Nor98 
in Norwegian sheep flocks. J Gen Virol 87, 3729-36. 
Horiuchi, M., Yamazaki, N., Ikeda, T., Ishiguro, N. & Shinagawa, M. (1995). A 
cellular form of prion protein (PrPC) exists in many non-neuronal tissues of 
sheep. J Gen Virol 76 ( Pt 10), 2583-7. 
Hornshaw, M. P., McDermott, J. R. & Candy, J. M. (1995). Copper binding to the N-
terminal tandem repeat regions of mammalian and avian prion protein. 
Biochem Biophys Res Commun 207, 621-9. 
    
 192
Houston, E. F., Halliday, S. I., Jeffrey, M., Goldmann, W. & Hunter, N. (2002a). 
New Zealand sheep with scrapie-susceptible PrP genotypes succumb to 
experimental challenge with a sheep-passaged scrapie isolate (SSBP/1). J 
Gen Virol 83, 1247-50. 
Houston, F., Halliday, S. I., Jeffrey, M., Goldmann, W. & Hunter, N. (2002b). New 
Zealand sheep with scrapie-susceptible PrP genotypes succumb to 
experimental challenge with a sheep-passaged scrapie isolate (SSBP/1). . 
Journal of General Virology 83, 1247-1250. 
Houston, E. F. & Gravenor, M. B. (2003). Clinical signs in sheep experimentally 
infected with scrapie and BSE. Vet Rec 152, 333-4. 
Houston, E. F., Goldmann, W., Chong, A., Jeffrey, M., Gonzalez, L., Foster, J., 
Parnham, D. & Hunter, N. (2003). Prion diseases: BSE in sheep bred for 
resistance to infection. Nature 423, 498. 
Houston, F., McCutcheon, S., Goldmann, W., Chong, A., Foster, J., Siso, S., 
Gonzalez, L., Jeffrey, M. & Hunter, N. (2008). Prion diseases are efficiently 
transmitted by blood transfusion in sheep. Blood 112, 4739-45. 
Hsiao, K. K., Scott, M., Foster, D., Groth, D. F., DeArmond, S. J. & Prusiner, S. B. 
(1990). Spontaneous neurodegeneration in transgenic mice with mutant prion 
protein. Science 250, 1587-90. 
Huang, S., Liang, J., Zheng, M., Li, X., Wang, M., Wang, P., Vanegas, D., Wu, D., 
Chakraborty, B., Hays, A. P., Chen, K., Chen, S. G., Booth, S., Cohen, M., 
Gambetti, P. & Kong, Q. (2007). Inducible overexpression of wild-type prion 
protein in the muscles leads to a primary myopathy in transgenic mice. Proc 
Natl Acad Sci U S A 104, 6800-5. 
Huber, R., Deboer, T. & Tobler, I. (2002). Sleep deprivation in prion protein 
deficient mice sleep deprivation in prion protein deficient mice and control 
mice: genotype dependent regional rebound. Neuroreport 13, 1-4. 
Hunter, N., Foster, J. D., Goldmann, W., Stear, M. J., Hope, J. & Bostock, C. (1996). 
Natural scrapie in a closed flock of Cheviot sheep occurs only in specific PrP 
genotypes. Arch Virol 141, 809-24. 
Hunter, N. (1997). PrP genetics in sheep and the applications for scrapie and BSE. 
Trends Microbiol 5, 331-4. 
    
 193
Hunter, N., Cairns, D., Foster, J. D., Smith, G., Goldmann, W. & Donnelly, K. 
(1997). Is scrapie solely a genetic disease? Nature 386, 137. 
Hunter, N. (2007). Scrapie: uncertainties, biology and molecular approaches. 
Biochim Biophys Acta 1772, 619-28. 
Ierna, M., Farquhar, C. F., Outram, G. W. & Bruce, M. E. (2006). Resistance of 
neonatal mice to scrapie is associated with inefficient infection of the 
immature spleen. J Virol 80, 474-82. 
Iwata, N., Sato, Y., Higuchi, Y., Nohtomi, K., Nagata, N., Hasegawa, H., Tobiume, 
M., Nakamura, Y., Hagiwara, K., Furuoka, H., Horiuchi, M., Yamakawa, Y. 
& Sata, T. (2006). Distribution of PrP(Sc) in cattle with bovine spongiform 
encephalopathy slaughtered at abattoirs in Japan. Jpn J Infect Dis 59, 100-7. 
Jarrett, J. T. & Lansbury, P. T., Jr. (1993). Seeding "one-dimensional crystallization" 
of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 
73, 1055-8. 
Jeffrey, M., Martin, S., Thomson, J. R., Dingwall, W. S., Begara-McGorum, I. & 
Gonzalez, L. (2001). Onset and distribution of tissue prp accumulation in 
scrapie-affected suffolk sheep as demonstrated by sequential necropsies and 
tonsillar biopsies. J Comp Pathol 125, 48-57. 
Jeffrey, M., Gonzalez, L., Chong, A., Foster, J., Goldmann, W., Hunter, N. & Martin, 
S. (2006). Ovine infection with the agents of scrapie (CH1641 isolate) and 
bovine spongiform encephalopathy: immunochemical similarities can be 
resolved by immunohistochemistry. J Comp Pathol 134, 17-29. 
Jeffrey, M. & Gonzalez, L. (2007). Classical sheep transmissible spongiform 
encephalopathies: pathogenesis, pathological phenotypes and clinical disease. 
Neuropathol Appl Neurobiol 33, 373-94. 
Jiayu, W., Zhu, H., Ming, X., Xiong, W., Songbo, W., Bocui, S., Wensen, L., Jiping, 
L., Keying, M., Zhongyi, L. & Hongwei, G. (2009). Mapping the interaction 
site of prion protein and Sho. Mol Biol Rep. 
Jimenez-Huete, A., Lievens, P. M., Vidal, R., Piccardo, P., Ghetti, B., Tagliavini, F., 
Frangione, B. & Prelli, F. (1998). Endogenous proteolytic cleavage of normal 
and disease-associated isoforms of the human prion protein in neural and 
non-neural tissues. Am J Pathol 153, 1561-72. 
    
 194
Jobling, M. F., Stewart, L. R., White, A. R., McLean, C., Friedhuber, A., Maher, F., 
Beyreuther, K., Masters, C. L., Barrow, C. J., Collins, S. J. & Cappai, R. 
(1999). The hydrophobic core sequence modulates the neurotoxic and 
secondary structure properties of the prion peptide 106-126. J Neurochem 73, 
1557-65. 
Johnson, C. J., Phillips, K. E., Schramm, P. T., McKenzie, D., Aiken, J. M. & 
Pedersen, J. A. (2006). Prions adhere to soil minerals and remain infectious. 
PLoS Pathog 2, e32. 
Jones, M., Head, M. W., Connolly, J. G., Farquhar, C. F., Hornsey, V. S., Pepper, D. 
S. & MacGregor, I. R. (2005). Purification of normal cellular prion protein 
from human platelets and the formation of a high molecular weight prion 
protein complex following platelet activation. Biochem Biophys Res Commun 
335, 48-56. 
Jones, M., McLoughlin, V., Connolly, J. G., Farquhar, C. F., MacGregor, I. R. & 
Head, M. W. (2009). Production and characterization of a panel of 
monoclonal antibodies against native human cellular prion protein. 
Hybridoma (Larchmt) 28, 13-20. 
Kaneko, K., Zulianello, L., Scott, M., Cooper, C. M., Wallace, A. C., James, T. L., 
Cohen, F. E. & Prusiner, S. B. (1997). Evidence for protein X binding to a 
discontinuous epitope on the cellular prion protein during scrapie prion 
propagation. Proc Natl Acad Sci U S A 94, 10069-74. 
Kim, J. I., Kuizon, S. & Rubenstein, R. (2003). Comparison of PrP transcription and 
translation in two murine myeloma cell lines. J Neuroimmunol 140, 137-42. 
Kimberlin, R. H. & Marsh, R. F. (1975). Comparison of scrapie and transmissible 
mink encephalopathy in hamsters. I. Biochemical studies of brain during 
development of disease. J Infect Dis 131, 97-103. 
Kimberlin, R. H. & Walker, C. A. (1989a). Pathogenesis of scrapie in mice after 
intragastric infection. Virus Res 12, 213-20. 
Kimberlin, R. H. & Walker, C. A. (1989b). The role of the spleen in the 
neuroinvasion of scrapie in mice. Virus Res 12, 201-11. 
    
 195
Kimberlin, R. H., Walker, C. A. & Fraser, H. (1989). The genomic identity of 
different strains of mouse scrapie is expressed in hamsters and preserved on 
reisolation in mice. J Gen Virol 70 ( Pt 8), 2017-25. 
Klamt, F., Dal-Pizzol, F., Conte da Frota, M. J., Walz, R., Andrades, M. E., da Silva, 
E. G., Brentani, R. R., Izquierdo, I. & Fonseca Moreira, J. C. (2001). 
Imbalance of antioxidant defense in mice lacking cellular prion protein. Free 
Radic Biol Med 30, 1137-44. 
Kocisko, D. A., Come, J. H., Priola, S. A., Chesebro, B., Raymond, G. J., Lansbury, 
P. T. & Caughey, B. (1994). Cell-free formation of protease-resistant prion 
protein. Nature 370, 471-4. 
Konold, T., Moore, S. J., Bellworthy, S. J. & Simmons, H. A. (2008). Evidence of 
scrapie transmission via milk. BMC Vet Res 4, 14. 
Kovacs, G. G. & Budka, H. (2008). Prion diseases: from protein to cell pathology. 
Am J Pathol 172, 555-65. 
Kramer, M. L., Kratzin, H. D., Schmidt, B., Romer, A., Windl, O., Liemann, S., 
Hornemann, S. & Kretzschmar, H. (2001). Prion protein binds copper within 
the physiological concentration range. J Biol Chem 276, 16711-9. 
Kretzschmar, H. A., Prusiner, S. B., Stowring, L. E. & DeArmond, S. J. (1986). 
Scrapie prion proteins are synthesized in neurons. Am J Pathol 122, 1-5. 
Kuczius, T., Grassi, J., Karch, H. & Groschup, M. H. (2007a). Binding of N- and C-
terminal anti-prion protein antibodies generates distinct phenotypes of 
cellular prion proteins (PrPC) obtained from human, sheep, cattle and mouse. 
FEBS J 274, 1492-502. 
Kuczius, T., Koch, R., Keyvani, K., Karch, H., Grassi, J. & Groschup, M. H. 
(2007b). Regional and phenotype heterogeneity of cellular prion proteins in 
the human brain. Eur J Neurosci 25, 2649-55. 
Laffont-Proust, I., Faucheux, B. A., Hassig, R., Sazdovitch, V., Simon, S., Grassi, J., 
Hauw, J. J., Moya, K. L. & Haik, S. (2005). The N-terminal cleavage of 
cellular prion protein in the human brain. FEBS Lett 579, 6333-7. 
Laffont-Proust, I., Hassig, R., Haik, S., Simon, S., Grassi, J., Fonta, C., Faucheux, B. 
A. & Moya, K. L. (2006). Truncated PrP(c) in mammalian brain: interspecies 
variation and location in membrane rafts. Biol Chem 387, 297-300. 
    
 196
Laplanche, J. L., Chatelain, J., Westaway, D., Thomas, S., Dussaucy, M., Brugere-
Picoux, J. & Launay, J. M. (1993). PrP polymorphisms associated with 
natural scrapie discovered by denaturing gradient gel electrophoresis. 
Genomics 15, 30-7. 
Lasmezas, C. I., Deslys, J. P., Robain, O., Jaegly, A., Beringue, V., Peyrin, J. M., 
Fournier, J. G., Hauw, J. J., Rossier, J. & Dormont, D. (1997). Transmission 
of the BSE agent to mice in the absence of detectable abnormal prion protein. 
Science 275, 402-5. 
Le Dur, A., Beringue, V., Andreoletti, O., Reine, F., Lai, T. L., Baron, T., Bratberg, 
B., Vilotte, J. L., Sarradin, P., Benestad, S. L. & Laude, H. (2005). A newly 
identified type of scrapie agent can naturally infect sheep with resistant PrP 
genotypes. Proc Natl Acad Sci U S A 102, 16031-6. 
Le Pichon, C. E., Valley, M. T., Polymenidou, M., Chesler, A. T., Sagdullaev, B. T., 
Aguzzi, A. & Firestein, S. (2009). Olfactory behavior and physiology are 
disrupted in prion protein knockout mice. Nat Neurosci 12, 60-9. 
Legname, G., Baskakov, I. V., Nguyen, H. O., Riesner, D., Cohen, F. E., DeArmond, 
S. J. & Prusiner, S. B. (2004). Synthetic mammalian prions. Science 305, 
673-6. 
Lewis, V., Hill, A. F., Haigh, C. L., Klug, G. M., Masters, C. L., Lawson, V. A. & 
Collins, S. J. (2009). Increased proportions of C1 truncated prion protein 
protect against cellular M1000 prion infection. J Neuropathol Exp Neurol 68, 
1125-35. 
Li, A., Christensen, H. M., Stewart, L. R., Roth, K. A., Chiesa, R. & Harris, D. A. 
(2007). Neonatal lethality in transgenic mice expressing prion protein with a 
deletion of residues 105-125. EMBO J 26, 548-58. 
Liang, J., Parchaliuk, D., Medina, S., Sorensen, G., Landry, L., Huang, S., Wang, M., 
Kong, Q. & Booth, S. A. (2009). Activation of p53-regulated pro-apoptotic 
signaling pathways in PrP-mediated myopathy. BMC Genomics 10, 201. 
Linden, R., Martins, V. R., Prado, M. A., Cammarota, M., Izquierdo, I. & Brentani, 
R. R. (2008). Physiology of the prion protein. Physiol Rev 88, 673-728. 
    
 197
Liu, M. L., Li, Y. X., Zhou, X. M. & Zhao, D. M. (2008). Copper(II) inhibits in vitro 
conformational conversion of ovine prion protein triggered by low pH. J 
Biochem 143, 333-7. 
Lowe, J. B. & Marth, J. D. (2003). A genetic approach to Mammalian glycan 
function. Annu Rev Biochem 72, 643-91. 
Lucassen, P. J., Williams, A., Chung, W. C. & Fraser, H. (1995). Detection of 
apoptosis in murine scrapie. Neurosci Lett 198, 185-8. 
Lugaresi, E., Tobler, I., Gambetti, P. & Montagna, P. (1998). The pathophysiology of 
fatal familial insomnia. Brain Pathol 8, 521-6. 
Lysek, D. A., Schorn, C., Nivon, L. G., Esteve-Moya, V., Christen, B., Calzolai, L., 
von Schroetter, C., Fiorito, F., Herrmann, T., Guntert, P. & Wuthrich, K. 
(2005). Prion protein NMR structures of cats, dogs, pigs, and sheep. Proc 
Natl Acad Sci U S A 102, 640-5. 
Mabbott, N. A., Mackay, F., Minns, F. & Bruce, M. E. (2000). Temporary 
inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat 
Med 6, 719-20. 
Mabbott, N. A. & Bruce, M. E. (2001). The immunobiology of TSE diseases. J Gen 
Virol 82, 2307-18. 
Mabbott, N. A. & MacPherson, G. G. (2006). Prions and their lethal journey to the 
brain. Nat Rev Microbiol 4, 201-11. 
Maddison, B. C., Whitelam, G. C. & Gough, K. C. (2007). Cellular prion protein in 
ovine milk. Biochem Biophys Res Commun 353, 195-9. 
Mange, A., Beranger, F., Peoc'h, K., Onodera, T., Frobert, Y. & Lehmann, S. (2004). 
Alpha- and beta- cleavages of the amino-terminus of the cellular prion 
protein. Biol Cell 96, 125-32. 
Manson, J. C., Clarke, A. R., Hooper, M. L., Aitchison, L., McConnell, I. & Hope, J. 
(1994). 129/Ola mice carrying a null mutation in PrP that abolishes mRNA 
production are developmentally normal. Mol Neurobiol 8, 121-7. 
Manson, J. C., Hope, J., Clarke, A. R., Johnston, A., Black, C. & MacLeod, N. 
(1995). PrP gene dosage and long term potentiation. Neurodegeneration 4, 
113-4. 
    
 198
Maruyama, K., Kametani, F., Usami, M., Yamao-Harigaya, W. & Tanaka, K. (1991). 
"Secretase," Alzheimer amyloid protein precursor secreting enzyme is not 
sequence-specific. Biochem Biophys Res Commun 179, 1670-6. 
Matthews, L., Coen, P. G., Foster, J. D., Hunter, N. & Woolhouse, M. E. (2001). 
Population dynamics of a scrapie outbreak. Arch Virol 146, 1173-86. 
Maue, A. C. H., L (2008). CD4+ T Cells and Immunosenescence – 
A Mini-Review. Gerontology 55, 491-495. 
McBride, P. A., Eikelenboom, P., Kraal, G., Fraser, H. & Bruce, M. E. (1992). PrP 
protein is associated with follicular dendritic cells of spleens and lymph 
nodes in uninfected and scrapie-infected mice. J Pathol 168, 413-8. 
McGowan, J. P. (1922). Scrapie in sheep. Scottish Journal of Agriculture 5, 365-375. 
McKinley, M., Bolton, D. & Prusiner, S. (1983). A protease-resistant protein is a 
structural component of the scrapie prion. Cell 35, 57-62. 
McMahon, H. E., Mange, A., Nishida, N., Creminon, C., Casanova, D. & Lehmann, 
S. (2001). Cleavage of the amino terminus of the prion protein by reactive 
oxygen species. J Biol Chem 276, 2286-91. 
Melchior, M. B., Windig, J. J., Hagenaars, T. J., Bossers, A., Davidse, A. & van 
Zijderveld, F. G. (2010). Eradication of scrapie with selective breeding: are 
we nearly there? BMC Vet Res 6, 24. 
Michalczyk, K. & Ziman, M. (2007). Current concepts in human prion protein (Prp) 
misfolding, Prnp gene polymorphisms and their contribution to Creutzfeldt-
Jakob Disease (CJD). Histol Histopathol 22, 1149-59. 
Micklem, L. R., McCann, M. C. & James, K. (1987). The use of rat mixed-
thymocyte culture-conditioned medium for hybridoma production, cloning 
and revival. J Immunol Methods 104, 81-6. 
Mironov, A., Jr., Latawiec, D., Wille, H., Bouzamondo-Bernstein, E., Legname, G., 
Williamson, R. A., Burton, D., DeArmond, S. J., Prusiner, S. B. & Peters, P. 
J. (2003). Cytosolic prion protein in neurons. J Neurosci 23, 7183-93. 
Mitsios, N., Saka, M., Krupinski, J., Pennucci, R., Sanfeliu, C., Miguel Turu, M., 
Gaffney, J., Kumar, P., Kumar, S., Sullivan, M. & Slevin, M. (2007). Cellular 
prion protein is increased in the plasma and peri-infarcted brain tissue after 
acute stroke. J Neurosci Res 85, 602-11. 
    
 199
Mo, H., Moore, R. C., Cohen, F. E., Westaway, D., Prusiner, S. B., Wright, P. E. & 
Dyson, H. J. (2001). Two different neurodegenerative diseases caused by 
proteins with similar structures. Proc Natl Acad Sci U S A 98, 2352-7. 
Mohri, S., Farquhar, C. F., Somerville, R. A., Jeffrey, M., Foster, J. & Hope, J. 
(1992). Immunodetection of a disease specific PrP fraction in scrapie-affected 
sheep and BSE-affected cattle. Vet Rec 131, 537-9. 
Moore, R. C., Redhead, N. J., Selfridge, J., Hope, J., Manson, J. C. & Melton, D. W. 
(1995). Double replacement gene targeting for the production of a series of 
mouse strains with different prion protein gene alterations. Biotechnology (N 
Y) 13, 999-1004. 
Moore, R. C. & Melton, D. W. (1997). Transgenic analysis of prion diseases. Mol 
Hum Reprod 3, 529-44. 
Moore, R. C., Lee, I. Y., Silverman, G. L., Harrison, P. M., Strome, R., Heinrich, C., 
Karunaratne, A., Pasternak, S. H., Chishti, M. A., Liang, Y., Mastrangelo, P., 
Wang, K., Smit, A. F., Katamine, S., Carlson, G. A., Cohen, F. E., Prusiner, 
S. B., Melton, D. W., Tremblay, P., Hood, L. E. & Westaway, D. (1999). 
Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of 
the novel PrP-like protein doppel. J Mol Biol 292, 797-817. 
Morel, N., Simon, S., Frobert, Y., Volland, H., Mourton-Gilles, C., Negro, A., 
Sorgato, M. C., Creminon, C. & Grassi, J. (2004). Selective and efficient 
immunoprecipitation of the disease-associated form of the prion protein can 
be mediated by nonspecific interactions between monoclonal antibodies and 
scrapie-associated fibrils. J Biol Chem 279, 30143-9. 
Moser, M., Colello, R. J., Pott, U. & Oesch, B. (1995). Developmental expression of 
the prion protein gene in glial cells. Neuron 14, 509-17. 
Moudjou, M., Frobert, Y., Grassi, J. & La Bonnardiere, C. (2001). Cellular prion 
protein status in sheep: tissue-specific biochemical signatures. J Gen Virol 
82, 2017-24. 
Moum, T., Olsaker, I., Hopp, P., Moldal, T., Valheim, M. & Benestad, S. L. (2005). 
Polymorphisms at codons 141 and 154 in the ovine prion protein gene are 
associated with scrapie Nor98 cases. J Gen Virol 86, 231-5. 
    
 200
Moya, K. L., Sales, N., Hassig, R., Creminon, C., Grassi, J. & Di Giamberardino, L. 
(2000). Immunolocalization of the cellular prion protein in normal brain. 
Microsc Res Tech 50, 58-65. 
Muramoto, T., DeArmond, S. J., Scott, M., Telling, G. C., Cohen, F. E. & Prusiner, 
S. B. (1997). Heritable disorder resembling neuronal storage disease in mice 
expressing prion protein with deletion of an alpha-helix. Nat Med 3, 750-5. 
Nentwig, A., Oevermann, A., Heim, D., Botteron, C., Zellweger, K., Drogemuller, 
C., Zurbriggen, A. & Seuberlich, T. (2007). Diversity in neuroanatomical 
distribution of abnormal prion protein in atypical scrapie. PLoS Pathog 3, 
e82. 
Nieznanski, K., Rutkowski, M., Dominik, M. & Stepkowski, D. (2005). Proteolytic 
processing and glycosylation influence formation of porcine prion protein 
complexes. Biochem J 387, 93-100. 
Nonno, R., Di Bari, M. A., Cardone, F., Vaccari, G., Fazzi, P., Dell'Omo, G., 
Cartoni, C., Ingrosso, L., Boyle, A., Galeno, R., Sbriccoli, M., Lipp, H. P., 
Bruce, M., Pocchiari, M. & Agrimi, U. (2006). Efficient transmission and 
characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS 
Pathog 2, e12. 
Norstrom, E. M. & Mastrianni, J. A. (2005). The AGAAAAGA palindrome in PrP is 
required to generate a productive PrPSc-PrPC complex that leads to prion 
propagation. J Biol Chem 280, 27236-43. 
Novak, U. (2004). ADAM proteins in the brain. J Clin Neurosci 11, 227-35. 
Oesch, B., Westaway, D., Walchli, M., McKinley, M. P., Kent, S. B., Aebersold, R., 
Barry, R. A., Tempst, P., Teplow, D. B., Hood, L. E. & et al. (1985). A 
cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-46. 
Oliveira-Martins, J. B., Yusa, S., Calella, A. M., Bridel, C., Baumann, F., Dametto, 
P. & Aguzzi, A. (2010). Unexpected tolerance of alpha-cleavage of the prion 
protein to sequence variations. PLoS One 5, e9107. 
Outram, G. W., Dickinson, A. G. & Fraser, H. (1973). Developmental maturation of 
susceptibility to scrapie in mice. Nature 241, 536-7. 
Owen, J. P., Rees, H. C., Maddison, B. C., Terry, L. A., Thorne, L., Jackman, R., 
Whitelam, G. C. & Gough, K. C. (2007). Molecular profiling of ovine prion 
    
 201
diseases by using thermolysin-resistant PrPSc and endogenous C2 PrP 
fragments. J Virol 81, 10532-9. 
Pan, T., Li, R., Wong, B. S., Liu, T., Gambetti, P. & Sy, M. S. (2002). Heterogeneity 
of normal prion protein in two- dimensional immunoblot: presence of various 
glycosylated and truncated forms. J Neurochem 81, 1092-101. 
Parchi, P., Castellani, R., Capellari, S., Ghetti, B., Young, K., Chen, S. G., Farlow, 
M., Dickson, D. W., Sima, A. A., Trojanowski, J. Q., Petersen, R. B. & 
Gambetti, P. (1996). Molecular basis of phenotypic variability in sporadic 
Creutzfeldt-Jakob disease. Ann Neurol 39, 767-78. 
Parchi, P., Capellari, S., Chin, S., Schwarz, H. B., Schecter, N. P., Butts, J. D., 
Hudkins, P., Burns, D. K., Powers, J. M. & Gambetti, P. (1999). A subtype of 
sporadic prion disease mimicking fatal familial insomnia. Neurology 52, 
1757-63. 
Parchi, P., Zou, W., Wang, W., Brown, P., Capellari, S., Ghetti, B., Kopp, N., 
Schulz-Schaeffer, W. J., Kretzschmar, H. A., Head, M. W., Ironside, J. W., 
Gambetti, P. & Chen, S. G. (2000). Genetic influence on the structural 
variations of the abnormal prion protein. Proc Natl Acad Sci U S A 97, 
10168-72. 
Parkin, E. T., Watt, N. T., Turner, A. J. & Hooper, N. M. (2004). Dual mechanisms 
for shedding of the cellular prion protein. J Biol Chem 279, 11170-8. 
Parry, H. B. (1962). Scrapie: a transmissible and hereditary disease of sheep. 
Heredity 17, 75-105. 
Pattison, I. H. & Millson, G. C. (1960). Further observations on the experimental 
production of scrapie in goats and sheep. J Comp Pathol 70, 182-93. 
Pattison, I. H. (1966). The relative susceptibility of sheep, goats and mice to two 
types of the goat scrapie agent. Res Vet Sci 7, 207-12. 
Pauly, P. C. & Harris, D. A. (1998). Copper stimulates endocytosis of the prion 
protein. J Biol Chem 273, 33107-10. 
Peters, P. J., Mironov, A., Jr., Peretz, D., van Donselaar, E., Leclerc, E., Erpel, S., 
DeArmond, S. J., Burton, D. R., Williamson, R. A., Vey, M. & Prusiner, S. 
B. (2003). Trafficking of prion proteins through a caveolae-mediated 
endosomal pathway. J Cell Biol 162, 703-17. 
    
 202
Piccardo, P., Manson, J. C., King, D., Ghetti, B. & Barron, R. M. (2007). 
Accumulation of prion protein in the brain that is not associated with 
transmissible disease. Proc Natl Acad Sci U S A 104, 4712-7. 
Porter, D. D., Porter, H. G. & Cox, N. A. (1973). Failure to demonstrate a humoral 
immune response to scrapie infection in mice. J Immunol 111, 1407-10. 
Powell, A. D., Toescu, E. C., Collinge, J. & Jefferys, J. G. (2008). Alterations in 
Ca2+-buffering in prion-null mice: association with reduced 
afterhyperpolarizations in CA1 hippocampal neurons. J Neurosci 28, 3877-
86. 
Premzl, M., Sangiorgio, L., Strumbo, B., Marshall Graves, J. A., Simonic, T. & 
Gready, J. E. (2003). Shadoo, a new protein highly conserved from fish to 
mammals and with similarity to prion protein. Gene 314, 89-102. 
Prinz, M., Huber, G., Macpherson, A. J., Heppner, F. L., Glatzel, M., Eugster, H. P., 
Wagner, N. & Aguzzi, A. (2003). Oral prion infection requires normal 
numbers of Peyer's patches but not of enteric lymphocytes. Am J Pathol 162, 
1103-11. 
Priola, S. A. (1999). Prion protein and species barriers in the transmissible 
spongiform encephalopathies. Biomed Pharmacother 53, 27-33. 
Prusiner, S. B. (1982). Novel proteinaceous infectious particles cause scrapie. 
Science 216, 136-44. 
Prusiner, S. B., Scott, M., Foster, D., Pan, K. M., Groth, D., Mirenda, C., Torchia, 
M., Yang, S. L., Serban, D., Carlson, G. A. & et al. (1990). Transgenetic 
studies implicate interactions between homologous PrP isoforms in scrapie 
prion replication. Cell 63, 673-86. 
Prusiner, S. B. (1991). Prion biology and diseases. Harvey Lect 87, 85-114. 
Prusiner, S. B. (1992). Chemistry and biology of prions. Biochemistry 31, 12277-88. 
Prusiner, S. B. (1993). Prion encephalopathies of animals and humans. Dev Biol 
Stand 80, 31-44. 
Prusiner, S. B. (1994). Neurodegeneration in humans caused by prions. West J Med 
161, 264-72. 
Prusiner, S. B. (1998). The prion diseases. Brain Pathol 8, 499-513. 
    
 203
Prusiner, S. B., Scott, M. R., DeArmond, S. J. & Cohen, F. E. (1998). Prion protein 
biology. Cell 93, 337-48. 
 
Race, R. E., Priola, S. A., Bessen, R. A., Ernst, D., Dockter, J., Rall, G. F., Mucke, 
L., Chesebro, B. & Oldstone, M. B. (1995). Neuron-specific expression of a 
hamster prion protein minigene in transgenic mice induces susceptibility to 
hamster scrapie agent. Neuron 15, 1183-91. 
Race, R., Jenny, A. & Sutton, D. (1998). Scrapie infectivity and proteinase K-
resistant prion protein in sheep placenta, brain, spleen, and lymph node: 
implications for transmission and antemortem diagnosis. J Infect Dis 178, 
949-53. 
Rachidi, W., Vilette, D., Guiraud, P., Arlotto, M., Riondel, J., Laude, H., Lehmann, 
S. & Favier, A. (2003). Expression of prion protein increases cellular copper 
binding and antioxidant enzyme activities but not copper delivery. J Biol 
Chem 278, 9064-72. 
Ranee, N.S., Chakrabarti, O., Feigenbaum, L. & Hedge, R.S. (2010). Signal 
sequence insufficency contribues to neurodegeneration caused by 
transmembrane prion protein. J Cell Biol 188, 515-526. 
Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R. & Wuthrich, K. 
(1996). NMR structure of the mouse prion protein domain PrP(121-321). 
Nature 382, 180-2. 
Riek, R., Hornemann, S., Wider, G., Glockshuber, R. & Wuthrich, K. (1997). NMR 
characterization of the full-length recombinant murine prion protein, 
mPrP(23-231). FEBS Lett 413, 282-8. 
Saa, P., Castilla, J. & Soto, C. (2005). Cyclic amplification of protein misfolding and 
aggregation. Methods Mol Biol 299, 53-65. 
Saborio, G. P., Permanne, B. & Soto, C. (2001). Sensitive detection of pathological 
prion protein by cyclic amplification of protein misfolding. Nature 411, 810-
3. 
Sabuncu, E., Paquet, S., Chapuis, J., Moudjou, M., Lai, T. L., Grassi, J., Baron, U., 
Laude, H. & Vilette, D. (2005). Prion proteins from susceptible and resistant 
    
 204
sheep exhibit some distinct cell biological features. Biochem Biophys Res 
Commun 337, 791-8. 
Sakaguchi, S., Katamine, S., Nishida, N., Moriuchi, R., Shigematsu, K., Sugimoto, 
T., Nakatani, A., Kataoka, Y., Houtani, T., Shirabe, S., Okada, H., Hasegawa, 
S., Miyamoto, T. & Noda, T. (1996). Loss of cerebellar Purkinje cells in aged 
mice homozygous for a disrupted PrP gene. Nature 380, 528-31. 
Sarnataro, D., Campana, V., Paladino, S., Stornaiuolo, M., Nitsch, L. & Zurzolo, C. 
(2004). PrP(C) association with lipid rafts in the early secretory pathway 
stabilizes its cellular conformation. Mol Biol Cell 15, 4031-42. 
Schatzl, H. M., Wopfner, F., Gilch, S., von Brunn, A. & Jager, G. (1997). Is codon 
129 of prion protein polymorphic in human beings but not in animals? Lancet 
349, 1603-4. 
Schlapfer, I., Saitbekova, N., Gaillard, C. & Dolf, G. (1999). A new allelic variant in 
the bovine prion protein gene (PRNP) coding region. Anim Genet 30, 386-7. 
Scott, M., Foster, D., Mirenda, C., Serban, D., Coufal, F., Walchli, M., Torchia, M., 
Groth, D., Carlson, G., DeArmond, S. J., Westaway, D. & Prusiner, S. B. 
(1989). Transgenic mice expressing hamster prion protein produce species-
specific scrapie infectivity and amyloid plaques. Cell 59, 847-57. 
Scott, M., Groth, D., Foster, D., Torchia, M., Yang, S. L., DeArmond, S. J. & 
Prusiner, S. B. (1993). Propagation of prions with artificial properties in 
transgenic mice expressing chimeric PrP genes. Cell 73, 979-88. 
Scott, M. R., Will, R., Ironside, J., Nguyen, H. O., Tremblay, P., DeArmond, S. J. & 
Prusiner, S. B. (1999). Compelling transgenetic evidence for transmission of 
bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S 
A 96, 15137-42. 
Seeger, H., Heikenwalder, M., Zeller, N., Kranich, J., Schwarz, P., Gaspert, A., 
Seifert, B., Miele, G. & Aguzzi, A. (2005). Coincident scrapie infection and 
nephritis lead to urinary prion excretion. Science 310, 324-6. 
Senior, K. (2000). Alzheimer's and prion disease; do they share a pathogenic 
mechanism? The Lancet 355, 1434-. 
Shmerling, D., Hegyi, I., Fischer, M., Blattler, T., Brandner, S., Gotz, J., Rulicke, T., 
Flechsig, E., Cozzio, A., von Mering, C., Hangartner, C., Aguzzi, A. & 
    
 205
Weissmann, C. (1998). Expression of amino-terminally truncated PrP in the 
mouse leading to ataxia and specific cerebellar lesions. Cell 93, 203-14. 
Shyng, S. L., Huber, M. T. & Harris, D. A. (1993). A prion protein cycles between 
the cell surface and an endocytic compartment in cultured neuroblastoma 
cells. J Biol Chem 268, 15922-8. 
Shyng, S. L., Lehmann, S., Moulder, K. L. & Harris, D. A. (1995). Sulfated glycans 
stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in 
cultured cells. J Biol Chem 270, 30221-9. 
Shyu, W. C., Lin, S. Z., Chiang, M. F., Ding, D. C., Li, K. W., Chen, S. F., Yang, H. 
I. & Li, H. (2005). Overexpression of PrPC by adenovirus-mediated gene 
targeting reduces ischemic injury in a stroke rat model. J Neurosci 25, 8967-
77. 
Sigurdsson, B., Pálsson, P. A. & Grímsson, H. (1957). Visna, a demyelinating 
transmissible disease of sheep. . Journal of Neuropathology 39, 519-528. 
Silverman, G. L., Qin, K., Moore, R. C., Yang, Y., Mastrangelo, P., Tremblay, P., 
Prusiner, S. B., Cohen, F. E. & Westaway, D. (2000). Doppel is an N-
glycosylated, glycosylphosphatidylinositol-anchored protein. Expression in 
testis and ectopic production in the brains of Prnp(0/0) mice predisposed to 
Purkinje cell loss. J Biol Chem 275, 26834-41. 
Simmons, M. M., Konold, T., Simmons, H. A., Spencer, Y. I., Lockey, R., 
Spiropoulos, J., Everitt, S. & Clifford, D. (2007). Experimental transmission 
of atypical scrapie to sheep. BMC Vet Res 3, 20. 
Singh, A., Kong, Q., Luo, X., Petersen, R. B., Meyerson, H. & Singh, N. (2009). 
Prion protein (PrP) knock-out mice show altered iron metabolism: a 
functional role for PrP in iron uptake and transport. PLoS One 4, e6115. 
Siso, S., Gonzalez, L., Jeffrey, M., Martin, S., Chianini, F. & Steele, P. (2006). Prion 
protein in kidneys of scrapie-infected sheep. Vet Rec 159, 327-8. 
Siso, S., Jeffrey, M., Houston, F., Hunter, N., Martin, S. & Gonzalez, L. (2010). 
Pathological phenotype of sheep scrapie after blood transfusion. J Comp 
Pathol 142, 27-35. 
    
 206
Sisodia, S. S., Koo, E. H., Beyreuther, K., Unterbeck, A. & Price, D. L. (1990). 
Evidence that beta-amyloid protein in Alzheimer's disease is not derived by 
normal processing. Science 248, 492-5. 
Somerville, R. A. (1999). Host and transmissible spongiform encephalopathy agent 
strain control glycosylation of PrP. J Gen Virol 80 ( Pt 7), 1865-72. 
Soto, C. & Castilla, J. (2004). The controversial protein-only hypothesis of prion 
propagation. Nat Med 10 Suppl, S63-7. 
 
Soto, C., Anderes, L., Suardi, S., Cardone, F., Castilla, J., Frossard, M. J., Peano, S., 
Saa, P., Limido, L., Carbonatto, M., Ironside, J., Torres, J. M., Pocchiari, M. 
& Tagliavini, F. (2005). Pre-symptomatic detection of prions by cyclic 
amplification of protein misfolding. FEBS Lett 579, 638-42. 
St Rose, S. G., Hunter, N., Foster, J. D., Drummond, D., McKenzie, C., Parnham, D., 
Will, R. G., Woolhouse, M. E. & Rhind, S. M. (2007). Quantification of 
Peyer's patches in Cheviot sheep for future scrapie pathogenesis studies. Vet 
Immunol Immunopathol 116, 163-71. 
Stahl, N., Borchelt, D. R. & Prusiner, S. B. (1990). Differential release of cellular 
and scrapie prion proteins from cellular membranes by phosphatidylinositol-
specific phospholipase C. Biochemistry 29, 5405-12. 
Stewart, R. S. & Harris, D. A. (2001). Most pathogenic mutations do not alter the 
membrane topology of the prion protein. J Biol Chem 276, 2212-20. 
Stewart, R. S. & Harris, D. A. (2005). A transmembrane form of the prion protein is 
localized in the Golgi apparatus of neurons. J Biol Chem 280, 15855-64. 
Stockel, J., Safar, J., Wallace, A. C., Cohen, F. E. & Prusiner, S. B. (1998). Prion 
protein selectively binds copper(II) ions. Biochemistry 37, 7185-93. 
Sunyach, C., Cisse, M. A., da Costa, C. A., Vincent, B. & Checler, F. (2007). The C-
terminal products of cellular prion protein processing, C1 and C2, exert 
distinct influence on p53-dependent staurosporine-induced caspase-3 
activation. J Biol Chem 282, 1956-63. 
Taylor, D. M., McConnell, I. & Fraser, H. (1996). Scrapie infection can be 
established readily through skin scarification in immunocompetent but not 
immunodeficient mice. J Gen Virol 77 ( Pt 7), 1595-9. 
    
 207
Terry, L. A., Marsh, S., Ryder, S. J., Hawkins, S. A., Wells, G. A. & Spencer, Y. I. 
(2003). Detection of disease-specific PrP in the distal ileum of cattle exposed 
orally to the agent of bovine spongiform encephalopathy. Vet Rec 152, 387-
92. 
Thackray, A. M., Hopkins, L., Spiropoulos, J. & Bujdoso, R. (2008). Molecular and 
transmission characteristics of primary-passaged ovine scrapie isolates in 
conventional and ovine PrP transgenic mice. J Virol 82, 11197-207. 
Tichopad, A., Pfaffl, M. W. & Didier, A. (2003). Tissue-specific expression pattern 
of bovine prion gene: quantification using real-time RT-PCR. Mol Cell 
Probes 17, 5-10. 
Tobler, I., Gaus, S. E., Deboer, T., Achermann, P., Fischer, M., Rulicke, T., Moser, 
M., Oesch, B., McBride, P. A. & Manson, J. C. (1996). Altered circadian 
activity rhythms and sleep in mice devoid of prion protein. Nature 380, 639-
42. 
Tongue, S. C., Wilesmith, J. W., Nash, J., Kossaibati, M. & Ryan, J. (2008). The 
importance of the PrP genotype in active surveillance for ovine scrapie. 
Epidemiol Infect 136, 703-12. 
Toumazos, P. (1991). Scrapie in Cyprus. Br Vet J 147, 147-54. 
Tuzi, N. L., Gall, E., Melton, D. & Manson, J. C. (2002). Expression of doppel in the 
CNS of mice does not modulate transmissible spongiform encephalopathy 
disease. J Gen Virol 83, 705-11. 
Tuzi, N. L., Cancellotti, E., Baybutt, H., Blackford, L., Bradford, B., Plinston, C., 
Coghill, A., Hart, P., Piccardo, P., Barron, R. M. & Manson, J. C. (2008). 
Host PrP glycosylation: a major factor determining the outcome of prion 
infection. PLoS Biol 6, e100. 
Tveit, H., Lund, C., Olsen, C. M., Ersdal, C., Prydz, K., Harbitz, I. & Tranulis, M. A. 
(2005). Proteolytic processing of the ovine prion protein in cell cultures. 
Biochem Biophys Res Commun 337, 232-40. 
Unterberger, U., Voigtlander, T. & Budka, H. (2005). Pathogenesis of prion diseases. 
Acta Neuropathol 109, 32-48. 
van Keulen, L. J., Schreuder, B. E., Meloen, R. H., Mooij-Harkes, G., Vromans, M. 
E. & Langeveld, J. P. (1996). Immunohistochemical detection of prion 
    
 208
protein in lymphoid tissues of sheep with natural scrapie. J Clin Microbiol 
34, 1228-31. 
van Keulen, L. J., Bossers, A. & van Zijderveld, F. (2008). TSE pathogenesis in 
cattle and sheep. Vet Res 39, 24. 
Vassar, R. (2001). The beta-secretase, BACE: a prime drug target for Alzheimer's 
disease. J Mol Neurosci 17, 157-70. 
Vilotte, J. L., Soulier, S., Essalmani, R., Stinnakre, M. G., Vaiman, D., Lepourry, L., 
Da Silva, J. C., Besnard, N., Dawson, M., Buschmann, A., Groschup, M., 
Petit, S., Madelaine, M. F., Rakatobe, S., Le Dur, A., Vilette, D. & Laude, H. 
(2001). Markedly increased susceptibility to natural sheep scrapie of 
transgenic mice expressing ovine prp. J Virol 75, 5977-84. 
Vincent, B., Paitel, E., Frobert, Y., Lehmann, S., Grassi, J. & Checler, F (2000). 
Phorbol ester-regulated cleavage of normal prion protein in HEK293 human 
cells and murine neurones. J Biol Chem 275, 35612-616. 
Vincent, B., Paitel, E., Saftig, P., Frobert, Y., Hartmann, D., De Strooper, B., Grassi, 
J., Lopez-Perez, E. & Checler, F. (2001). The disintegrins ADAM10 and 
TACE contribute to the constitutive and phorbol ester-regulated normal 
cleavage of the cellular prion protein. J Biol Chem 276, 37743-6. 
Wadsworth, J. D. & Collinge, J. (2007). Update on human prion disease. Biochim 
Biophys Acta 1772, 598-609. 
Wadsworth, J. D., Joiner, S., Linehan, J. M., Desbruslais, M., Fox, K., Cooper, S., 
Cronier, S., Asante, E. A., Mead, S., Brandner, S., Hill, A. F. & Collinge, J. 
(2008). Kuru prions and sporadic Creutzfeldt-Jakob disease prions have 
equivalent transmission properties in transgenic and wild-type mice. Proc 
Natl Acad Sci U S A 105, 3885-90. 
Walmsley, A. R., Watt, N. T., Taylor, D. R., Perera, W. S. & Hooper, N. M. (2009). 
alpha-cleavage of the prion protein occurs in a late compartment of the 
secretory pathway and is independent of lipid rafts. Mol Cell Neurosci 40, 
242-8. 
Wang, S., Foote, W. C., Sutton, D. L., Maciulis, A., Miller, J. M., Evans, R. C., 
Holyoak, G. R., Call, J. W., Bunch, T. D., Taylor, W. D. & Marshall, M. R. 
    
 209
(2001). Preventing experimental vertical transmission of scrapie by embryo 
transfer. Theriogenology 56, 315-27. 
Watt, N. T., Taylor, D. R., Gillott, A., Thomas, D. A., Perera, W. S. & Hooper, N. 
M. (2005). Reactive oxygen species-mediated beta-cleavage of the prion 
protein in the cellular response to oxidative stress. J Biol Chem 280, 35914-
21. 
Watts, J. C., Drisaldi, B., Ng, V., Yang, J., Strome, B., Horne, P., Sy, M. S., Yoong, 
L., Young, R., Mastrangelo, P., Bergeron, C., Fraser, P. E., Carlson, G. A., 
Mount, H. T., Schmitt-Ulms, G. & Westaway, D. (2007). The CNS 
glycoprotein Shadoo has PrP(C)-like protective properties and displays 
reduced levels in prion infections. EMBO J 26, 4038-50. 
Weber, P., Giese, A., Piening, N., Mitteregger, G., Thomzig, A., Beekes, M. & 
Kretzschmar, H. A. (2006). Cell-free formation of misfolded prion protein 
with authentic prion infectivity. Proc Natl Acad Sci U S A 103, 15818-23. 
Wegner, C., Romer, A., Schmalzbauer, R., Lorenz, H., Windl, O. & Kretzschmar, H. 
A. (2002). Mutant prion protein acquires resistance to protease in mouse 
neuroblastoma cells. J Gen Virol 83, 1237-45. 
Weise, J., Crome, O., Sandau, R., Schulz-Schaeffer, W., Bahr, M. & Zerr, I. (2004). 
Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and 
influence of lesion severity. Neurosci Lett 372, 146-50. 
Weissmann, C., Bueler, H., Fischer, M., Sauer, A. & Aguet, M. (1994). 
Susceptibility to scrapie in mice is dependent on PrPC. Philos Trans R Soc 
Lond B Biol Sci 343, 431-3. 
Wells, G. A., Scott, A. C., Johnson, C. T., Gunning, R. F., Hancock, R. D., Jeffrey, 
M., Dawson, M. & Bradley, R. (1987). A novel progressive spongiform 
encephalopathy in cattle. Vet Rec 121, 419-20. 
Westaway, D., Cooper, C., Turner, S., Da Costa, M., Carlson, G. A. & Prusiner, S. B. 
(1994a). Structure and polymorphism of the mouse prion protein gene. Proc 
Natl Acad Sci U S A 91, 6418-22. 
Westaway, D., Zuliani, V., Cooper, C. M., Da Costa, M., Neuman, S., Jenny, A. L., 
Detwiler, L. & Prusiner, S. B. (1994b). Homozygosity for prion protein 
    
 210
alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. 
Genes Dev 8, 959-69. 
Will, R. G., Ironside, J. W., Zeidler, M., Cousens, S. N., Estibeiro, K., Alperovitch, 
A., Poser, S., Pocchiari, M., Hofman, A. & Smith, P. G. (1996). A new 
variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-5. 
Williams, A., Lucassen, P. J., Ritchie, D. & Bruce, M. (1997). PrP deposition, 
microglial activation, and neuronal apoptosis in murine scrapie. Exp Neurol 
144, 433-8. 
Williams, E. S. & Young, S. (1980). Chronic wasting disease of captive mule deer: a 
spongiform encephalopathy. J Wildl Dis 16, 89-98. 
Williams, E. S. & Young, S. (1982). Spongiform encephalopathy of Rocky Mountain 
elk. J Wildl Dis 18, 465-71. 
Wong, B. S., Pan, T., Liu, T., Li, R., Petersen, R. B., Jones, I. M., Gambetti, P., 
Brown, D. R. & Sy, M. S. (2000). Prion disease: A loss of antioxidant 
function? Biochem Biophys Res Commun 275, 249-52. 
Wood, J. N., Done, S. H., Pritchard, G. C. & Wooldridge, M. J. (1992). Natural 
scrapie in goats: case histories and clinical signs. Vet Rec 131, 66-8. 
Wrathall, A. E., Holyoak, G. R., Parsonson, I. M. & Simmons, H. A. (2008). Risks of 
transmitting ruminant spongiform encephalopathies (prion diseases) by 
semen and embryo transfer techniques. Theriogenology 70, 725-45. 
Wyatt, J. M., Pearson, G. R., Smerdon, T. N., Gruffydd-Jones, T. J., Wells, G. A. & 
Wilesmith, J. W. (1991). Naturally occurring scrapie-like spongiform 
encephalopathy in five domestic cats. Vet Rec 129, 233-6. 
Yadavalli, R., Guttmann, R. P., Seward, T., Centers, A. P., Williamson, R. A. & 
Telling, G. C. (2004). Calpain-dependent endoproteolytic cleavage of PrPSc 
modulates scrapie prion propagation. J Biol Chem 279, 21948-56. 
Yedidia, Y., Horonchik, L., Tzaban, S., Yanai, A. & Taraboulos, A. (2001). 
Proteasomes and ubiquitin are involved in the turnover of the wild-type prion 
protein. EMBO J 20, 5383-91. 
Zahn, R., Liu, A., Luhrs, T., Riek, R., von Schroetter, C., Lopez Garcia, F., Billeter, 
M., Calzolai, L., Wider, G. & Wuthrich, K. (2000). NMR solution structure 
of the human prion protein. Proc Natl Acad Sci U S A 97, 145-50. 
    
 211
Zhou, G.P. (2009). Some insights into conversion process of the PrP(C) to PrP 
(beta). Biochem Biophys Res Commun 
 




Table I  Metadata for all genotyped animals 
Animal ID Breed 
Age 
(months) 
Sex 136/154/171 141 112 
014 CH 84  ARR/ARR L/L M/M 
017 CH 114  ARR/ARR L/L M/M 
022 CH 102  ARR/ARR L/L M/M 
030 CH 108  ARR/ARR L/L M/M 
051 CH 84  ARR/ARR L/L M/M 
75 x 49 CH 60  ARR/ARR L/L M/M 
050 CH 84  AHQ/ARR L/L M/M 
42 x 05 CH 36  AHQ/ARR L/L M/M 
47 x 29 CH 96  AHQ/ARR L/L M/M 
71 x 58 CH 72  AHQ/ARR L/L M/M 
81 x 80 CH 0  AHQ/ARR L/L M/M 
47 x 66 CH 48  AHQ/ARQ L/F M/M 
59 x 89 CH 108  AHQ/ARQ L/F M/M 
63 x 51 CH 72  AHQ/ARQ L/L M/M 
69 x 24 CH 84  AHQ/ARQ L/F M/M 
82 x 15 CH 0  AHQ/ARQ L/F M/M 
2018E S 0-3  ARQ/ARR L/L M/M 
005D S 3-6  ARQ/ARR L/L M/M 
2018E S 0-3  ARQ/ARR L/L M/M 
005D S 3-6  ARQ/ARR L/L M/M 
013D S 3-6  ARQ/ARR L/L M/M 
021D S 3-6  ARQ/ARR L/L M/M 
024D S 3-6  ARQ/ARR L/L M/M 
    
 213
43 x 39 CH 96  ARQ/ARR L/L M/M 
53 x 57 CH 120  ARQ/ARR L/F M/M 
61 x 13 CH 108  ARQ/ARR L/L M/M 
72 x 38 CH 72  ARQ/ARR L/L M/M 
74 x 00 CH 60  ARQ/ARR L/L M/M 
81 x 34 CH 0  ARQ/ARR L/L M/M 
J212 PD 12  VRQ/VRQ L/L M/M 
J225 PD 12  VRQ/VRQ L/L M/M 
J232 PD 12  VRQ/VRQ L/L M/M 
J236 PD 12  VRQ/VRQ L/L M/M 
J255 PD 12  VRQ/VRQ L/L M/M 
J368 CH 27  VRQ/VRQ L/L M/M 
J374 CH 27  VRQ/VRQ L/L M/M 
K295 CH 29  VRQ/VRQ L/L M/M 
K310 CH 29  VRQ/VRQ L/L M/M 
K320 CH 29  VRQ/VRQ L/L M/M 
H30 PD 24  VRQ/ARQ L/L M/M 
H41 PD 24  VRQ/ARQ L/L M/M 
H84 PD 24  VRQ/ARQ L/L M/M 
H50 PD 24  VRQ/ARQ L/L M/M 
Pg0109 NZCH 8  VRQ/ARQ L/L M/M 
Pg0437 NZCH 60  VRQ/ARQ L/L M/M 
Pg0490 NZCH 4   VRQ/ARQ L/L M/M 
Pg0675 NZCH 48  VRQ/ARQ L/F M/M 
Pg1226 NZCH 3   VRQ/ARQ L/F M/M 
6D S 0  ARQ/ARQ L/L T/T 
97A S 3-6  ARQ/ARQ L/L M/M 
2006E S 0  ARQ/ARQ L/L M/M 
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2016E S 0  ARQ/ARQ L/L M/M 
B1227 S 3-6  ARQ/ARQ L/L M/M 
69 x 67 CH 84  ARQ/ARQ L/L M/M 
Pg0416 NZCH 36  ARQ/ARQ L/L M/M 
Pg0433 NZCH 24  ARQ/ARQ L/L M/M 
Pg0854 NZCH 36  ARQ/ARQ L/L M/T 
 
CH = Cheviot 
CHNZ = New Zealand Cheviot 
PD = Poll Dorset 
S = Suffolk 
 = Female 
 = Male 
 
 
